10-Q

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended Feb. 28, 2014

or

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to

Commission file number 001-16167

MONSANTO COMPANY

(Exact name of registrant as specified in its charter)

Delaware	43-1878297
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
800 North Lindbergh Blvd.,	63167
St. Louis, MO	(Zip Code)
(Address of principal executive offices)

(314) 694-1000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o  (Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 524,170,807 shares of Common Stock, $0.01 par value, outstanding as of March 31, 2014.

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

In the interests of our investors, and in accordance with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, this section of our report explains some of the important reasons that actual results may be materially different from those that we anticipate. In this report, and from time to time throughout the year, we share our expectations for our company’s future performance. These forward-looking statements include statements about our business plans; the potential development, regulatory approval, and public acceptance of our products; our expected financial performance, including sales performance, and the anticipated effect of our strategic actions; the anticipated benefits of recent acquisitions; the outcome of contingencies, such as litigation and the previously announced SEC investigation; domestic or international economic, political and market conditions; and other factors that could affect our future results of operations or financial position, including, without limitation, statements under the captions “Overview — Executive Summary — Outlook,” “Seeds and Genomics Segment,” “Agricultural Productivity Segment,” “Financial Condition, Liquidity, and Capital Resources,” “Outlook,” “Critical Accounting Policies and Estimates” and “Legal Proceedings.” Any statements we make that are not matters of current reportage or historical fact should be considered forward-looking. Such statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “will,” and similar expressions. By their nature, these types of statements are uncertain and are not guarantees of our future performance.

Since these statements are based on factors that involve risks and uncertainties, our company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company’s research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company’s facilities; and other risks and factors described or referenced in Part II — Item 1A — Risk Factors — below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Our forward-looking statements represent our estimates and expectations and are based on currently available information at the time that we make those statements. However, circumstances change constantly, often unpredictably, and many events beyond our control will determine whether the expectations encompassed in our forward-looking statements will be realized. As a result, investors should not place undue reliance on these forward-looking statements. We disclaim any current intention or obligation to revise or update any forward-looking statements, or the factors that may affect their realization, whether in light of new information, future events or otherwise, and investors should not rely on us to do so.

1

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION		Page
Item 1.	Financial Statements	3
	Statements of Consolidated Operations	4
	Statements of Consolidated Comprehensive Income (Loss)	5
	Statements of Consolidated Financial Position	6
	Statements of Consolidated Cash Flows	7
	Statements of Consolidated Shareowners’ Equity	8
	Notes to Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	33
	Overview	33
	Results of Operations	36
	Seeds and Genomics Segment	39
	Agricultural Productivity Segment	40
	Financial Condition, Liquidity and Capital Resources	41
	Outlook	45
	Critical Accounting Policies and Estimates	47
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	47
Item 4.	Controls and Procedures	47
PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	48
Item 1A.	Risk Factors	48
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	48
Item 6.	Exhibits	48
SIGNATURE		49
EXHIBIT INDEX		50

2

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The Statements of Consolidated Operations of Monsanto Company and its consolidated subsidiaries for the three and six months ended Feb. 28, 2014, and Feb. 28, 2013, the Statements of Consolidated Comprehensive Income (Loss) for the three and six months ended Feb. 28, 2014, and Feb. 28, 2013, the Statements of Consolidated Financial Position as of Feb. 28, 2014, and Aug. 31, 2013, the Statements of Consolidated Cash Flows for the six months ended Feb. 28, 2014, and Feb. 28, 2013, the Statements of Consolidated Shareowners’ Equity for the six months ended Feb. 28, 2014, and year ended Aug. 31, 2013, and related Notes to the Consolidated Financial Statements follow. Unless otherwise indicated, “Monsanto” and the “company” are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Unless otherwise indicated, “earnings per share” and “per share” mean diluted earnings per share. In the notes to the consolidated financial statements, all dollars are expressed in millions, except per share amounts. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its subsidiaries are shown in special type. Unless otherwise indicated, references to “Roundup herbicides” mean Roundup branded herbicides, excluding all lawn-and-garden herbicides, and references to “Roundup and other glyphosate-based herbicides” exclude all lawn-and-garden herbicides.

3

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Statements of Consolidated Operations

Unaudited (Dollars in millions)	Three Months Ended						Six Months Ended
	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Net Sales	$	5,832		$	5,472		$	8,975		$	8,411
Cost of goods sold	2,385			2,402			3,965			3,944
Gross Profit	3,447			3,070			5,010			4,467
Operating Expenses:
Selling, general and administrative expenses	625			598			1,214			1,140
Research and development expenses	404			360			813			706
Total Operating Expenses	1,029			958			2,027			1,846
Income from Operations	2,418			2,112			2,983			2,621
Interest expense	40			35			93			86
Interest income	(23		)	(27		)	(47		)	(50		)
Other expense, net	61			22			81			39
Income from Continuing Operations Before Income Taxes	2,340			2,082			2,856			2,546
Income tax provision	672			603			824			725
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	$	1,668		$	1,479		$	2,032		$	1,821
Discontinued Operations:
Income from operations of discontinued businesses	8			6			22			17
Income tax provision	4			2			9			6
Income from Discontinued Operations	4			4			13			11
Net Income	$	1,672		$	1,483		$	2,045		$	1,832
Less: Net income attributable to noncontrolling interest	2			—			7			10
Net Income Attributable to Monsanto Company	$	1,670		$	1,483		$	2,038		$	1,822
Amounts Attributable to Monsanto Company:
Income from continuing operations	$	1,666		$	1,479		$	2,025		$	1,811
Income from discontinued operations	4			4			13			11
Net Income Attributable to Monsanto Company	$	1,670		$	1,483		$	2,038		$	1,822
Basic Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	3.18		$	2.77		$	3.86		$	3.39
Income from discontinued operations	—			0.01			0.02			0.02
Net Income Attributable to Monsanto Company	$	3.18		$	2.78		$	3.88		$	3.41
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	3.15		$	2.73		$	3.81		$	3.35
Income from discontinued operations	—			0.01			0.02			0.02
Net Income Attributable to Monsanto Company	$	3.15		$	2.74		$	3.83		$	3.37
Weighted Average Shares Outstanding:
Basic	524.8			534.8			525.9			534.8
Diluted	530.3			540.9			531.6			540.9
Dividends Declared per Share	$	0.86		$	0.75		$	0.86		$	0.75

The accompanying notes are an integral part of these consolidated financial statements.

4

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Statements of Consolidated Comprehensive Income (Loss)

Unaudited (Dollars in millions)	Three Months Ended						Six Months Ended
	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Comprehensive Income Attributable to Monsanto Company
Net Income Attributable to Monsanto Company	$	1,670		$	1,483		$	2,038		$	1,822
Other Comprehensive Income (Loss), Net of Tax:
Foreign currency translation, net of tax of $(4) , $0, $(12), and $0, respectively	(48		)	114			79			166
Postretirement benefit plan activity, net of tax of $4, $7, $9, and $14, respectively	6			12			14			23
Unrealized net gains on investment holdings, net of tax of $2, $0, $5, and $3, respectively	3			—			8			6
Realized net gains (losses) on investment holdings, net of tax of $0, $(4), $0, and $(3), respectively	1			(7		)	1			(6		)
Unrealized net derivative gains (losses), net of tax of $9, $(31), $(16), and $(37), respectively	12			(51		)	(31		)	(63		)
Realized net derivative gains (losses), net of tax of $3, $(15), $6, and $(20), respectively	6			(24		)	11			(34		)
Total Other Comprehensive Income (Loss), Net of Tax	(20		)	44			82			92
Comprehensive Income Attributable to Monsanto Company	$	1,650		$	1,527		$	2,120		$	1,914
Comprehensive Income Attributable to Noncontrolling Interests
Net Income Attributable to Noncontrolling Interests	2			—			7			10
Other Comprehensive Income
Foreign currency translation	1			12			6			8
Total Other Comprehensive Income	1			12			6			8
Comprehensive Income Attributable to Noncontrolling Interests	$	3		$	12		$	13		$	18
Total Comprehensive Income	$	1,653		$	1,539		$	2,133		$	1,932

The accompanying notes are an integral part of these consolidated financial statements.

5

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Statements of Consolidated Financial Position

Unaudited (Dollars in millions)	As of
	Feb. 28, 2014			Aug. 31, 2013
Assets
Current Assets:
Cash and cash equivalents (variable interest entity restricted - 2014: $15 and 2013: $140)	$	3,805		$	3,668
Short-term investments	45			254
Trade receivables, net (variable interest entity restricted - 2014: $129 and 2013: $0)	2,515			1,715
Miscellaneous receivables	668			748
Deferred tax assets	591			579
Inventory, net	3,692			2,947
Other current assets	234			166
Total Current Assets	11,550			10,077
Total property, plant and equipment	9,815			9,491
Less accumulated depreciation	5,080			4,837
Property, Plant and Equipment, Net	4,735			4,654
Goodwill	4,327			3,520
Other Intangible Assets, Net	1,645			1,226
Noncurrent Deferred Tax Assets	459			454
Long-Term Receivables, Net	131			237
Other Assets	610			496
Total Assets	$	23,457		$	20,664
Liabilities and Shareowners’ Equity
Current Liabilities:
Short-term debt, including current portion of long-term debt	$	104		$	51
Accounts payable	847			995
Income taxes payable	630			91
Accrued compensation and benefits	334			492
Accrued marketing programs	1,018			1,078
Deferred revenues	863			517
Grower production accruals	225			60
Dividends payable	226			228
Customer payable	31			12
Miscellaneous short-term accruals	773			812
Total Current Liabilities	5,051			4,336
Long-Term Debt	3,051			2,061
Postretirement Liabilities	333			357
Long-Term Deferred Revenue	94			138
Noncurrent Deferred Tax Liabilities	507			469
Long-Term Portion of Environmental and Litigation Liabilities	187			193
Other Liabilities	393			382
Shareowners’ Equity:
Common stock (authorized: 1,500,000,000 shares, par value $0.01)
Issued 604,208,684 and 601,631,267 shares, respectively
Outstanding 524,459,766 and 529,029,712 shares, respectively	6			6
Treasury stock 79,748,918 and 72,601,555 shares, respectively, at cost	(4,904		)	(4,140		)
Additional contributed capital	10,997			10,783
Retained earnings	8,775			7,188
Accumulated other comprehensive loss	(1,196		)	(1,278		)
Total Monsanto Company Shareowners’ Equity	13,678			12,559
Noncontrolling Interest	163			169
Total Shareowners’ Equity	13,841			12,728
Total Liabilities and Shareowners’ Equity	$	23,457		$	20,664

The accompanying notes are an integral part of these consolidated financial statements.

6

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Statements of Consolidated Cash Flows

Unaudited (Dollars in millions)	Six Months Ended
	Feb. 28, 2014			Feb. 28, 2013
Operating Activities:
Net Income	$	2,045		$	1,832
Adjustments to reconcile cash provided by operating activities:
Items that did not require (provide) cash:
Depreciation and amortization	332			305
Bad-debt expense	20			10
Stock-based compensation expense	57			49
Excess tax benefits from stock-based compensation	(36		)	(47		)
Deferred income taxes	32			52
Equity affiliate (income) expense, net	4			(2		)
Net gain on sales of a business or other assets	(2		)	(14		)
Other items	42			(37		)
Changes in assets and liabilities that provided (required) cash, net of acquisitions:
Trade receivables, net	(705		)	(201		)
Inventory, net	(742		)	(243		)
Deferred revenues	313			301
Accounts payable and other accrued liabilities	588			25
Pension contributions	(49		)	(24		)
Other items	(53		)	(149		)
Net Cash Provided by Operating Activities	1,846			1,857
Cash Flows (Required) Provided by Investing Activities:
Purchases of short-term investments	(105		)	(320		)
Maturities of short-term investments	314			312
Capital expenditures	(471		)	(261		)
Acquisition of businesses, net of cash acquired	(922		)	(79		)
Purchases of long-term debt and equity securities	(12		)	—
Technology and other investments	(378		)	(48		)
Other proceeds	18			95
Net Cash Required by Investing Activities	(1,556		)	(301		)
Cash Flows Provided (Required) by Financing Activities:
Net change in financing with less than 90-day maturities	(44		)	142
Short-term debt proceeds	28			1
Short-term debt reductions	—			(29		)
Long-term debt proceeds	999			16
Long-term debt reductions	(3		)	(2		)
Payments on other financing	(39		)	—
Debt issuance costs	(8		)	—
Treasury stock purchases	(764		)	(327		)
Stock option exercises	128			136
Excess tax benefits from stock-based compensation	36			47
Tax withholding on restricted stock and restricted stock units	(8		)	(3		)
Dividend payments	(453		)	(402		)
Dividend payments to noncontrolling interests	(19		)	(1		)
Net Cash Required by Financing Activities	(147		)	(422		)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(6		)	26
Net Increase in Cash and Cash Equivalents	137			1,160
Cash and Cash Equivalents at Beginning of Period	3,668			3,283
Cash and Cash Equivalents at End of Period	$	3,805		$	4,443

See Note 1 — Background and Basis of Presentation and Note 19 — Supplemental Cash Flow Information for further details.

The accompanying notes are an integral part of these consolidated financial statements.

7

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Statements of Consolidated Shareowners’ Equity

	Monsanto Shareowners
Unaudited (Dollars in millions, except per share data)	Common Stock		Treasury Stock			Additional Contributed Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss) (1)			Non-Controlling Interest			Total
Balance as of Aug. 31, 2012	$	6	$	(3,045	)	$	10,371		$	5,537		$	(1,036	)	$	203		$	12,036
Net income	—		—			—			2,482			—			43			2,525
Other comprehensive loss for 2013	—		—			—			—			(242		)	(27		)	(269		)
Treasury stock purchases	—		(1,095		)	—			—			—			—			(1,095		)
Restricted stock withholding	—		—			(10		)	—			—			—			(10		)
Issuance of shares under employee stock plans	—		—			257			—			—			—			257
Excess tax benefits from stock-based compensation	—		—			69			—			—			—			69
Stock-based compensation expense	—		—			97			—			—			—			97
Cash dividends of $1.56 per common share	—		—			—			(831		)	—			—			(831		)
Dividend payments to noncontrolling interest	—		—			—			—			—			(174		)	(174		)
Acquisition of noncontrolling interest	—		—			(1		)	—			—			(9		)	(10		)
Proceeds from noncontrolling interest	—		—			—			—			—			133			133
Balance as of Aug. 31, 2013	$	6	$	(4,140	)	$	10,783		$	7,188		$	(1,278	)	$	169		$	12,728
Net income	—		—			—			2,038			—			7			2,045
Other comprehensive income for 2014	—		—			—			—			82			6			88
Treasury stock purchases	—		(764		)	—			—			—			—			(764		)
Restricted stock withholding	—		—			(8		)	—			—			—			(8		)
Issuance of shares under employee stock plans	—		—			128			—			—			—			128
Excess tax benefits from stock-based compensation	—		—			37			—			—			—			37
Stock-based compensation expense	—		—			57			—			—			—			57
Cash dividends of $0.86 per common share	—		—			—			(451		)	—			—			(451		)
Dividend payments to noncontrolling interest	—		—			—			—			—			(19		)	(19		)
Balance as of Feb. 28, 2014	$	6	$	(4,904	)	$	10,997		$	8,775		$	(1,196	)	$	163		$	13,841

(1) See Note 17 — Accumulated Other Comprehensive Loss — for further details of the components of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

8

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED

NOTE 1. BACKGROUND AND BASIS OF PRESENTATION

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto’s seeds, biotechnology trait products, and herbicides provide farmers with solutions that improve productivity, reduce the costs of farming, and produce better foods for consumers and better feed for animals.

Monsanto manages its business in two segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and Monsanto develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other seed companies with genetic material and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the company manufactures Roundup and Harness brand herbicides and other herbicides. See Note 21 — Segment Information — for further details.

In the fourth quarter of 2008, the company announced plans to divest its animal agricultural products business, which focused on dairy cow productivity (the Dairy business) and was previously reported as part of the Agricultural Productivity segment. This transaction was consummated on Oct. 1, 2008. As a result, financial data for this business has been presented as discontinued operations.

Certain reclassifications of prior year amounts within the operating activities section of the Statement of Consolidated Cash Flows have been made to conform to current year presentation. The company has evaluated the impact and does not consider the reclassifications to be material to the consolidated financial statements.

The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first six months of fiscal year 2014 should not be annualized because of the seasonality of the company’s business.

NOTE 2. NEW ACCOUNTING STANDARDS

In July 2013, the FASB issued accounting guidance requiring entities to present unrecognized tax benefits as a reduction to any related deferred tax assets for net operating losses, similar tax losses, or tax credit carryforwards if such settlement is required or expected in the event an uncertain tax position is disallowed. Currently, U.S. Generally Accepted Accounting Principles ("U.S. GAAP") does not provide explicit guidance on the topic. This new presentation guidance will become effective prospectively for fiscal years, and interim periods within those years, beginning after Dec. 15, 2013. Accordingly, Monsanto will adopt this standard in the first quarter of fiscal year 2015. While the company is evaluating the impact this standard will have on the presentation of unrecognized tax benefits in the company's Statements of Consolidated Financial Position, it will not affect the company's results of operations, financial condition or cash flows.

In February 2013, the Financial Accounting Standards Board ("FASB") issued "Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," which requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, entities are required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, entities are required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail on these amounts. This standard is effective prospectively for reporting periods beginning after Dec. 15, 2012. Accordingly, Monsanto adopted this standard in the first quarter of fiscal year 2014. See Note 17 - Accumulated Other Comprehensive Loss - for additional disclosures.

In July 2012, the FASB issued amendments to the Intangibles-Goodwill and Other topic of the Accounting Standards Codification ("ASC"). Prior to this amendment the company performs a two-step test as outlined by the ASC. Step one of the two-step indefinite-lived intangible asset impairment test is performed by calculating the fair value of the indefinite-lived intangible asset and comparing the fair value with its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, then the company is required to perform the second step of the impairment test to measure the amount of the impairment loss, if any. Under the amendment, an entity has the option to first assess qualitative factors to

9

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

determine whether it is necessary to perform the current two-step test. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, the quantitative impairment test is required. Otherwise, no further testing is required. An entity can choose to perform the qualitative assessment on none, some or all of its indefinite-lived intangible assets. Moreover, an entity can bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to step one of the impairment test, and then resume performing the qualitative assessment in any subsequent period. The amendment is effective for annual and interim indefinite-lived intangible asset impairment tests performed for fiscal years beginning after Sep. 15, 2012. Accordingly, Monsanto will adopt this amendment in fiscal year 2014 for the annual impairment test of indefinite-lived intangible assets and does not expect the adoption to have a material impact on the consolidated financial statements.

In December 2011 and February 2013, the FASB issued an amendment to the Balance Sheet topic of the ASC, which requires entities to disclose both gross and net information about both derivatives and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting agreement. The objective of the disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of International Financial Reporting Standards. This standard is effective for fiscal years, and interim periods within those years, beginning on or after Jan. 1, 2013. Retrospective presentation for all comparative periods presented is required. Accordingly, Monsanto adopted this amendment in the first quarter of fiscal year 2014. See Note 14 - Financial Instruments - for additional disclosures.

NOTE 3. BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS

Business Combinations

2014 Acquisitions: In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper-local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s research and development ("R&D") capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The acquisition of the company qualifies as a business under the Business Combinations topic of the ASC. Acquisition costs were $17 million, of which $1 million were recorded in 2014. These costs were classified as selling, general and administrative expenses. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

The business operations and employees of the acquired entity described above were included in the Seeds and Genomics segment results upon acquisition. The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

10

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	787
Other Intangible Assets	142
Total Assets Acquired	997
Current Liabilities	10
Other Liabilities	55
Total Liabilities Assumed	65
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Pro forma information related to the 2014 acquisition is not presented because the impact of the acquisition on Monsanto's consolidated results of operations is not significant.

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	138
Customer Relationships	1	1	4
Other Intangible Assets			$	142

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co. KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. Acquisition costs were approximately $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations.  The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.  The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.  The goodwill is deductible for tax purposes.

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

11

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. Acquisition costs incurred were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

For the acquisitions described above, the business operations and employees of the acquired entities were included in the Seeds and Genomics segment results upon acquisition.

Pro forma information related to the 2013 acquisitions is not presented because the impact of these acquisitions, either individually or in the aggregate, on Monsanto's consolidated results of operations is not expected to be significant.

Collaborative Arrangements

In the normal course of business, Monsanto enters into collaborative arrangements for the research, development, manufacture and/or commercialization of agricultural products. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, such as research and development and commercialization of a collaboration product, where both Monsanto and the third party are active participants in the activities of the collaboration and are exposed to significant risks and rewards of the collaboration. These collaborations generally include cost sharing and profit sharing. Monsanto's collaboration agreements are performed with no guarantee of either technological or commercial success. The company's significant arrangements are discussed below.

Monsanto has entered into various multi-year research, development, manufacturing and commercialization collaborations related to various activities including plant biotechnology and microbial solutions. Under these collaborations, Monsanto and the third parties participate in the R&D and/or manufacturing activities and Monsanto has the primary responsibility for the commercialization of the collaboration products. The collaborations are accounted for in accordance with the Collaborative Arrangements topic of the ASC.

During both the three and six months ended Feb. 28, 2014, Monsanto expensed royalties, purchases and profit sharing payments to third parties under collaborative agreements in the amount of $4 million. These amounts were classified as cost of goods sold on the Statements of Consolidated Operations. There were no expensed royalties, purchases or profit sharing payments to third parties under collaborative agreements during both the three and six months ended Feb. 28, 2013. During each of the three months ended Feb. 28, 2014, and Feb. 28, 2013, Monsanto recorded a net R&D reimbursement from third parties under collaboration agreements in the amount of $12 million. During the six months ended Feb. 28, 2014, and Feb. 28, 2013, Monsanto recorded a net R&D reimbursement from third parties under collaboration agreements in the amounts of $20 million and $27 million, respectively. These amounts were classified as a reduction to research and development expenses on the Statements of Consolidated Operations.

NOTE 4. CUSTOMER FINANCING PROGRAMS

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	10	$	348
Maximum future payout under recourse provisions	1		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	9	$	44
Maximum future payout under recourse provisions	9		41
Agreements with Lenders(3)
Outstanding balance	$	84	$	45
Maximum future payout under the guarantee	60		32

12

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	—	$	—	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	3		3		10		3

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

In addition to the arrangements in the above table, Monsanto also participates in a financing program in Brazil that allowed Monsanto to transfer up to 1 billion Brazilian reais (approximately $430 million) for select customers in Brazil to a revolving financing program. Under the arrangement, a recourse provision requires Monsanto to cover the first credit losses within the program up to the amount of our investment. The company evaluated its relationship with the entity under the guidance within the Consolidation topic of the ASC and, as a result, the entity has been consolidated. For further information on this topic, see Note 5 — Variable Interest Entities.

There were no significant recourse or non-recourse liabilities for all programs as of Feb. 28, 2014, and Aug. 31, 2013. There were no significant delinquent loans for all programs as of Feb. 28, 2014, and Aug. 31, 2013.

NOTE 5. VARIABLE INTEREST ENTITIES

Monsanto is involved with entities that are deemed to be variable interest entities (VIEs). Monsanto has determined that the company holds variable interests in an entity that is established as a revolving financing program. In addition, Monsanto has various variable interests in biotechnology companies that focus on plant gene and agricultural fungicide research, development and commercialization. These variable interests have also been determined to be VIEs.

Consolidated VIEs

Monsanto has a financing program in Brazil that is recorded as a consolidated VIE. For the most part, the VIE consists of a revolving financing program that is funded by investments from the company and other third parties, primarily investment funds, and have been established to service Monsanto’s customer receivables. A 91 percent senior interest in the entity is held by third parties, primarily investment funds, as of Feb. 28, 2014, and Aug. 31, 2013, and Monsanto holds the remaining nine percent interest. Under the arrangement, Monsanto is required to maintain an investment in the VIE of at least nine percent and could be required to provide additional contributions to the VIE. Monsanto currently has no unfunded commitments to the VIE. See Note 4 — Customer Financing Programs — for additional information regarding the revolving financing arrangement.

Creditors have no recourse against Monsanto in the event of default by the VIE. The company’s financial or other support provided to the VIE is limited to its investment. Even though Monsanto holds a subordinate interest in the VIE, the VIE was established to service transactions involving the company and the company determines the receivables that are included in the revolving financing program. Therefore, the determination is that Monsanto has the power to direct the activities most significant to the economic performance of the VIE. As a result, the company is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto’s consolidated financial statements. The assets of the VIE may only be used to settle the obligations of the respective entity. Third-party investors in the VIE do not have recourse to the general assets of Monsanto

13

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

other than the maximum exposure to loss relating to the VIE. The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Cash and cash equivalents	$	15	$	140
Trade receivables, net	129		—
Total Assets	$	144	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	13	$	—

Monsanto has entered into several agreements with third parties to establish entities to focus on research and development related to various activities including agricultural fungicides and biologicals for agricultural applications. All entities are recorded as consolidated VIEs of Monsanto. Under each of the arrangements, Monsanto holds call options to acquire the majority of the equity interests in each VIE from the third party owners. Monsanto will fund the operations of the VIEs in return for either additional equity interests or to retain the call options. The funding, which may total up to $108 million, will be provided in separate research phases if research milestones are met over the next several years. The VIEs were established to perform agricultural-based research and development activities for the benefit of Monsanto, and Monsanto provides all funding of the VIEs' activities. Further, Monsanto has the power to direct the activities most significant to the VIEs. As a result, Monsanto is the primary beneficiary of the VIEs and the VIEs have been consolidated in Monsanto's consolidated financial statements. As of Feb. 28, 2014, and Aug. 31, 2013, the VIEs had no significant assets or liabilities. Monsanto's maximum exposure to loss was $43 million and $11 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, which includes our current investment in the VIEs, the funding required to be provided to the VIEs during the research phases and/or the initial consideration paid related to the call options. The third party owners of the VIEs do not have recourse to the general assets of Monsanto beyond Monsanto's maximum exposure to loss at any given time relating to the VIE.

Non-Consolidated VIE

Monsanto has a variable interest through an investment with a software company that develops software with agricultural applications. The company has not provided financial or other support other than its original investment, has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity and is not significant. There were no significant assets or liabilities for the VIE as of Feb. 28, 2014, and Aug. 31, 2013.

NOTE 6. RECEIVABLES

Trade receivables on the Statements of Consolidated Financial Position are net of allowances of $72 million and $68 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively.

The company has financing receivables that represent long-term customer receivable balances related to past due accounts which are not expected to be collected within the current year. The long-term customer receivables were $128 million and $112 million with a corresponding allowance for credit losses on these receivables of $105 million and $104 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively. These long-term customer receivable balances and the corresponding allowance are included in long-term receivables, net on the Statements of Consolidated Financial Position. For these long-term customer receivables, interest is no longer accrued when the receivable is determined to be delinquent and classified as long-term based on estimated timing of collection.

14

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	5
Recoveries	(2		)
Write-offs	(10		)
Other(1)	8
Balance as of Feb. 28, 2014	$	105

(1)Includes reclassifications from trade receivables, net and foreign currency translation adjustments.

In addition, the company has long-term contractual receivables. These receivables are collected at fixed and determinable dates in accordance with the customer long-term agreement. The long-term contractual receivables were $108 million and $229 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, and did not have any allowance recorded related to these balances. These receivables are included in long-term receivables, net on the Statements of Consolidated Financial Position. There are no balances related to these long-term contractual receivables that are past due. These receivables are outstanding with large, reputable companies who have been timely with scheduled payments thus far and are considered to be fully collectible. Interest is accrued on these receivables in accordance with the agreements and is included within interest income in the Statements of Consolidated Operations.

On an ongoing basis, the company evaluates credit quality of its financing receivables utilizing aging of receivables, collection experience and write-offs, as well as evaluating existing economic conditions, to determine if an allowance is necessary.

NOTE 7. INVENTORY

Components of inventory are:

	As of
(Dollars in millions)	Feb. 28, 2014			Aug. 31, 2013
Finished Goods	$	1,700		$	1,079
Goods In Process	1,679			1,619
Raw Materials and Supplies	479			418
Inventory at FIFO Cost	3,858			3,116
Excess of FIFO over LIFO Cost	(166		)	(169		)
Total	$	3,692		$	2,947

NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the net carrying amount of goodwill for the first six months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity		Total
Balance as of Aug. 31, 2013	$	3,461	$	59	$	3,520
Acquisition activity (see Note 3)	787		—		787
Effect of foreign currency translation adjustments	20		—		20
Balance as of Feb. 28, 2014	$	4,268	$	59	$	4,327

Goodwill increased during the six months endedFeb. 28, 2014, due to the acquisition of The Climate Corporation. See Note 3 - Business Combinations and Collaborative Arrangements - for further information. There were no events or circumstances

15

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

indicating that goodwill might be impaired as of Feb. 28, 2014. The fiscal year 2014 annual goodwill impairment test will be performed as of March 1, 2014.

Information regarding the company’s other intangible assets is as follows:

	As of Feb. 28, 2014							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,187	$	(492	)	$	695	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,119		(735		)	384		1,113		(717		)	396
Trademarks	368		(135		)	233		341		(131		)	210
Customer Relationships	340		(193		)	147		306		(179		)	127
Other	181		(99		)	82		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,195	$	(1,654	)	$	1,541	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,299	$	(1,654	)	$	1,645	$	3,135	$	(1,909	)	$	1,226

The increase in total other intangible assets during the six months endedFeb. 28, 2014, is primarily related to the acquisition of The Climate Corporation and the Novozymes collaborative arrangement. Total amortization expense of other intangible assets was $33 million and $31 million in second quarter of fiscal years 2014 and 2013, respectively. Total amortization expense of other intangible assets was $60 million and $59 million for the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	144
2015	176
2016	173
2017	152
2018	118

NOTE 9. INVESTMENTS

As of Feb. 28, 2014, and Aug. 31, 2013, Monsanto has short-term investments outstanding of $45 million and $254 million, respectively. The investments at Feb. 28, 2014, and Aug. 31, 2013, are comprised of commercial paper with original maturities of one year or less. See Note 13 — Fair Value Measurements.

Monsanto has investments in long-term equity securities, which are considered available-for-sale. As of Feb. 28, 2014, and Aug. 31, 2013, these long-term equity securities are recorded in other assets in the Statements of Consolidated Financial Position at a fair value of $47 million and $22 million, respectively. See Note 17 — Accumulated Other Comprehensive Loss.

Monsanto has cost basis investments recorded in other assets in the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, these investments were recorded at $81 million and $67 million, respectively. Due to the nature of these investments, the fair market value is not readily determinable. These investments are reviewed for impairment indicators.

No significant impairments were recorded on any investments for each of the three and six month periods ended Feb. 28, 2014, and Feb. 28, 2013.

NOTE 10. DEFERRED REVENUE

As of Feb. 28, 2014, and Aug. 31, 2013, short-term deferred revenue was $863 million and $517 million, respectively. This balance primarily consists of cash received related to Monsanto's prepayment programs in the United States and Brazil. These programs allow Monsanto's customers to receive a discount if they prepay by a certain date, and the short-term deferred revenue balance is consistent with the seasonality of Monsanto's business. Prepayment options are attractive to customers given

16

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

the discounted pricing and the ability to utilize cash flow from the current year grain harvest to pay for the next season seed purchases. The deferred revenue balance related to these prepayment programs is considered short-term in nature and thus classified in current liabilities as the prepayments are for products to be shipped within the next 12 months.

In 2008, Monsanto entered into a corn herbicide tolerance and insect control trait technologies agreement with Pioneer Hi-Bred International, Inc. Among its provisions, the agreement modified certain existing corn license agreements between the parties. Under the agreement, which requires fixed annual payments, the company recorded a receivable and deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725 million over an eight-year period. Revenue of$20 million was recorded for each of the three months ended Feb. 28, 2014, and Feb. 28, 2013, and revenue of $40 million was recorded for each of the six months ended Feb. 28, 2014, and Feb. 28, 2013. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining receivable balance is $147 million and $230 million, respectively, of which $85 million is current in both periods and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining deferred revenue balance is $119 million and $159 million, respectively, of which $79 million is included in current deferred revenue in both periods. The interest income recorded on this receivable is $1 million and $2 million for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. Interest income recorded on this receivable is $2 million and $3 million for the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.    

In 2008, Monsanto and Syngenta entered into a Genuity Roundup Ready 2 Yield Soybean License Agreement, which grants Syngenta access to Monsanto’s Genuity Roundup Ready 2 Yield Soybean technology in consideration of royalty payments from Syngenta, based on sales. The minimum obligation from Syngenta over the nine-year contract period is $81 million. Revenue of $11 million and $8 million related to this agreement was recorded for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively, and revenue of $14 million and $12 million was recorded for the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining receivable balance is $42 million and $58 million, respectively. The majority of this balance is current and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining deferred revenue balance is $27 million and $34 million, respectively, of which $20 million is included in current deferred revenue in both periods.

NOTE 11. INCOME TAXES

Monsanto recorded a tax benefit of $47 million in the first half of 2013 primarily as a result of a capital loss from a deemed liquidation of a subsidiary, the retroactive extension of the research and development credit pursuant to the enactment of the American Taxpayer Relief Act of 2012 on Jan. 2, 2013, and the favorable resolution of domestic and ex-US tax matters.

NOTE 12. DEBT AND OTHER CREDIT ARRANGEMENTS

In November 2011, Monsanto filed a new shelf registration with the SEC (2011 shelf registration) that allows the company to issue an unlimited capacity of debt, equity and hybrid offerings. The 2011 shelf registration will expire in November 2014.

In November 2013, Monsanto issued $400 million of Floating Rate Senior Notes which are due on Nov. 7, 2016, (Floating Rate Notes), $300 million of 1.85% Senior Notes which are due on Nov. 15, 2018, (2018 Senior Notes) and $300 million of 4.65% Senior Notes which are due on Nov. 15, 2043, (2043 Senior Notes). All notes were issued under the 2011 shelf registration.

The net proceeds from the sale of the Floating Rate, 2018, and 2043 Senior Notes were used for the acquisition of The Climate Corporation and general corporate purposes.

In July 2012, Monsanto issued $250 million of 2.20% Senior Notes which are due on July 15, 2022, (2022 Senior Notes) and $250 million of 3.60% Senior Notes which are due on July 15, 2042, (2042 Senior Notes). Both were issued under the 2011 shelf registration.

The net proceeds from the sale of the 2022 and 2042 Senior Notes were used for general corporate purposes, including refinancing of the company’s indebtedness.

Monsanto has a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016.

The fair value of the total short-term debt was $104 million and $51 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively. The fair value of the total long-term debt was $3,246 million and $2,231 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively.

17

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

NOTE 13. FAIR VALUE MEASUREMENTS

Monsanto determines the fair market value of its financial assets and liabilities based on quoted market prices, estimates from brokers, and other appropriate valuation techniques. The company uses the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the ASC, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with Level 3 representing the lowest level of input:

Level 1 — Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2 — Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, discounted cash flow models, or model-based valuation techniques adjusted, as necessary, for credit risk.

Level 3 — Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions would reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques could include use of option pricing models, discounted cash flow models and similar techniques.

The following tables set forth by level Monsanto’s assets and liabilities that were accounted for at fair value on a recurring basis as of Feb. 28, 2014, and Aug. 31, 2013. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.

	Fair Value Measurements at Feb. 28, 2014, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,263	$	—	$	—	$	3,263
Short-term investments	45		—		—		45
Equity securities	47		—		—		47
Derivative assets related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	5		4		—		9
Total Assets at Fair Value	$	3,360	$	12	$	—	$	3,372
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	12	$	—	$	12
Commodity contracts	51		6		—		57
Total Liabilities at Fair Value	$	51	$	18	$	—	$	69
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	104	$	—	$	104
Long-term debt instruments(1)	—		3,246		—		3,246
Total Liabilities Not Recorded at Fair Value	$	—	$	3,350	$	—	$	3,350
Total Liabilities Recorded and Not Recorded at Fair Value	$	51	$	3,368	$	—	$	3,419

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

18

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

The company’s derivative contracts are measured at fair value, including forward commodity purchase and sale contracts, exchange-traded commodity futures and option contracts, and over the counter (OTC) instruments related primarily to agricultural commodities, energy and raw materials, interest rates, and foreign currencies. Exchange-traded futures and options contracts are valued based on unadjusted quoted prices in active markets and are classified as Level 1. Fair value for forward commodity purchase and sale contracts is estimated based on exchange-quoted prices adjusted for differences in local markets. These differences are generally determined using inputs from broker or dealer quotations or market transactions in either the listed or OTC markets. When observable inputs are available for substantially the full term of the contract, it is classified as Level 2. Based on historical experience with the company’s suppliers and customers, the company’s own credit risk and knowledge of current market conditions, the company does not view nonperformance risk to be a significant input to the fair value for the majority of its forward commodity purchase and sale contracts. The effective portions of changes in the fair value of derivatives designated as cash flow hedges are recognized in the Statements of Consolidated Financial Position as a component of accumulated other comprehensive loss until the hedged items are recorded in earnings or it is probable the hedged transaction will no longer occur. Changes in the fair value of derivatives are recognized in the Statements of Consolidated Operation as a component of net sales, cost of goods sold and other expense, net.

The company’s short-term investments are comprised of commercial paper. The company’s equity securities are comprised of publicly traded equity investments. Commercial paper and publicly traded equity investments are valued using quoted market prices and are classified as Level 1.

The fair value of short-term and long-term debt was determined based on current market yields for our debt traded in the secondary market.

19

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

For the six months endedFeb. 28, 2014, and Feb. 28, 2013, the company had no transfers between Level 1, Level 2 and Level 3. Monsanto does not have any assets with fair value determined using Level 3 inputs as of Feb. 28, 2014, and Aug. 31, 2013. The following table summarizes the change in fair value of the Level 3 liability for the six months endedFeb. 28, 2014.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Feb. 28, 2014	$	—

There were no significant measurements of assets or liabilities to their implied fair value on a nonrecurring basis during the six months endedFeb. 28, 2014, and Feb. 28, 2013.

The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees, accounts payable, grower production accruals, accrued marketing programs and miscellaneous short-term accruals approximate their fair values as of Feb. 28, 2014, and Aug. 31, 2013.

Management is ultimately responsible for all fair values presented in the company’s consolidated financial statements. The company performs analysis and review of the information and prices received from third parties to ensure that the prices represent a reasonable estimate of fair value. This process involves quantitative and qualitative analysis. As a result of the analysis, if the company determines there is a more appropriate fair value based upon the available market data, the price received from the third party is adjusted accordingly.

NOTE 14. FINANCIAL INSTRUMENTS

Cash Flow Hedges

The company uses foreign currency forward and foreign currency option contracts to hedge anticipated sales or purchases denominated in foreign currencies. The company enters into these contracts to protect itself against the risk that the eventual net cash flows will be adversely affected by changes in exchange rates.

Monsanto’s commodity price risk management strategy is to use derivative instruments to minimize significant unanticipated earnings fluctuations that may arise from volatility in commodity prices. Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto uses commodity futures and options contracts to manage these risks. Monsanto’s energy and raw material risk management strategy is to use derivative instruments to minimize significant unanticipated manufacturing cost fluctuations that may arise from volatility in natural gas, diesel and ethylene prices.

Monsanto’s interest rate risk management strategy is to use derivative instruments, such as forward-starting interest rate swaps, to minimize significant unanticipated earnings fluctuations that may arise from volatility in interest rates of the company’s borrowings and to manage the interest rate sensitivity of its debt.

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

The maximum term over which the company is hedging exposures to the variability of cash flow (for all forecasted transactions) is 18 months for foreign currency hedges and 39 months for commodity hedges. During the next 12 months, a pretax net loss of approximately $50 million is expected to be reclassified from accumulated other comprehensive loss into earnings. During the three and six months endedFeb. 28, 2014, and Feb. 28, 2013, no cash flow hedges were discontinued.

Fair Value Hedges

The company uses commodity futures and options contracts as fair value hedges to manage the value of its soybean inventory. For derivative instruments that are designated and qualify as fair value hedges, both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. No fair value hedges were discontinued during the three and six months endedFeb. 28, 2014, and Feb. 28, 2013.

20

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Derivatives Not Designated as Hedging Instruments

The company uses foreign exchange contracts to hedge the effects of fluctuations in exchange rates on foreign currency denominated third-party and intercompany receivables and payables. Both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.

The company uses commodity contracts to hedge anticipated cash payments to growers in the United States, Argentina, Mexico and Brazil, which can fluctuate with changes in commodity price. Because these contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC, they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts in grain. Such payments in grain are negotiated at or near the time Monsanto’s products are sold to the customers and are valued at the prevailing grain commodity prices. By entering into forward sales contracts related to grain, Monsanto mitigates the commodity price exposure from the time a contract is signed with a customer until the time a grain merchant collects the grain from the customer on Monsanto’s behalf. The forward sales contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Monsanto uses interest rate contracts to minimize the variability of forecasted cash flows arising from one of the company’s VIEs. The interest rate contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging Topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Financial instruments are neither held nor issued by the company for trading purposes.

The notional amounts of the company’s derivative instruments outstanding as of Feb. 28, 2014, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	243	$	261
Commodity contracts	949		872
Total Derivatives Designated as Hedges	$	1,192	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,269	$	1,188
Commodity contracts	145		217
Interest rate contracts	137		—
Total Derivatives Not Designated as Hedges	$	1,551	$	1,405

21

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

The net presentation of the company’s derivative instruments outstanding was as follows:

			As of Feb. 28, 2014
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts	$	2	$	—		$	2		$	—	$	2
Total trade receivables, net			2		—			2			—		2		$	2,513	$	2,515
Miscellaneous receivables
	Derivatives not designated as hedges:
		Foreign exchange contracts	8		—			8			—		8
Total miscellaneous receivables			8		—			8			—		8		660		668
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	3		(46		)	(43		)	43		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	2		(1		)	1			1		2
Total other current assets			5		(47		)	(42		)	44		2		232		234
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	2		(4		)	(2		)	2		—
Total other assets			2		(4		)	(2		)	2		—		610		610
Total Asset Derivatives			$	17	$	(51	)	$	(34	)	$	46	$	12
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	46	$	(46	)	$	—		$	—	$	—
	Derivatives not designated as hedges:
		Commodity contracts(1)	1		(1		)	—			—		—
Total other current assets			47		(47		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other assets			4		(4		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	9		—			9			—		9
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			16		—			16			—		16		$	757	$	773
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	2		—			2			—		2
Total other liabilities			2		—			2			—		2		391		393
Total Liability Derivatives			$	69	$	(51	)	$	18		$	—	$	18

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an

22

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1

23

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

		Commodity contracts	4		—			4		—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7		—		7
Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(12	)	$	(6	)	Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	4		$	4		4			—			Net sales
Foreign currency contracts	(1		)	1			—			(1		)	Cost of goods sold
Commodity contracts(4)	18			(87		)	(10		)	43			Cost of goods sold
Interest rate contracts	—			—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	21			(82		)	(21		)	33
Derivatives Not Designated as Hedges:
Foreign currency contracts(5)							3			(1		)	Other expense, net
Commodity contracts							1			(12		)	Net sales
Commodity contracts							2			(3		)	Cost of goods sold
Total Derivatives Not Designated as Hedges							6			(16		)
Total Derivatives	$	21		$	(82	)	$	(15	)	$	17

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $2 million and $4 million from ineffectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and $2 million from ineffectiveness for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013.

(5) Gain and loss on foreign currency contracts not designated as hedges includes foreign currency transaction losses of $60 million and $34 million during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

24

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Six Months Ended						Six Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(14	)	$	—		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	2		$	3		2			(2		)	Net sales
Foreign currency contracts	(4		)	(3		)	—			2			Cost of goods sold
Commodity contracts(4)	(43		)	(100		)	(13		)	60			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(6		)	(6		)	Interest expense
Total Derivatives Designated as Hedges	(47		)	(100		)	(31		)	54
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							25			30			Other expense, net
Commodity contracts							3			(7		)	Net sales
Commodity contracts							7			1			Cost of goods sold
Total Derivatives Not Designated as Hedges							35			24
Total Derivatives	$	(47	)	$	(100	)	$	4		$	78

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $3 million and $4 million from ineffectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $2 million from ineffectiveness for each of the six months endedFeb. 28, 2014, and Feb. 28, 2013. No gains or losses were excluded from the assessment of hedge effectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the six months endedFeb. 28, 2014.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $101 million and $82 million during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

Several of the company’s outstanding foreign currency derivatives are covered by International Swap Dealers’ Association (ISDA) Master Agreements with the counterparties. There are no requirements to post collateral under these agreements; however, should Monsanto’s credit rating fall below a specified rating immediately following the merger of the company with another entity, the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be settled immediately at current market value, which equals carrying value. Foreign currency derivatives that are not covered by ISDA Master Agreements do not have credit-risk-related contingent provisions. Most of Monsanto’s outstanding commodity derivatives are listed commodity futures, and the company is required by the relevant commodity exchange to post collateral each day to cover the change in the fair value of these futures in the case of an unrealized loss position. Non-exchange-traded commodity derivatives may be covered by the aforementioned ISDA Master Agreements and would be subject to the same credit-risk-related contingent provisions. The aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a liability position was $9 million and $7 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, which is the amount that would be required for settlement if the credit-risk-related contingent provisions underlying these agreements were triggered.

25

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Credit Risk Management

Monsanto invests its excess cash in deposits with major banks or money market funds throughout the world in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of Feb. 28, 2014, and Aug. 31, 2013, the company had no financial instruments that represented a significant concentration of credit risk. Limited amounts are invested in any single institution to minimize risk. The company has not incurred any credit risk losses related to those investments.

The company sells a broad range of agricultural products to a diverse group of customers throughout the world. In the United States, the company makes substantial sales to relatively few large wholesale customers. The company’s business is highly seasonal, and it is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize the risk of loss. Collateral is secured when it is deemed appropriate by the company.

Monsanto regularly evaluates its business practices to minimize its credit risk and periodically engages multiple banks in the United States, Argentina, Brazil and Europe in the development of customer financing options that involve direct bank financing of customer purchases. For further information on these programs, see Note 4 — Customer Financing Programs.

NOTE 15. POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER

Most of Monsanto’s U.S. employees hired prior to July 8, 2012, are covered by noncontributory pension plans sponsored by the company. Effective July 8, 2012, the U.S. pension plan was closed to new entrants; there were no changes to the U.S. pension plan for eligible employees hired prior to that date. The company also provides certain postretirement health care and life insurance benefits for retired employees through insurance contracts. The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Feb. 28, 2014									Three Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	16		$	2		$	18
Interest Cost on Benefit Obligation	23			2			25			18			2			20
Assumed Return on Plan Assets	(34		)	(2		)	(36		)	(32		)	(2		)	(34		)
Amortization of Unrecognized Net Loss	15			(1		)	14			17			1			18
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	3		$	22		$	19		$	4		$	23

	Six Months Ended Feb. 28, 2014									Six Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	30		$	6		$	36		$	36		$	5		$	41
Interest Cost on Benefit Obligation	46			4			50			40			4			44
Assumed Return on Plan Assets	(69		)	(4		)	(73		)	(72		)	(4		)	(76		)
Amortization of Unrecognized Net Loss	31			—			31			38			2			40
Curtailment and Settlement Charge	—			2			2			—			2			2
Total Net Periodic Benefit Cost	$	38		$	8		$	46		$	42		$	9		$	51

26

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Health Care and Other Postretirement Benefits	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Service Cost for Benefits Earned During the Period	$	1		$	1		$	4		$	6
Interest Cost on Benefit Obligation	1			1			4			4
Amortization of Unrecognized Net Gain	(4		)	(1		)	(8		)	(4		)
Total Net Periodic Benefit Cost	$	(2	)	$	1		$	—		$	6

Monsanto contributed $30 million to its U.S. qualified plan in the six month period ended Feb. 28, 2014, and $11 million in the six month period ended Feb. 28, 2013. Monsanto contributed $12 million to plans outside the United States in the six month period ended Feb. 28, 2014, and$9 million in the six month period ended Feb. 28, 2013. As of Feb. 28, 2014, management expects to make additional contributions of approximately $30 million and $6 million to the company’s pension plans in the United States and outside the United States, respectively, during the remainder of fiscal year 2014.

NOTE 16. STOCK-BASED COMPENSATION PLANS

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the six months ended Feb. 28,2014, and Feb. 28, 2013. Stock-based compensation cost capitalized in inventory was $3 million as of both Feb. 28, 2014, and Aug. 31, 2013.

	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Cost of Goods Sold	$	2		$	3		$	4		$	7
Selling, General and Administrative Expenses	23			18			43			33
Research and Development Expenses	5			5			10			10
Pre-Tax Stock-Based Compensation Expense	30			26			57			50
Income Tax Benefit	(10		)	(9		)	(19		)	(17		)
Net Stock-Based Compensation Expense	$	20		$	17		$	38		$	33

The following table summarizes stock-based compensation activity for and as of the six months endedFeb. 28, 2014. Monsanto Stock Plans include employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012 and employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013. The Director Plan includes members of the Board of Directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan.

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,285,346		927,909		18,520		2,554
Weighted-average grant date fair value per share	$	38.34	$	101.30	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	$	91.4	$	113.9	$	0.9	$	0.1
Remaining weighted-average period of expense recognition/requisite service periods (in years)	2		2		1		1

27

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

NOTE 17. ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the six months ended Feb. 28, 2014:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	79			8		(31		)	—			56
Amounts reclassified from accumulated other comprehensive loss	—			1		11			14			26
Net current-period other comprehensive income (loss)	79			9		(20		)	14			82
Balance as of Feb. 28, 2014	$	(752	)	$	17	$	(135	)	$	(326	)	$	(1,196	)

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three and six months ended Feb. 28, 2014:

	Amount Reclassified from Accumulated Other Comprehensive Loss						Affected Line Item in the Statement of Consolidated Operations
	Three months ended Feb. 28, 2014			Six months ended Feb. 28, 2014
Net Unrealized Gain on Available for Sale Securities:
Impairment	$	1		$	1		Other expense, net
	1			1			Total before income taxes
	—			—			Income tax provision
	$	1		$	1		Net of tax
Cash Flow Hedges:
Foreign Exchange Contracts	$	(4	)	$	(2	)	Net sales
Commodity Contracts	10			13			Cost of goods sold
Interest Rate Contracts	3			6			Interest expense
	9			17			Total before income taxes
	(3		)	(6		)	Income tax provision
	$	6		$	11		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		$	6		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	7			17			Selling, general and administrative expenses
	10			23			Total before income taxes
	(4		)	(9		)	Income tax provision
	$	6		$	14		Net of tax
Total Reclassifications For The Period	$	13		$	26		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million and $6 million of net periodic benefit cost to inventory, of which approximately $2 million and $6 million was recognized in cost of goods sold during the three and six months ended Feb. 28, 2014, respectively. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

28

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

NOTE 18. EARNINGS PER SHARE

Basic earnings per share (EPS) was computed using the weighted-average number of common shares outstanding during the periods shown in the table below. The diluted EPS computation takes into account the effect of dilutive potential common shares, as shown in the table below. Potential common shares consist primarily of stock options, restricted stock, restricted stock units and directors’ deferred shares calculated using the treasury stock method and are excluded if their effect is antidilutive. Of those antidilutive options, certain options were excluded from the computations of dilutive potential common shares as their exercise prices were greater than the average market price of the common shares for the period.

	Three Months Ended		Six Months Ended
(Shares in millions)	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Weighted-Average Number of Common Shares	524.8	534.8	525.9	534.8
Dilutive Potential Common Shares	5.5	6.1	5.7	6.1
Antidilutive Potential Common Shares	1.7	1.9	1.8	1.9
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	—	0.1	0.1	0.1

NOTE 19. SUPPLEMENTAL CASH FLOW INFORMATION

Cash payments for interest and taxes were as follows:

	Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013
Interest	$	80	$	98
Taxes	233		288

In second quarter2014 and 2013, the board of directors declared a dividend which is payable in third quarter 2014 and 2013, respectively. As of Feb. 28, 2014, and Feb. 28, 2013, a dividend payable of $226 million and $201 million, respectively, was recorded.

NOTE 20. COMMITMENTS AND CONTINGENCIES

Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and legal proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. In addition, Monsanto has liabilities established for various product claims. With respect to certain of these proceedings, Monsanto has a liability recorded of $271 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, for the estimated contingent liabilities. Information regarding the environmental liabilities appears in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Litigation: The above liability includes amounts related to certain third-party litigation with respect to Monsanto’s business, as well as tort litigation related to Pharmacia’s former chemical business, including lawsuits involving polychlorinated biphenyls (PCBs), dioxins, and other chemical and premises liability litigation. Additional matters that are not reflected in the liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages with respect thereto in order to mitigate contesting potential liability. Following is a description of one of the more significant litigation matters reflected in the liability.

• As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, and our Report on Form 10-Q for the quarterly period ended Nov. 30, 2013, on Dec. 17, 2004, 15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al. v. Monsanto, et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia and seven other defendants. Monsanto is named as the successor in interest to the liabilities of Pharmacia. The alleged class consists of all current and former residents, workers, and students who, between 1949 and the present, were allegedly exposed to dioxins/furans contamination in counties surrounding Nitro, West Virginia. The complaint alleges that the source of the contamination is a chemical plant in Nitro, formerly owned and operated by Pharmacia and later by Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc. (Akzo Nobel). Akzo Nobel and Flexsys were named defendants

29

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

in the case but Solutia was not, due to its then pending bankruptcy proceeding. The suit seeks damages for property cleanup costs, loss of real estate value, funds to test property for contamination levels, funds to test for human exposure, and future medical monitoring costs. The complaint also seeks an injunction against further contamination and punitive damages. Monsanto has agreed to indemnify and defend Akzo Nobel and the Flexsys defendant group, but on May 27, 2011, the judge dismissed both Akzo Nobel and Flexsys from the case. The class action certification hearing was held on Oct. 29, 2007. On Jan. 8, 2008, the trial court issued an order certifying the Allen (now Zina G. Bibb et al. v. Monsanto et al., because Bibb replaced Allen as class representative) case as a class action for property damage and for medical monitoring. On Nov. 2, 2011, the court, in response to defense motions, entered an order decertifying the property class. After the trial for the Bibb medical monitoring class action began on Jan. 3, 2012, the parties reached a settlement in principle as to both the medical monitoring and the property class claims. The proposed settlement provides for a 30 year medical monitoring program consisting of a primary fund of up to $21 million and an additional fund of up to $63 million over the life of the program, and a three year property remediation plan with funding up to $9 million. On Feb. 24, 2012, the court preliminarily approved the parties’ proposed settlement. A fairness hearing was held June 18, 2012, resulting in the trial court's final approval of the settlement. Certain plaintiffs objected to the approval of the settlement and appealed to the West Virginia Supreme Court of Appeals. On Nov. 22, 2013, the West Virginia Supreme Court of Appeals dismissed the appeal and upheld the fairness of the class action settlements. On Jan. 21, 2014, the objector filed a petition for writ of certiorari, which we opposed, with the U.S. Supreme Court.

In October 2007 and November 2009, a total of approximately 200 separate, single plaintiff civil actions were filed in Putnam County, West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and several of its affiliates), Flexsys America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. These cases allege personal injury occasioned by exposure to dioxin generated by the Nitro Plant during production of 2,4,5T (1949-1969) and thereafter. Monsanto has agreed to accept the tenders of defense in the matters by Pharmacia, Solutia, Akzo Nobel, Flexsys America, and Apogee Coal under a reservation of rights. During the discovery phase of these several claims, the parties reached an agreement in principle to resolve all pending personal injury claims which is reflected in the above liability.

Including litigation reflected in the liability, Monsanto is involved in various legal proceedings that arise in the ordinary course of its business or pursuant to Monsanto’s indemnification obligations to Pharmacia, as well as proceedings that management has considered to be material under SEC regulations. Some of the lawsuits seek damages in very large amounts, or seek to restrict the company’s business activities. Monsanto believes that it has meritorious legal arguments and will continue to represent its interests vigorously in all of the proceedings that it is defending or prosecuting. Management does not anticipate the ultimate liabilities resulting from such proceedings, or the proceedings reflected in the above liability, will have a material adverse effect on Monsanto’s consolidated results of operations, financial position, cash flows or liquidity.

Legal actions have been filed in Brazil that raise issues challenging the right to collect certain royalties for Roundup Ready soybeans. Although Brazilian law clearly states that the pipeline patents protecting these products have the duration of the corresponding U.S. patent (2014 for Roundup Ready soybeans), the duration (and application) of these pipeline patents is currently under judicial review in Brazil. Monsanto believes it has meritorious legal arguments and will continue to represent its interests vigorously in these proceedings. The current estimate of the company’s reasonably possible loss contingency is not material to consolidated results of operations, financial position, cash flows or liquidity.

Other Contingencies: The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith.  It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in the United States, Brazil, Europe, and Argentina can be found in Note 4 — Customer Financing Programs — of this Form 10-Q. Except as described in that note, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2013. Disclosures regarding these guarantees made by Monsanto can be found in Note 26 — Commitments and Contingencies — of the notes to the consolidated financial statements contained in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Off-Balance Sheet Arrangement: In December 2013, Monsanto executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements Monsanto has transferred the Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables the company to reduce the cost of constructing and operating the expansion by reducing certain state and local tax expenditures. Monsanto immediately

30

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

leased the facility back from the County of St. Louis and has an option to purchase the facility upon tendering the Industrial Revenue Bonds received to the County. The payments due to the company in relation to the Industrial Revenue Bonds and owed by the company in relation to the lease of the facilities qualify for the right of offset under ASC 210, Balance Sheet, on the Statements of Consolidated Financial Position. As such, neither the Industrial Revenue Bonds nor the lease obligation are recorded on the Statements of Consolidated Financial Position as an asset or liability, respectively. The Chesterfield facilities and the expansion is being treated as being owned by Monsanto.

NOTE 21. SEGMENT INFORMATION

Monsanto conducts its worldwide operations through global businesses, which are aggregated into reportable segments based on similarity of products, production processes, customers, distribution methods and economic characteristics. The operating segments are aggregated into two reportable segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Within the Seeds and Genomics segment, Monsanto’s significant operating segments are corn seed and traits, soybean seed and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The Agricultural Productivity reportable segment consists of the Agricultural Productivity operating segment. EBIT is defined as earnings before interest and taxes and is an operating performance measure for the two reportable segments. EBIT is useful to management in demonstrating the operational profitability of the segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. Sales between segments were not significant. Certain SG&A expenses are allocated between segments based on the segment’s relative contribution to total Monsanto operations. Allocation percentages remain relatively consistent for fiscal years 2013 and 2014.

31

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Net Sales(1)
Corn seed and traits	$	3,414	$	3,280	$	4,468	$	4,419
Soybean seed and traits	820		677		1,087		908
Cotton seed and traits	49		60		186		245
Vegetable seeds	219		199		376		355
All other crops seeds and traits	146		130		207		174
Total Seeds and Genomics	$	4,648	$	4,346	$	6,324	$	6,101
Agricultural productivity	1,184		1,126		2,651		2,310
Total Agricultural Productivity	$	1,184	$	1,126	$	2,651	$	2,310
Total	$	5,832	$	5,472	$	8,975	$	8,411

Gross Profit
Corn seed and traits	$	2,253	$	2,083	$	2,903	$	2,769
Soybean seed and traits	539		395		707		513
Cotton seed and traits	28		44		120		171
Vegetable seeds	96		106		164		189
All other crops seeds and traits	77		71		104		82
Total Seeds and Genomics	$	2,993	$	2,699	$	3,998	$	3,724
Agricultural productivity	454		371		1,012		743
Total Agricultural Productivity	$	454	$	371	$	1,012	$	743
Total	$	3,447	$	3,070	$	5,010	$	4,467

EBIT(2)(3)
Seeds and Genomics	$	2,055	$	1,840	$	2,159	$	2,060
Agricultural Productivity	308		256		758		526
Total	$	2,363	$	2,096	$	2,917	$	2,586

Depreciation and Amortization Expense
Seeds and Genomics	$	140	$	123	$	271	$	246
Agricultural Productivity	30		30		61		59
Total	$	170	$	153	$	332	$	305

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $8 million and $22 million for the three and six months ended Feb. 28, 2014, respectively. Agricultural Productivity EBIT includes income from operations of discontinued businesses of $6 million and $17 million for the three and six months ended Feb. 28, 2013, respectively.

32

MONSANTO COMPANY	SECOND QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
EBIT(1)	$	2,363	$	2,096	$	2,917	$	2,586
Interest Expense — Net	17		8		46		36
Income Tax Provision(2)	676		605		833		728
Net Income Attributable to Monsanto Company	$	1,670	$	1,483	$	2,038	$	1,822

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Background

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Our seeds, biotechnology trait products and herbicides provide farmers with solutions that help improve productivity, reduce the costs of farming and produce better foods for consumers and better feed for animals.

We manage our business in two segments: Seeds and Genomics and Agricultural Productivity. Through our Seeds and Genomics segment, we produce leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and we develop biotechnology traits that assist farmers in controlling insects and weeds and precision agriculture to assist farmers in decision making. We also provide other seed companies with genetic material and biotechnology traits for their seed brands. Through our Agricultural Productivity segment, we manufacture Roundup and Harness brand herbicides and other herbicides.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with Monsanto’s consolidated financial statements and the accompanying notes. This Report on Form 10-Q should also be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first six months of fiscal year 2014 should not be annualized because of the seasonality of our business. The notes to the consolidated financial statements referred to throughout this MD&A are included in Part I — Item 1 — Financial Statements — of this Report on Form 10-Q. Unless otherwise indicated, “Monsanto,” the “company,” “we,” “our” and “us” are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Unless otherwise indicated, “earnings per share” and “per share” mean diluted earnings per share. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its subsidiaries are shown in special type. Unless otherwise noted, all amounts and analyses are based on continuing operations. Unless otherwise indicated, references to “Roundup herbicides” mean Roundup branded herbicides, excluding all lawn-and-garden herbicides, and references to “Roundup and other glyphosate-based herbicides” exclude all lawn-and-garden herbicides.

Non-GAAP Financial Measures

MD&A includes financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), as well as two other financial measures, EBIT and free cash flow, that are considered “non-GAAP financial measures.” Generally, a non-GAAP financial measure is a numerical measure of a company’s financial performance, financial position or cash flows that exclude (or include) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of EBIT and free cash flow information is intended to supplement investors’ understanding of our operating performance and liquidity. Our EBIT and free cash flow measures may not be comparable to other companies’ EBIT and free cash flow measures. Furthermore, these measures are not intended to replace net income (loss), cash flows, financial position, or comprehensive income (loss), as determined in accordance with GAAP.

33

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

EBIT is defined as earnings (loss) before interest and taxes. Earnings (loss) is intended to mean net income (loss) attributable to Monsanto as presented in the Statements of Consolidated Operations under GAAP. EBIT is an operating performance measure for our two business segments. We believe that EBIT is useful to investors and management to demonstrate the operational profitability of our segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. EBIT is also one of the measures used by Monsanto management to determine resource allocations within the company. See Note 21— Segment Information — for a reconciliation of EBIT to net income for the three and six months ended Feb. 28, 2014, and Feb. 28, 2013.

We also provide information regarding free cash flow, an important liquidity measure for Monsanto. We define free cash flow as the total of net cash provided or required by operating activities and net cash provided or required by investing activities. Free cash flow does not represent the residual cash flow available for discretionary expenditures. We believe that free cash flow is useful to investors and management as a measure of the ability of our business to generate cash. Once business needs and obligations are met, this cash can be used to reinvest in the company for future growth or to return to our shareowners through dividend payments or share repurchases. Free cash flow is also used by management as one of the performance measures in determining incentive compensation. See the “Financial Condition, Liquidity and Capital Resources - Cash Flow” section of MD&A for a reconciliation of free cash flow to net cash provided by operating activities and net cash required by investing activities on the Statements of Consolidated Cash Flows.

Executive Summary

Consolidated Operating Results — Net sales increased $360 million, or 7 percent, in the three-month comparison and $564 million, or 7 percent, in the six-month comparison. The primary contributor to the increase in second quarter 2014 was an increase in soybean and corn seeds and traits. The increase in soybean seed and traits was driven by increased licensed trait revenue in the United States and the launch of Intacta RR2 PRO, primarily in Brazil. The increase in corn seed and traits was primarily driven by increases in pricing in the United States and volume growth in Europe, offset by lower volume in Latin America and the United States and unfavorable foreign currency changes.

The primary contributor to the increase in the first half of 2014 was an increase in Roundup and other glyphosate-based herbicides and soybean seed and traits. The increase in Roundup and other glyphosate-based herbicides was due to an increase in the average net selling price. The increase in soybean seed and traits again was driven by increased licensed trait revenue in the United States and the launch of Intacta RR2 PRO, primarily in Brazil.

Net income attributable to Monsanto Company in the first half of 2014 was $3.83 per share, compared with $3.37 per share in the first half of 2013.

Financial Condition, Liquidity and Capital Resources — In the first half of 2014, working capital was $6,499 million compared with $6,825 million in the first half of 2013, a decrease of $326 million, and compared with $5,741 million at Aug. 31, 2013, an increase of $758 million. For a detailed discussion of the factors affecting the working capital comparison, see the "Working Capital and Financial Condition" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

In the first half of 2014, net cash provided by operating activities was $1,846 million compared with $1,857 million in first half of 2013. Net cash required by investing activities was $1,556 million in the first half of 2014 compared with $301 million in the first half of 2013. Free cash flow was $290 million in the first half of 2014 compared with $1,556 million in the first half of 2013. For a detailed discussion of the factors affecting the free cash flow comparison, see the "Cash Flow" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

In first half of 2014, our debt-to-capital ratio was 19 percent compared with 14 percent at Feb. 28, 2013, and Aug. 31, 2013, an increase of 5 percentage points. The increases were primarily driven by the $1 billion debt issuance that occurred in November 2013, offset by the increase in shareowners' equity as a result of increased earnings.

In February 2014, we entered into a collaboration agreement with Novozymes to launch a BioAg Alliance. Monsanto paid Novozymes an aggregate upfront cash payment of $300 million for recognition of Novozymes ongoing business and capabilities in microbials and for Novozymes' ability to supply the alliance products. For a detailed discussion see the "Capital Resources and Liquidity" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

Outlook — We plan to continue to innovate and improve our products in order to maintain market leadership and to support near-term performance. We are focused on applying innovation and technology to make our farmer customers more productive and profitable by protecting and improving yields and improving the ways they can produce food, fiber, feed and fuel. We use the tools of modern biology and technology in an effort to make seeds easier to grow, to allow farmers to do more with fewer resources, and to help produce healthier foods for consumers. Our current R&D strategy and commercial priorities are focused on bringing our farmer customers second- and third-generation traits, on delivering multiple solutions in one seed (“stacking”),

34

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

and on developing new pipeline products. Our capabilities in biotechnology and breeding research are generating a rich product pipeline that is expected to drive long-term growth. The viability of our product pipeline depends in part on the speed of regulatory approvals globally, continued patent and legal rights to offer our products, general public acceptance of the products and the value they will deliver to the market.

Roundup herbicides remain the largest crop protection brand globally. We have oriented the focus of Monsanto’s crop protection business to strategically support Monsanto’s Roundup Ready crops through our weed management platform that delivers weed control offerings for farmers. We are focused on managing the costs associated with our agricultural chemistry business as that sector matures globally.

See the “Outlook” section of MD&A for a more detailed discussion of some of the opportunities and risks we have identified for our business. For additional information related to the outlook for Monsanto, see “Caution Regarding Forward-Looking Statements” at the beginning of this Report on Form 10-Q, Part II — Item 1A — Risk Factors below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

New Accounting Pronouncements — See Note 2 — New Accounting Standards — for a description of recently issued and adopted accounting pronouncements, including the dates of adoption and impacts on our results of operations, financial position and cash flows, as applicable.

35

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

RESULTS OF OPERATIONS

	Three Months Ended								Six Months Ended
(Dollars in millions, except per share amounts)	Feb. 28, 2014			Feb. 28, 2013			Change		Feb. 28, 2014			Feb. 28, 2013			Change
Net Sales	$	5,832		$	5,472		7	%	$	8,975		$	8,411		7	%
Cost of goods sold	2,385			2,402			(1	)%	3,965			3,944			1	%
Gross Profit	3,447			3,070			12	%	5,010			4,467			12	%
Operating Expenses:
Selling, general and administrative expenses	625			598			5	%	1,214			1,140			6	%
Research and development expenses	404			360			12	%	813			706			15	%
Total Operating Expenses	1,029			958			7	%	2,027			1,846			10	%
Income from Operations	2,418			2,112			14	%	2,983			2,621			14	%
Interest expense	40			35			14	%	93			86			8	%
Interest income	(23		)	(27		)	(15	)%	(47		)	(50		)	(6	)%
Other expense, net	61			22			177	%	81			39			108	%
Income from Continuing Operations Before Income Taxes	2,340			2,082			12	%	2,856			2,546			12	%
Income tax provision	672			603			11	%	824			725			14	%
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	1,668			1,479			13	%	2,032			1,821			12	%
Discontinued Operations:
Income from operations of discontinued businesses	8			6			NM		22			17			NM
Income tax provision	4			2			NM		9			6			NM
Income from Discontinued Operations	4			4			NM		13			11			NM
Net Income	$	1,672		$	1,483		13	%	$	2,045		$	1,832		12	%
Less: Net income attributable to noncontrolling interest	2			—			NM		7			10			NM
Net Income Attributable to Monsanto Company	$	1,670		$	1,483		13	%	$	2,038		$	1,822		12	%
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	3.15		$	2.73		15	%	$	3.81		$	3.35		14	%
Income from discontinued operations	—			0.01			NM		0.02			0.02			NM
Net Income Attributable to Monsanto Company	$	3.15		$	2.74		15	%	$	3.83		$	3.37		14	%
NM = Not Meaningful
Effective Tax Rate	29		%	29		%			29		%	28		%
Comparison as a Percent of Net Sales:
Cost of Goods Sold	41		%	44		%			44		%	47		%
Gross Profit	59		%	56		%			56		%	53		%
Selling, general and administrative expenses	11		%	11		%			14		%	14		%
Research and development expenses	7		%	7		%			9		%	8		%
Total operating expenses	18		%	18		%			23		%	22		%
Income from continuing operations before income taxes	40		%	38		%			32		%	30		%
Net income attributable to Monsanto Company	29		%	27		%			23		%	22		%

36

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Second Quarter Fiscal Year 2014

The following explanations discuss the significant components of our results of operations that affected the quarter-to-quarter comparison of our second quarter income from continuing operations:

Net sales increased $360 million in second quarter2014 from the same quarter a year ago. Our Seeds and Genomics segment net sales increased $302 million, and our Agricultural Productivity segment net sales increased $58 million in the three-month comparison.

The following table presents the percentage changes in second quarter2014 worldwide net sales by segment compared with net sales in the prior-year quarter, including the effects of volume, price and currency:

	Second Quarter 2014 Percentage Change in Net Sales vs. Second Quarter 2013
	Volume(1)	Price(2)	Currency	Total
Seeds and Genomics Segment	3%	5%	(1)%	7%
Agricultural Productivity Segment	1%	5%	(1)%	5%
Total Monsanto Company	3%	5%	(1)%	7%

(1) Includes the affects of unit volume change and some affects of mix.

(2) Includes the affects of unit price/cost change and some affects of mix.

Cost of goods sold for the total company decreased $17 million in the three-month comparison. Cost of goods sold as a percent of net sales for the total company decreased 3 percentage points to 41 percent. Our Seeds and Genomics segment cost of goods sold as a percent of net sales decreased 2 percent percentage points to 36 percent, and our Agricultural Productivity segment cost of goods sold as a percent of net sales decreased 5 percentage points to 62 percent.

The following table represents the percentage changes in second quarter2014 worldwide cost of goods sold by segment compared with cost of goods sold in the prior-year quarter, including the effects of volume, costs and currency:

	Second Quarter 2014 Percentage Change in Cost of Goods Sold vs. Second Quarter 2013
	Volume(1)	Costs(2)	Currency	Total
Seeds and Genomics Segment	4%	(2)%	(2)%	—%
Agricultural Productivity Segment	—%	(1)%	(2)%	(3)%
Total Monsanto Company	2%	(1)%	(2)%	(1)%

(1) Includes the affects of unit volume change and some affects of mix.

(2) Includes the affects of unit price/cost change and some affects of mix.

Gross profit increased $377 million in the three-month comparison. Gross profit as a percent of net sales for the total company increased 3 percentage points to 59 percent in the second quarter2014. Our Seeds and Genomics segment gross profit as a percent of net sales increased 2 percent percentage points to 64 percent, and our Agricultural Productivity segment gross profit as a percent of net sales increased 5 percentage points to 38 percent.

For a detailed discussion of the factors affecting net sales, cost of goods sold and gross profit comparison, see the “Seeds and Genomics Segment” and the “Agricultural Productivity Segment” sections.

Operating expenses increased $71 million in second quarter2014 compared to the prior-year comparable quarter. In the second quarter 2014, selling, general and administrative (SG&A) increased $27 million primarily due to increased investment in additional growth platforms, including the acquisition of The Climate Corporation and increased activity related to administrative functions. In the second quarter 2014, R&D increased $44 million primarily because of The Climate Corporation acquisition, breeding expansion and increased investment in our product pipeline. As a percent of net sales, SG&A expenses remained consistent at 11 percent, and R&D expenses remained consistent at 7 percent.

Other expense — net increased $39 million in the second quarter 2014 compared to the prior-year comparable quarter. The increase was primarily the result of current period foreign currency losses largely related to the Argentina currency devaluation.

Income tax provision was $672 million in second quarter 2014, an increase of $69 million over the prior-year quarter, primarily as a result of the increase in pretax income. The effective tax rate was 29 percent in second quarter 2014 and in

37

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

second quarter 2013. We recorded a discrete tax charge of $1 million during second quarter 2014, primarily as a result of deferred tax adjustments. We recorded a discrete tax benefit of $25 million during second quarter 2013. The majority of this benefit resulted from the retroactive extension of the R&D credit pursuant to the enactment of the American Taxpayer Relief Act of 2012 on Jan. 2, 2013, and the favorable resolution of domestic and ex-US tax matters.

First Half of Fiscal Year 2014

The following explanations discuss the significant components of our results of operations that affected the six-month comparison of our first half of fiscal years 2014 and 2013 income from continuing operations:

Net sales increased $564 million in the first half of 2014 from the same period a year ago. Our Seeds and Genomics segment net sales increased $223 million, and our Agricultural Productivity segment net sales increased $341 million.

The following table presents the percentage changes in the first half of 2014 worldwide net sales by segment compared with net sales in the prior-year first half, including the effects of volume, price and currency:

	First Half 2014 Percentage Change in Net Sales vs. First Half 2013
	Volume(1)		Price(2)		Currency		Total
Seeds and Genomics Segment	(1	)%	7	%	(2	)%	4	%
Agricultural Productivity Segment	4	%	14	%	(3	)%	15	%
Total Monsanto Company	1	%	8	%	(2	)%	7	%

(1) Includes the affects of unit volume change and some affects of mix.

(2) Includes the affects of unit price/cost change and some affects of mix.

Cost of goods sold increased $21 million in the first half of 2014 from the same period a year ago. Cost of goods sold as a percent of net sales for the total company decreased 3 percentage points to 44 percent. Our Seeds and Genomics segment cost of goods sold as a percent of net sales decreased 2 percentage points to 37 percent, and our Agricultural Productivity segment cost of goods sold as a percent of net sales decreased 6 percentage points to 62 percent.

The following table represents the percentage changes in the first half of 2014 worldwide cost of goods sold by segment compared with cost of goods sold in the first half of prior-year, including the effects of volume, costs and currency:

	First Half 2014 Percentage Change in Cost of Goods Sold vs. First Half 2013
	Volume(1)		Costs(2)		Currency		Total
Seeds and Genomics Segment	—	%	—	%	(2	)%	(2	)%
Agricultural Productivity Segment	4	%	3	%	(2	)%	5	%
Total Monsanto Company	2	%	1	%	(2	)%	1	%

(1) Includes the affects of unit volume change and some affects of mix.

(2) Includes the affects of unit price/cost change and some affects of mix.

Gross profit increased $543 million in the first half of 2014. Gross profit as a percent of net sales for the total company increased 3 percentage points 56 percent in the first half of 2014. Our Seeds and Genomics segment gross profit as a percent of net sales increased 2 percentage points to 63 percent, and our Agricultural Productivity segment gross profit as a percent of net sales increased 6 percentage points to 38 percent.

For a detailed discussion of the factors affecting net sales, cost of goods sold and gross profit comparison, see the “Seeds and Genomics Segment” and the “Agricultural Productivity Segment” sections.

Operating expenses increased $181 million in the first half of 2014 from the prior-year comparable period. In the six-month comparison, SG&A expenses increased $74 million primarily because of our increased investment in additional growth platforms, including the acquisition of The Climate Corporation, and increased activity related to administrative functions. R&D expenses increased $107 million due to The Climate Corporation acquisition, breeding expansion and increased investment in our product pipeline. As a percent of net sales, SG&A expenses remained consistent at 14 percent, and R&D expenses increased 1 percentage point to 9 percent.

Other expense — net increased $42 million in the first half of 2014. The increase was primarily the result of current period foreign currency losses largely related to the Argentine peso.

38

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Income tax provision was $824 million in the first half of 2014, an increase of $99 million from the prior-year comparable period, primarily as a result of the increase in pretax income. The effective tax rate increased to 29 percent from 28 percent in the prior year comparable period. We recorded a discrete tax benefit of $6 million during the first half of 2014, primarily as a result of deferred tax adjustments. The first half of 2013 included several discrete tax adjustments resulting in a tax benefit of $47 million. The majority of this benefit resulted from a capital loss from a deemed liquidation of a subsidiary, the retroactive extension of the R&D credit pursuant to the enactment of the American Taxpayer Relief Act of 2012 on Jan. 2, 2013, and the favorable resolution of domestic and ex-US tax matters. 

SEEDS AND GENOMICS SEGMENT

	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Change		Feb. 28, 2014		Feb. 28, 2013		Change
Net Sales
Corn seed and traits	$	3,414	$	3,280	4	%	$	4,468	$	4,419	1	%
Soybean seed and traits	820		677		21	%	1,087		908		20	%
Cotton seed and traits	49		60		(18	)%	186		245		(24	)%
Vegetable seeds	219		199		10	%	376		355		6	%
All other crops seeds and traits	146		130		12	%	207		174		19	%
Total Net Sales	$	4,648	$	4,346	7	%	$	6,324	$	6,101	4	%
Gross Profit
Corn seed and traits	$	2,253	$	2,083	8	%	$	2,903	$	2,769	5	%
Soybean seed and traits	539		395		36	%	707		513		38	%
Cotton seed and traits	28		44		(36	)%	120		171		(30	)%
Vegetable seeds	96		106		(9	)%	164		189		(13	)%
All other crops seeds and traits	77		71		8	%	104		82		27	%
Total Gross Profit	$	2,993	$	2,699	11	%	$	3,998	$	3,724	7	%
EBIT(1)	$	2,055	$	1,840	12	%	$	2,159	$	2,060	5	%

(1) EBIT is defined as earnings before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 21 — Segment Information and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details.

Seeds and Genomics Financial Performance — Second Quarter Fiscal Year 2014

The net sales increase of $143 million in soybean seeds and traits was driven by increased licensed trait revenue in the United States and the launch of Intacta RR2 PRO, primarily in Brazil. The net sales increase of $134 million in corn seed and traits was primarily driven by increases in pricing in the United States and volume growth in Europe, offset by lower volume in Latin America and the United States and unfavorable foreign currency changes. The pricing increases were driven by improved germplasm and trait mix in the United States. Volume growth was driven by market share growth in Eastern Europe offset by lower planted areas in Latin America and the United States.

Cost of goods sold in the Seeds and Genomics segment primarily represents field growing, plant processing and distribution costs. Cost of goods sold increased $8 million to $1,655 million in the second quarter 2014 compared to $1,647 million in the second quarter 2013. The increase was primarily the result of the corn seed and trait volume growth in Europe and higher obsolescence expense in the vegetable seed business offset by lower costs in the corn seed and traits business in the United States.

Gross profit for the Seeds and Genomics segment increased $294 million in the second quarter of fiscal year 2014 compared to the second quarter of fiscal year 2013. Gross profit as a percent of net sales for the segment increased 2 percentage points to 64 percent in the second quarter of 2014 compared to the second quarter of 2013. Gross profit for soybean seed and traits increased 36 percent compared to the 21 percent increase in net sales primarily due to the increase in trait revenue in the United States and Brazil.

Seeds and Genomics Financial Performance — First Half Fiscal Year 2014

The net sales increase of $179 million in soybean seeds and traits was driven by increased licensed trait revenue in the United States and the launch of Intacta RR2 PRO, primarily in Brazil. The net sales decrease of $59 million in cotton seed and traits was driven primarily by unfavorable foreign currency changes and lower planted area in Australia due to decreased cotton commodity prices. The net sales increase of $49 million in corn seed and traits was primarily driven by increases in pricing in

39

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

the United States and volume growth in Europe, offset by lower volumes in Latin America and the United States and unfavorable foreign currency changes. The pricing increases were driven by improved germplasm and trait mix in the United States. Volume growth was driven by market share growth in Eastern Europe offset by lower planted areas in Latin America and the United States.

Cost of goods sold in the Seeds and Genomics segment primarily represents field growing, plant processing and distribution costs. Cost of goods sold decreased $51 million, or 2 percent, to $2,326 million in the first half of 2014 compared to $2,377 million in the first half of 2013. The decrease was primarily the result of lower costs in the corn seed and traits business in the United States offset by higher obsolescence expense in the vegetable seed business.

Gross profit for the Seeds and Genomics segment increased $274 million in the first half of fiscal year 2014 compared to the first half of fiscal year 2013. Gross profit as a percent of net sales for the segment increased 2 percentage points to 63 percent in the first half of fiscal year 2014 compared to the first half of fiscal year 2013. Gross profit for soybean seed and traits increased 38 percent compared to the 20 percent increase in net sales primarily due to the increase in trait revenue in the United States and Brazil. Gross profit for cotton seed and traits decreased 30 percent compared to the 24 percent decrease in net sales primarily due to the lower Australia revenue as noted in the net sales discussion.

AGRICULTURAL PRODUCTIVITY SEGMENT

	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Change		Feb. 28, 2014		Feb. 28, 2013		Change
Net Sales
Agricultural productivity	$	1,184	$	1,126	5	%	$	2,651	$	2,310	15	%
Total Net Sales	$	1,184	$	1,126	5	%	$	2,651	$	2,310	15	%
Gross Profit
Agricultural productivity	$	454	$	371	22	%	$	1,012	$	743	36	%
Total Gross Profit	$	454	$	371	22	%	$	1,012	$	743	36	%
EBIT(1)	$	308	$	256	20	%	$	758	$	526	44	%

(1) EBIT is defined as earnings before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 21 — Segment Information — and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details.

Agricultural Productivity Financial Performance — Second Quarter Fiscal Year 2014

Net sales in our Agricultural Productivity segment increased $58 million in the second quarter of 2014 from the second quarter of 2013 primarily due to increased sales of Roundup and other glyphosate-based herbicides in the United States, Latin America and Europe during the three-month period. This improvement was due to an increase in the average net selling price of Roundup and other glyphosate-based herbicides as sales shifted to higher priced branded products in the first half of fiscal year 2014 compared to the first half of fiscal year 2013.

Cost of goods sold in the Agricultural Productivity segment primarily represents material, conversion and distribution costs. Cost of goods sold decreased $25 million, or 3 percent, in the second quarter of 2014 to $730 million compared to $755 million in the second quarter of 2013. Roundup and other glyphosate-based herbicides cost of goods sold declined from the lower sales volume of our Roundup and other glyphosate-based herbicides business partially offset by higher cost of goods sold as fiscal year 2014 sales shifted to branded products, which are more costly to produce.

The net sales and cost of goods sold discussed above resulted in $83 million higher gross profit in the second quarter of 2014 compared to the second quarter of 2013. Gross profit as a percent of net sales for the Agricultural Productivity segment increased 5 percentage points to 38 percent in 2014 primarily due to the increased average net selling price discussed above.

Agricultural Productivity Financial Performance — First Half Fiscal Year 2014

Net sales in our Agricultural Productivity segment increased $341 million in the six-month period primarily due to increased sales of Roundup and other glyphosate-based herbicides in the United States, Latin America and Europe. This improvement was due to an increase in the average net selling price of Roundup and other glyphosate-based herbicides.  In addition, the average net selling price for Roundup and other glyphosate-based herbicides increased as sales shifted to higher priced branded products in the first half of fiscal year 2014 compared to the first half of fiscal year 2013.

40

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

Cost of goods sold in the Agricultural Productivity segment primarily represents material, conversion and distribution costs. Cost of goods sold increased $72 million, or 5 percent, in the first half of 2014 to $1,639 million compared to $1,567 million in the first half of 2013. Roundup and other glyphosate-based herbicides cost of goods sold increased as fiscal year 2014 sales shifted to branded products, which are more costly to produce. In addition, the cost of goods sold for Roundup and other glyphosate-based herbicides increased from higher priced raw materials when compared to the first half of 2013.

The net sales and cost of goods sold discussed above resulted in $269 million higher gross profit in the first half of 2014. Gross profit as a percent of net sales for the Agricultural Productivity segment increased 6 percentage points to 38 percent in 2014 primarily due to the increased average net selling price discussed above.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Working Capital and Financial Condition
	As of				As of Aug. 31,
(Dollars in millions, except current ratio)	Feb. 28, 2014		Feb. 28, 2013		2013
Cash and Cash Equivalents(1)	$	3,805	$	4,443	$	3,668
Trade Receivables, Net(1)	2,515		2,219		1,715
Inventory, Net	3,692		3,095		2,947
Other Current Assets(2)	1,538		1,777		1,747
Total Current Assets	$	11,550	$	11,534	$	10,077
Short-Term Debt, including current portion of long-term debt	$	104	$	152	$	51
Accounts Payable	847		751		995
Accrued Liabilities(3)	4,100		3,806		3,290
Total Current Liabilities	$	5,051	$	4,709	$	4,336
Working Capital(4)	$	6,499	$	6,825	$	5,741
Current Ratio(4)	2.29:1		2.45:1		2.32:1

(1) May include restrictions as a result of variable interest entities. See the Statements of Consolidated Financial Position and Note 5 — Variable Interest Entities — for more information.

(2) Includes short-term investments, miscellaneous receivables, deferred tax assets and other current assets.

(3) Includes income taxes payable, accrued compensation and benefits, accrued marketing programs, deferred revenues, grower production accruals, dividends payable, customer payable and miscellaneous short-term accruals.

(4) Working capital is total current assets less total current liabilities; current ratio represents total current assets divided by total current liabilities.

Feb. 28, 2014, compared with Aug. 31, 2013: Working capital increased $758 million, or 13 percent, between Aug. 31, 2013, and Feb. 28, 2014, primarily because of the following factors:

• Trade receivables, net increased $800 million due to normal ongoing sales activity because of the seasonality of our business and the recording of marketing programs with the right of offset at Aug. 31, 2013.

• Inventory, net increased $745 million between respective periods primarily because of the affects of the prior year drought on fiscal year 2013 inventory levels and seasonality of our U.S. corn and soybean seed business in which the fall harvest of seed products occurs in the first half of the fiscal year resulting in a higher inventory balance.

• Cash and cash equivalents increased $137 million between respective periods primarily because of customer prepayments that have occurred in the first half of 2014. This is consistent with the seasonality of our business.

• Accounts payable decreased $148 million due to timing of payments.

These increases to working capital between Feb. 28, 2014, and Aug. 31, 2013, were partially offset by the following factors:

• Accrued liabilities increased $810 million between respective periods due to the following fluctuations:

◦ Income taxes payable increased $539 million due to the seasonality of our U.S. business and timing of tax payments.

◦ Deferred revenues increased $346 million between respective periods primarily because of the customer prepayments that occur in the first quarter on which we have yet to deliver.

41

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

◦ Grower production accruals increased $165 million due to corn and soybean deliveries in advance of the commercial selling season due to the seasonality of our business.

These increases in accrued liabilities were primarily offset by the following decrease:

• Accrued compensation and benefits decreased $158 million due to the payment of annual employee incentive awards during the first quarter of fiscal year 2014, offset by current year incentive accruals.

• Short-term investments decreased $209 million between respective periods due to less commercial paper investment given our recent strategic investment activity and funding of operations.

Feb. 28, 2014, compared with Feb. 28, 2013: Working capital decreased $326 million, or 5 percent, between Feb. 28, 2013, and Feb. 28, 2014, primarily because of the following factors:

• Cash and cash equivalents decreased $638 million between respective periods primarily due to increased treasury stock purchases and dividend payments, offset by the debt issuances that occurred in the first quarter of 2014.

• Accrued liabilities increased $294 million between respective periods primarily due to the following fluctuations:

◦ Income taxes payable increased $200 million due to increased earnings and the timing of tax payments.

◦ Deferred revenue increased $107 million due to increased prepayments as a result of expected stronger sales.

• Other Assets decreased $239 million between respective periods primarily due to the following fluctuation:

◦ Short-term investments decreased $265 million due to less commercial paper investment given our recent strategic investment activity and funding of operations.

These decreases to working capital between Feb. 28, 2014, and Feb. 28, 2013, were partially offset by the following factors:

• Inventory, net increased $597 million primarily because of increased inventories from our U.S. seeds and genomics segment due to larger production plans, higher yields and timing of grower payments. Agricultural productivity also contributed to this increase to meet current year demand.

• Trade receivables, net increased $296 million due to increased sales activity.

Customer Financing Programs: We participate in various customer financing programs in an effort to reduce our receivable risk and to reduce our reliance on commercial paper borrowings. As of Feb. 28, 2014, the programs had $19 million in outstanding balances and we received $33 million of proceeds during the six-month period under these programs. Our future maximum payout under the programs, including our responsibility for our guarantees with lenders, was $70 million as of Feb. 28, 2014. See Note 4 — Customer Financing Programs — for further discussion of these programs.

Cash Flow

	Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013
Net Cash Provided by Operating Activities	$	1,846		$	1,857
Net Cash Required by Investing Activities	(1,556		)	(301		)
Free Cash Flow(1)	290			1,556
Net Cash Required by Financing Activities	(147		)	(422		)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(6		)	26
Net Increase in Cash and Cash Equivalents	137			1,160
Cash and Cash Equivalents at Beginning of Period	3,668			3,283
Cash and Cash Equivalents at End of Period	$	3,805		$	4,443

(1) Free cash flow represents the total of net cash provided or required by operating activities and provided or required by investing activities (see the “Non-GAAP Financial Measures” section in MD&A for a further discussion).

Operating: The slight decrease in cash provided by continuing operations in the first half of 2014 compared to the first half of 2013 was primarily due to working capital changes, offset by an increase in net income for the six-months of 2014 compared to the six-months of 2013.

Investing: The increase in cash required by investing activities in the first half of 2014 compared to the first half of 2013 was primarily due to the acquisition of The Climate Corporation, our collaboration with Novozymes and an increase in capital

42

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

expenditures, as detailed below. These increases were partially offset by less investment in short-term vehicles as discussed above in working capital.

Financing: The decrease in cash required by financing activities in the first half of 2014 compared to the first half of 2013 was primarily due to the $1 billion debt issuance that occurred in November 2013, as discussed below, offset by increased treasury stock purchases and a reduction in short-term borrowings due to higher borrowings in the prior year to support ex-U.S. operations.

Capital Resources and Liquidity

	As of						As of Aug. 31,
(Dollars in millions, except debt-to-capital ratio)	Feb. 28, 2014			Feb. 28, 2013			2013
Short-Term Debt	$	104		$	152		$	51
Long-Term Debt	3,051			2,054			2,061
Total Monsanto Company Shareowners’ Equity	13,678			13,240			12,559
Debt-to-Capital Ratio(1)	19		%	14		%	14		%

(1) Debt-to-Capital ratio represents short-term and long-term debt divided by total Monsanto Company shareowners' equity, short-term and long-term debt.

A major source of our liquidity is operating cash flows, which can be derived from net income. This cash-generating capability and access to long-term investment grade debt financing markets provides us with the financial flexibility we need to meet operating, investing and financing needs. We believe our sources of liquidity will be sufficient to sustain operations and to finance anticipated investments. To the extent that cash provided by operating activities is not sufficient to fund our cash needs, we believe short-term commercial paper borrowings can be used to finance these requirements. We had no commercial paper borrowings outstanding at Feb. 28, 2014.

We have a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016. As of Feb. 28, 2014, we did not have any borrowings under this credit facility and we were in compliance with all debt covenants.

In November 2013, we issued $1 billion senior notes with a group of banks, primarily to fund the acquisition of The Climate Corporation, as discussed below, and for general business purposes.

Our debt-to-capital ratio increased 5 percentage points compared with the Feb. 28, 2013 and Aug. 31, 2013 ratios, primarily because of the debt issuance, as discussed above, offset by the increase in shareowners' equity as a result of increased earnings.

We held cash and cash equivalents and short-term investments of $3,850 million and $3,922 million at Feb. 28, 2014, and Aug. 31, 2013, respectively, of which $1,402 million and $2,319 million was held by foreign entities, respectively. Our intent is to indefinitely reinvest earnings of our foreign operations and our current operating plans do not demonstrate a need to repatriate foreign earnings to fund our U.S. operations. However, if these funds were needed for our operations in the United States, we would be required to accrue and pay any applicable U.S. and local taxes to repatriate these funds.

Dividends: In the first half of fiscal year 2014, we declared the following dividends:

Quarter Ending	Declaration Date	Dividend	Payable Date	To Shareowners of Record as of:
Feb. 28, 2014	Jan. 28, 2014	43 cents	April 25, 2014	April 4, 2014
Feb. 28, 2014	Dec. 9, 2014	43 cents	Jan. 31, 2014	Jan. 10, 2014

Capital Expenditures: We expect fiscal year 2014 capital expenditures to be in the range of $1 billion to $1.2 billion compared with $741 million in fiscal year 2013. The primary driver of this increase compared with 2013 is expected global seed manufacturing expansions and additional investment in one of our technology research facilities.

2014 Collaboration: In February 2014, we entered into a collaborative agreement with Novozymes to launch the BioAg Alliance. The BioAg Alliance will focus on the next wave of microbial solutions by bringing together Novozymes' capabilities for discovering, developing and producing microbial solutions with Monsanto's discovery programs, and advanced development, testing and commercial capabilities. Value from commercialization will be shared 50-50 between both companies. Monsanto paid Novozymes an aggregate upfront cash payment of $300 million for recognition of Novozymes ongoing business and capabilities in microbials and for Novozymes' ability to supply alliance products.

43

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

2014 Acquisitions:In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper-local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s R&D capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co.KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. 

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina, that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles.

2014 Contractual Obligations: Other than the increase in our long-term debt, discussed above, there have been no significant changes to the contractual obligations table as disclosed in our Annual Report on Form 10-K for the year ended Aug. 31, 2013.

Off-Balance Sheet Arrangements

Under our Separation Agreement with Pharmacia, we are required to indemnify Pharmacia for certain matters, such as environmental remediation obligations and litigation. To the extent we are currently managing any such matters, we evaluate them in the course of managing our own potential liabilities and establish reserves as appropriate. However, additional matters may arise in the future, and we may manage, settle or pay judgments or damages with respect to those matters in order to mitigate contingent liability and protect Pharmacia and Monsanto. See Note 20 — Commitments and Contingencies and Part II — Item 1 — Legal Proceedings — for further information.

We have entered into various customer financing programs which are accounted for in accordance with the Transfers and Servicing topic of the ASC. See Note 4 — Customer Financing Programs — for further information.

We are in the process of making a significant expansion of our Chesterfield, Missouri, facility. In December 2013, we executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements we have transferred our Chesterfield, Missouri, facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables us to reduce our cost of constructing and operating the expansion by reducing certain state and local tax expenditures. We immediately leased the facility back from the County of St. Louis and have an option to purchase the facility upon tendering the Industrial Revenue Bonds we received to the County. The payments due to us in relation to the Industrial Revenue Bonds and owed by us in relation to the lease of the facilities qualify for the right of offset under ASC 210, Balance Sheet, on our Statements of Consolidated Financial Position, and as a result we will not include the Industrial Revenue Bonds or the lease obligation on our Statements of Consolidated Financial Position as an asset or liability, respectively. The Chesterfield facilities and the expansion is being treated as being owned by Monsanto. It is anticipated that we will execute certain additional incentive agreements in the future with the State of Missouri in connection with such expansion to provide additional benefits.

44

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

OUTLOOK

We believe we have achieved an industry-leading position in the areas in which we compete in both of our business segments. However, the outlook for each part of our businesses is quite different. In the Seeds and Genomics segment, our seeds and traits business is expected to expand via our investment in new products. In the Agricultural Productivity segment, we expect to deliver competitive products in a more steady-state business.

We believe that our company is positioned to deliver value-added products to growers enabling us to grow our gross profit in the future. We expect to see strong cash flow in the future, and we remain committed to returning value to shareowners through vehicles such as investments that expand the business, dividends and share repurchases. We will remain focused on cost and cash management, both to support the progress we have made in managing our investment in working capital and to realize the full earnings potential of our businesses. We plan to continue to seek additional external financing opportunities for our customers as a way to manage receivables for each of our segments.

Outside of the United States, our businesses will continue to face additional challenges related to the risks inherent in operating in emerging markets. We will continue to consider, assess and address these developments and the challenges and issues they place on our businesses. We believe we have taken appropriate measures to manage our credit exposure, which has the potential to affect sales negatively in the near term. In addition, volatility in foreign currency exchange rates may negatively affect our profitability, the book value of our assets outside the United States, and our shareowners’ equity. We continuously monitor the potential currency devaluation in Venezuela and currency volatility in Argentina and the potential impact on future periods.

Seeds and Genomics

Our capabilities in plant breeding and biotechnology research and development are generating a rich and balanced product pipeline that we expect will drive long-term growth. We plan to continue to invest in the areas of seeds, genomics and biotechnology and to invest in technology arrangements that have the potential to increase the efficiency and effectiveness of our R&D efforts. We believe that our seeds and traits businesses will have significant near-term growth opportunities through a combination of improved breeding and continued growth of stacked and second- and third-generation biotech traits.

We expect advanced breeding techniques combined with improved production practices and capital investments will continue to contribute to improved germplasm quality and yields for our seed offerings, leading to increased global demand for both our branded germplasm and our licensed germplasm. We plan to improve the overall performance of our vegetable seeds business, which has a portfolio focused on 21 crops. While near term financial results for the vegetable business could be affected by lower sales in certain regions experiencing political or economic instability, the business integration into a global platform, along with a number of process improvements, are expected to continue to improve our ability to develop and deliver new innovative products to our customer base. We plan to continue to pursue strategic acquisitions in our seed businesses to grow our branded seed share, expand our germplasm library, and strengthen our global breeding programs. We expect to see continued competition in seeds and genomics. We believe we will have a competitive advantage because of our global breeding capabilities and our multiple-channel sales approach in the United States for corn and soybean seeds.

Commercialization of second- and third-generation traits and the stacking of multiple traits in corn, soy and cotton are expected to increase penetration in approved markets, particularly as we continue to price our traits in line with the value growers have experienced. We experienced an increase in competition in biotechnology as more competitors launched traits in the United States and internationally. Acquisitions may also present mid-to-longer term opportunities to increase penetration of our traits. We believe our competitive position continues to enable us to deliver second- and third-generation traits when our competitors are delivering their first-generation traits.

In Brazil, we expect to continue to operate our business model of collecting on the sale of certified seeds, a point-of-delivery payment system (Roundup Ready soybeans and Intacta RR2 PRO soybeans) and our indemnification collection system (Bollgard cotton), to capture value on all of our Roundup Ready soybeans and Bollgard cotton crops grown there. Following an adverse ruling from a panel of five judges in the Brazilian Superior Court of Justice denying our term correction for the first generation Roundup Ready patent term to 2014, we continue to defer collection of royalties for first generation Roundup Ready soybeans in Brazil until a final decision is reached by the courts. Growers can agree to gain royalty-free use of first generation Roundup Ready for the 2013-2014 seasons in exchange for a waiver of any claim for refunds for past payments by signing a new Grower License Agreement with a reciprocal release governing Monsanto’s technology. Almost all of the major grower unions in Mato Grosso (a key soybean state in Brazil) have committed to promote the new Grower License Agreements with their membership. The Supreme Court of Brazil has granted certiorari of the patent term correction case.

Longer term, income is expected to grow in Brazil as farmers choose to plant more of our approved traits in soybeans, corn and cotton. The agricultural economy in Brazil could be impacted by global commodity prices, particularly for corn and soybeans.

45

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

We continue to maintain our strict credit policy, expand our grain-based collection system and focus on cash collection and sales, as part of a continuous effort to manage our risk in Brazil against such volatility.

Our international traits businesses, in particular, probably will continue to face unpredictable regulatory environments that may be highly politicized. We operate in volatile, and often difficult, economic and political environments. Growth in India's cotton germplasm and traits business continues to be impacted by government controlled pricing and uncertainties in the regulatory approval process for new trait introductions.

Efforts to secure an orderly system in Argentina to support the introduction of new technology products are underway. To achieve this, we are pursuing grower and grain handler agreements to ensure we will be compensated for providing the technology. The majority of grain handlers have enrolled in the point of delivery system and we are selling Intacta RR2 PRO in Argentina in this dual-path business model. Intacta RR2 PRO technology has been fully approved by Argentina and export markets. We intend to broaden our grower experience with Ground Breakers in the main production areas and modest commercial sales in the north. We also intend to finalize the last steps of the business model approach to enable farmer payments on new and legally saved seed as already exists in Brazil and Paraguay. We do not plan to collect on first generation Roundup Ready soybeans in Argentina.

In May 2013, the USDA announced an investigation into alleged glyphosate-resistant volunteer wheat reported on a single field on an Oregon farm, and we are cooperating in the investigation. The USDA noted that glyphosate-tolerant wheat does not present a public health or food safety concern as the FDA completed its assessment of the product in 2004. The consultative process at the FDA was completed and the agency concluded that this product is as safe as non-GM wheat currently on the market. Initial development of glyphosate-tolerant wheat was discontinued in 2005 under stringent stewardship procedures which were in compliance with USDA regulations. The USDA has reported that there is no indication that the genetically modified wheat product is found in U.S. wheat supplied to domestic or export markets. The USDA's investigation remains ongoing and the agency has indicated that civil and criminal penalties could be imposed if circumstances warranted. Lawsuits which assert numerous legal claims have been filed against the company and have been consolidated in the Federal District Court of Kansas. Monsanto properly discontinued the development of the glyphosate-tolerant wheat event in 2005, has meritorious legal arguments against liability and will vigorously represent its interests in this matter.

Agricultural Productivity

Our Agricultural Productivity businesses operate in markets that are competitive. Gross profit and cash flow levels will fluctuate in the future based on global business dynamics including market supply, demand and manufacturing capacity. We expect to maintain our brand prices at a slight premium over generic products and we believe our Roundup herbicide business will continue to be a sustainable source of cash and gross profit. We have oriented the focus of Monsanto’s crop protection business to strategically support Monsanto’s Roundup Ready crops through our weed management platform that delivers weed control offerings for farmers. In addition, we expect our lawn-and-garden business will continue to be a solid contributor to our Agricultural Productivity segment.

Global glyphosate producers have the capacity to supply the market, but global dynamics including demand, environmental regulation compliance and raw material availability can cause fluctuation in supply and the price of those generic products. We expect the fluctuation in global capacity will impact the selling price and margin of Roundup brands and our third party sourcing opportunities.

The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith. It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Other Information

As discussed in Note 20 — Commitments and Contingencies — and Part II — Item 1 — Legal Proceedings, Monsanto is involved in a number of lawsuits and claims relating to a variety of issues. Many of these lawsuits relate to intellectual property disputes. We expect that such disputes will continue to occur as the agricultural biotechnology industry evolves. Third parties, including non-governmental organizations, have challenged the validity or enforceability of patents issued to the company regarding our biotechnology products. For additional information related to the outlook for Monsanto, see “Caution Regarding Forward-Looking Statements” at the beginning of this Report on Form 10-Q, Part II — Item 1A — Risk Factors below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

46

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In preparing our financial statements, we must select and apply various accounting policies. Our most significant policies are described in Part II — Item 8 — Note 2 — Significant Accounting Policies — to the consolidated financial statements contained in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013. In order to apply our accounting policies, we often need to make estimates based on judgments about future events. In making such estimates, we rely on historical experience, market and other conditions, and on assumptions that we believe to be reasonable. However, the estimation process is by its nature uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our financial condition, results of operations or liquidity may be affected materially. In addition, if our assumptions change, we may need to revise our estimates or take other corrective actions, either of which may have a material effect on our financial condition, results of operations or liquidity.

The estimates that have a higher degree of inherent uncertainty and require our most significant judgments are outlined in Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Report on Form 10-K for fiscal year ended Aug. 31, 2013. Had we used estimates different from any of those contained in such Report on Form 10-K, our financial condition, profitability or liquidity for the current period could have been materially different from those presented in this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There are no material changes related to market risk from the disclosures in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of Feb. 28, 2014. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of Feb. 28, 2014.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

47

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in various legal proceedings that arise in the ordinary course of our business, as well as proceedings that we have considered to be material under SEC regulations. These include proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. Information regarding certain material proceedings and the possible effects on our business of proceedings we are defending is disclosed in Note 20 — Commitments and Contingencies — under the subheading “Environmental and Litigation Liabilities ” and is incorporated by reference herein. Other information with respect to legal proceedings appears in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

ITEM 1A. RISK FACTORS

Please see “Caution Regarding Forward-Looking Statements,” at the beginning of this Report on Form 10-Q and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, for information regarding risk factors. There have been no material changes from the risk factors previously disclosed in our Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table is a summary of any purchases of equity securities during the second quarter of fiscal year 2014 by Monsanto and any affiliated purchasers, pursuant to SEC rules. 

Period	(a) Total Number of Shares Purchased		(b) Average Price Paid per Share(1)		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
December 2013:
Dec. 1, 2013, through Dec. 31, 2013	450,000		$	112.06	450,000	$	1,359,043,537
January 2014:
Jan. 1, 2014, through Jan. 31, 2014	959,610	(2)	$	111.84	914,600	$	1,256,750,887
February 2014:
Feb. 1, 2014, through Feb. 28, 2014	459,700		$	109.29	459,700	$	1,206,511,275
Total	1,869,310		$	111.26	1,824,300	$	1,206,511,275

(1) The average price paid per share is calculated on a trade date basis and excludes commission.

(2) Includes 45,010 shares purchased by affiliated purchaser.

In June 2013, the board of directors authorized a new share repurchase program, effective July 1, 2013, for up to $2 billion of the company's common stock over a three-year period. This repurchase program commenced on Aug. 20, 2013.

There were no other publicly announced plans outstanding as of Feb. 28, 2014.

ITEM 6. EXHIBITS

Exhibits: The list of exhibits in the Exhibit Index to this Report is incorporated herein by reference.

48

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MONSANTO COMPANY
	(Registrant)
By:	/s/ NICOLE M. RINGENBERG
	Nicole M. Ringenberg
	Vice President and Controller
	(On behalf of the Registrant and as Principal Accounting Officer)

Date: April 3, 2014

49

MONSANTO COMPANY SECOND QUARTER 2014 FORM 10-Q

EXHIBIT INDEX

These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.

Exhibit No.	Description
2	Omitted
3	Omitted
4	Omitted
11	Omitted — see Note 18 of Notes to Consolidated Financial Statements — Earnings Per Share.
12	Computation of Ratio of Earnings to Fixed Charges.
15	Omitted
18	Omitted
19	Omitted
22	Omitted
23	Omitted
24	Omitted
31.1	Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer).
31.2	Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Financial Officer).
32	Rule 13a-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer and the Chief Financial Officer).
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

50

EX-12

Exhibit 12

MONSANTO COMPANY

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES⁽¹⁾⁽²⁾ 

(Dollars in millions)

	Six Months Ended Feb. 28,			Year Ended Aug. 31,
	2014			2013			2012			2011			2010			2009
EARNINGS:
Income from Continuing Operations Before Income Taxes	$	2,856		$	3,429		$	2,988		$	2,374		$	1,490		$	2,918
Add:
Fixed charges	131			246			257			234			227			178
Equity affiliate income — net	5			(15		)	(10		)	(21		)	(16		)	(17		)
Amortization of capitalized interest	9			16			15			15			14			13
Less:
Capitalized interest	(13		)	(23		)	(21		)	(22		)	(25		)	(34		)
Earnings available for fixed charges	$	2,988		$	3,653		$	3,229		$	2,580		$	1,690		$	3,058
FIXED CHARGES:
Interest expense(3)	$	95		$	176		$	191		$	172		$	167		$	107
Capitalized interest	13			23			21			22			25			34
Portion of rents representative of interest factor	23			47			45			40			35			37
Total fixed charges	$	131		$	246		$	257		$	234		$	227		$	178
Ratio of Earnings to Fixed Charges	22.81			14.85			12.56			11.03			7.44			17.18

(1) Monsanto has not paid any preference security dividends and, therefore, has not included the ratio of combined fixed charges and preference security dividends to earnings for the relevant periods.

(2) The operating results of the Dairy business has been conformed to discontinued operations presentation for all relevant fiscal years presented.

(3) Includes amortization of deferred debt issuance costs and the interest component of the income tax provision.

EX-31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Hugh Grant, certify that:

1. I have reviewed this report on Form 10-Q of Monsanto Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 3, 2014

/s/ Hugh Grant

Hugh Grant

Chairman and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Pierre Courduroux, certify that:

1. I have reviewed this report on Form 10-Q of Monsanto Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 3, 2014

/s/ Pierre Courduroux

Pierre Courduroux

Senior Vice President and Chief Financial Officer

EX-32

EXHIBIT 32

CERTIFICATIONS PURSUANT TO

EXCHANGE ACT RULE 13a-14(b) AND 18 U.S.C. SECTION 1350

In connection with the report of Monsanto Company (the “Company”) on Form 10-Q for the period ended Feb. 28, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), and pursuant to Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350, each of the undersigned officers of the Company does hereby certify that, to the best of such officer’s knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Hugh Grant

Hugh Grant

Chairman and Chief Executive Officer

/s/ Pierre Courduroux

Pierre Courduroux

Senior Vice President and Chief Financial Officer

April 3, 2014

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Tables)

6 Months Ended

Feb. 28, 2014

Compensation and Retirement Disclosure [Abstract]

Components of Net Periodic Benefit Cost

The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Feb. 28, 2014									Three Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	16		$	2		$	18
Interest Cost on Benefit Obligation	23			2			25			18			2			20
Assumed Return on Plan Assets	(34		)	(2		)	(36		)	(32		)	(2		)	(34		)
Amortization of Unrecognized Net Loss	15			(1		)	14			17			1			18
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	3		$	22		$	19		$	4		$	23

	Six Months Ended Feb. 28, 2014									Six Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	30		$	6		$	36		$	36		$	5		$	41
Interest Cost on Benefit Obligation	46			4			50			40			4			44
Assumed Return on Plan Assets	(69		)	(4		)	(73		)	(72		)	(4		)	(76		)
Amortization of Unrecognized Net Loss	31			—			31			38			2			40
Curtailment and Settlement Charge	—			2			2			—			2			2
Total Net Periodic Benefit Cost	$	38		$	8		$	46		$	42		$	9		$	51

Net Periodic Cost Postretirement

Health Care and Other Postretirement Benefits	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Service Cost for Benefits Earned During the Period	$	1		$	1		$	4		$	6
Interest Cost on Benefit Obligation	1			1			4			4
Amortization of Unrecognized Net Gain	(4		)	(1		)	(8		)	(4		)
Total Net Periodic Benefit Cost	$	(2	)	$	1		$	—		$	6

XML

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of estimated amortization expense (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2014	$ 144
2015	176
2016	173
2017	152
2018	$ 118

XML

VARIABLE INTEREST ENTITIES Narrative (Details)	6 Months Ended	12 Months Ended
	Feb. 28, 2014	Aug. 31, 2013
Revolving Financing Programs [Line Items]
Variable Interest Entity, Financial or Other Support, Percentage	9.00%
Senior Interest [Member]
Revolving Financing Programs [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	91.00%	91.00%
Monsanto Interest [Member]
Revolving Financing Programs [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	9.00%	9.00%

XML

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013
Supplemental Cash Flow Information [Abstract]
Interest	$ 80	$ 98
Taxes	233	288
Dividends payable	$ 226	$ 201	$ 228

XML

INVESTMENTS Investments (Details) (USD $)	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013
Schedule of Investments and Equity Affiliates [Line Items]
Short-term investments	$ 45,000,000		$ 45,000,000		$ 254,000,000
Fair Value	47,000,000		47,000,000		22,000,000
Available-for-sale Securities [Member]
Schedule of Investments and Equity Affiliates [Line Items]
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities	0	0	0	0
Fair Value	47,000,000		47,000,000		22,000,000
Cost-method Investments [Member]
Schedule of Investments and Equity Affiliates [Line Items]
Recorded cost	81,000,000		81,000,000		67,000,000
Cost-method Investments, Other than Temporary Impairment	$ 0	$ 0	$ 0	$ 0

XML

BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended			1 Months Ended				6 Months Ended	1 Months Ended				6 Months Ended			3 Months Ended	6 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013	Nov. 30, 2013 The Climate Corporation [Member]	Feb. 28, 2014 The Climate Corporation [Member]	Feb. 26, 2014 The Climate Corporation [Member]	Nov. 29, 2013 The Climate Corporation [Member]	Feb. 28, 2014 Twenty Fourteen Acquisitions [Member]	Aug. 31, 2013 Diekmann GMBH & Co. KG [Member]	Jun. 30, 2013 GrassRoots Biotechnology, Inc. [Member]	Mar. 31, 2013 Rosetta Green Ltd. [Member]	Jan. 31, 2013 Agradis, Inc. [Member]	Feb. 28, 2014 Acquired Biotechnology [Member] Twenty Fourteen Acquisitions [Member]	Feb. 28, 2014 Customer Relationships [Member] Twenty Fourteen Acquisitions [Member]	Feb. 28, 2014 Other Intangible Assets [Member] Twenty Fourteen Acquisitions [Member]	Feb. 28, 2014 Cost of Sales [Member]	Feb. 28, 2014 Cost of Sales [Member]	Feb. 28, 2014 Research and Development Expense [Member]	Feb. 28, 2013 Research and Development Expense [Member]	Feb. 28, 2014 Research and Development Expense [Member]	Feb. 28, 2013 Research and Development Expense [Member]
Business Acquisition [Line Items]
Acquiree percentage							100.00%			100.00%
Transaction cost					$ 17	$ 1			$ 1	$ 1	$ 1	$ 1
Business Acquisition, Cost of Acquired Entity, Cash Paid									30		35	85
Payments to Acquire Businesses, Net of Cash Acquired	922	79		917				917		15
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets								59
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment								9
Goodwill	4,327		3,520					787
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill								142					138	4	142
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets								997
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities								10
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other								55
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities								65
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net								932
Cash Acquired from Acquisition								15
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life													10 years	1 year
Finite-Lived Intangible Asset, Useful Life													10 years	1 year
Fair Value of Acquisition							$ 932		$ 30	$ 15	$ 35	$ 85
Collaborative Arrangement, Income Statement Classification																4	4	12	12	20	27

XML

VARIABLE INTEREST ENTITIES (Tables)

6 Months Ended

Feb. 28, 2014

VARIABLE INTEREST ENTITIES [Abstract]

Schedule of Consolidated Variable Interest Entity, Amount of Assets, Liabilities, and Maximum Exposure to Loss

The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Cash and cash equivalents	$	15	$	140
Trade receivables, net	129		—
Total Assets	$	144	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	13	$	—

XML

SEGMENT AND GEOGRAPHIC DATA (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014 segment		Feb. 28, 2013
Segment Reporting Information [Line Items]
Number of Operating Segments					2
Net Sales	$ 5,832	[1]	$ 5,472	[1]	$ 8,975	[1]	$ 8,411	[1]
Gross Profit	3,447		3,070		5,010		4,467
EBIT	2,363	[2],[3],[4]	2,096	[2],[3],[4]	2,917	[2],[3],[4]	2,586	[2],[3],[4]
Depreciation and Amortization Expense	170		153		332		305
Income from operations of discontinued businesses	8		6		22		17
Reconciliation of EBIT to Net Income [Abstract]
EBIT	2,363	[2],[3],[4]	2,096	[2],[3],[4]	2,917	[2],[3],[4]	2,586	[2],[3],[4]
Interest Expense — Net	17		8		46		36
Income Tax Provision	676	[5]	605	[5]	833	[5]	728	[5]
Net Income Attributable to Monsanto Company	1,670		1,483		2,038		1,822
Corn seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	3,414	[1]	3,280	[1]	4,468	[1]	4,419	[1]
Gross Profit	2,253		2,083		2,903		2,769
Soybean seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	820	[1]	677	[1]	1,087	[1]	908	[1]
Gross Profit	539		395		707		513
Cotton seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	49	[1]	60	[1]	186	[1]	245	[1]
Gross Profit	28		44		120		171
Vegetable seeds [Member]
Segment Reporting Information [Line Items]
Net Sales	219	[1]	199	[1]	376	[1]	355	[1]
Gross Profit	96		106		164		189
All other crops seeds and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	146	[1]	130	[1]	207	[1]	174	[1]
Gross Profit	77		71		104		82
Total Seeds and Genomics [Member]
Segment Reporting Information [Line Items]
Net Sales	4,648	[1]	4,346	[1]	6,324	[1]	6,101	[1]
Gross Profit	2,993		2,699		3,998		3,724
EBIT	2,055	[2],[4]	1,840	[2],[4]	2,159	[2],[4]	2,060	[2],[4]
Depreciation and Amortization Expense	140		123		271		246
Reconciliation of EBIT to Net Income [Abstract]
EBIT	2,055	[2],[4]	1,840	[2],[4]	2,159	[2],[4]	2,060	[2],[4]
Agricultural Productivity [Member]
Segment Reporting Information [Line Items]
Net Sales	1,184	[1]	1,126	[1]	2,651	[1]	2,310	[1]
Gross Profit	454		371		1,012		743
Total Agricultural Productivity [Member]
Segment Reporting Information [Line Items]
Net Sales	1,184	[1]	1,126	[1]	2,651	[1]	2,310	[1]
Gross Profit	454		371		1,012		743
EBIT	308	[2],[4]	256	[2],[4]	758	[2],[4]	526	[2],[4]
Depreciation and Amortization Expense	30		30		61		59
Reconciliation of EBIT to Net Income [Abstract]
EBIT	$ 308	[2],[4]	$ 256	[2],[4]	$ 758	[2],[4]	$ 526	[2],[4]

[1] Represents net sales from continuing operations.

[2] EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

[3] Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

[4] Agricultural Productivity EBIT includes income from operations of discontinued businesses of $8 million and $22 million for the three and six months ended Feb. 28, 2014, respectively. Agricultural Productivity EBIT includes income from operations of discontinued businesses of $6 million and $17 million for the three and six months ended Feb. 28, 2013, respectively.

[5] Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

INCOME TAXES (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Feb. 28, 2014
Income Tax Disclosure [Abstract]
Other Tax Benefit	$ 47

XML

ENVIRONMENTAL AND LITIGATION (Details) (USD $) In Millions, unless otherwise specified			6 Months Ended				26 Months Ended	0 Months Ended
	Feb. 28, 2014	Aug. 31, 2013	Feb. 28, 2014 Medical Monitoring Program [Member]	Feb. 28, 2014 Medical Monitoring Program [Member] Primary Fund [Member]	Feb. 28, 2014 Medical Monitoring Program [Member] Additional Fund [Member]	Feb. 28, 2014 Property Remediation Plan [Member]	Nov. 30, 2009 Putnam County, West Virginia [Member] claim	Dec. 17, 2004 Virdie Allen [Member] plaintiff
Accrual For Environmental And Litigation Loss Contingencies [Abstract]
Accrual For Environmental And Litigation Loss Contingencies	$ 271	$ 271
Loss Contingency, Number of Plaintiffs								15
Gain (Loss) Related to Litigation Settlement [Abstract]
Litigation Settlement, Gross				$ 21	$ 63	$ 9
Loss Contingency, Settlement Agreement, Terms			30 years			3 years
Loss Contingency, New Claims Filed, Number							200

XML

STOCK BASED COMPENSATION PLANS STOCK BASED COMPENSATION PLANS

6 Months Ended

Feb. 28, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the six months ended Feb. 28,2014, and Feb. 28, 2013. Stock-based compensation cost capitalized in inventory was $3 million as of both Feb. 28, 2014, and Aug. 31, 2013.

	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Cost of Goods Sold	$	2		$	3		$	4		$	7
Selling, General and Administrative Expenses	23			18			43			33
Research and Development Expenses	5			5			10			10
Pre-Tax Stock-Based Compensation Expense	30			26			57			50
Income Tax Benefit	(10		)	(9		)	(19		)	(17		)
Net Stock-Based Compensation Expense	$	20		$	17		$	38		$	33

The following table summarizes stock-based compensation activity for and as of the six months endedFeb. 28, 2014. Monsanto Stock Plans include employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012 and employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013. The Director Plan includes members of the Board of Directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan.

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,285,346		927,909		18,520		2,554
Weighted-average grant date fair value per share	$	38.34	$	101.30	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	$	91.4	$	113.9	$	0.9	$	0.1
Remaining weighted-average period of expense recognition/requisite service periods (in years)	2		2		1		1

XML

RECEIVABLES (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014		Aug. 31, 2013		Aug. 31, 2012
Allowance For Doubtful Accounts Current [Abstract]
Net allowances	$ 72		$ 68
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning Balance	105		104		141
Incremental Provision	5		7
Recoveries	(2)		(1)
Write-offs	(10)		(47)
Other	8	[1]	4	[1]
Ending Balance	105		104		141
Long Term Receivables [Abstract]
Long term customer receivables, gross	128		112
Long term contractual receivables, gross	$ 108		$ 229

[1] Includes reclassifications from trade receivables, net and foreign currency translation adjustments.

XML

EARNINGS PER SHARE (Tables)

6 Months Ended

Feb. 28, 2014

Earnings Per Share [Abstract]

Basic Earnings Per Share Table

	Three Months Ended		Six Months Ended
(Shares in millions)	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Weighted-Average Number of Common Shares	524.8	534.8	525.9	534.8
Dilutive Potential Common Shares	5.5	6.1	5.7	6.1
Antidilutive Potential Common Shares	1.7	1.9	1.8	1.9
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	—	0.1	0.1	0.1

XML

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Feb. 28, 2014

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables set forth by level Monsanto’s assets and liabilities that were accounted for at fair value on a recurring basis as of Feb. 28, 2014, and Aug. 31, 2013. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.

	Fair Value Measurements at Feb. 28, 2014, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,263	$	—	$	—	$	3,263
Short-term investments	45		—		—		45
Equity securities	47		—		—		47
Derivative assets related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	5		4		—		9
Total Assets at Fair Value	$	3,360	$	12	$	—	$	3,372
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	12	$	—	$	12
Commodity contracts	51		6		—		57
Total Liabilities at Fair Value	$	51	$	18	$	—	$	69
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	104	$	—	$	104
Long-term debt instruments(1)	—		3,246		—		3,246
Total Liabilities Not Recorded at Fair Value	$	—	$	3,350	$	—	$	3,350
Total Liabilities Recorded and Not Recorded at Fair Value	$	51	$	3,368	$	—	$	3,419

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

Level 3 Rollforward

The following table summarizes the change in fair value of the Level 3 liability for the six months endedFeb. 28, 2014.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Feb. 28, 2014	$	—

XML

GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of net carrying amount of goodwill (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Feb. 28, 2014
Goodwill [Roll Forward]
Balance	$ 3,520
Acquisition activity (see Note 3)	787
Effect of foreign currency translation adjustments	20
Balance	4,327
Seeds And Genomics [Member]
Goodwill [Roll Forward]
Balance	3,461
Acquisition activity (see Note 3)	787
Effect of foreign currency translation adjustments	20
Balance	4,268
Agricultural Productivity [Member]
Goodwill [Roll Forward]
Balance	59
Acquisition activity (see Note 3)	0
Effect of foreign currency translation adjustments	0
Balance	$ 59

XML

STOCK BASED COMPENSATION PLANS STOCK BASED COMPENSATION PLANS Restricted Stock (Details) (USD $) In Millions, except Share data, unless otherwise specified	6 Months Ended
	Feb. 28, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	2,285,346
Weighted-average grant date fair value per share	$ 38.34
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	$ 91.4
Remaining weighted-average period of expense recognition/requisite service periods (in years)	2 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	927,909
Weighted-average grant date fair value per share	$ 101.30
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	113.9
Remaining weighted-average period of expense recognition/requisite service periods (in years)	2 years
Directors Deferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	18,520
Weighted-average grant date fair value per share	$ 97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	0.9
Remaining weighted-average period of expense recognition/requisite service periods (in years)	1 year
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	2,554
Weighted-average grant date fair value per share	$ 97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	$ 0.1
Remaining weighted-average period of expense recognition/requisite service periods (in years)	1 year

XML

FINANCIAL INSTRUMENTS Narrative (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended				6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014 subject to master netting arrangement, or similar agreement [Member]	Aug. 31, 2013 subject to master netting arrangement, or similar agreement [Member]	Feb. 28, 2014 Foreign Exchange Contract [Member]	Feb. 28, 2014 Commodity Contracts
Derivatives, Fair Value [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge							18 months	39 months
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months			$ (50)
Derivative Liability Subject to Master Netting Arrangement, or Similar Agreement					9	7
Discontinuation of Cash Flow Hedge	$ 0	$ 0	$ 0	$ 0

XML

CUSTOMER FINANCING PROGRAMS (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013		Aug. 31, 2013
US agreement to sell trade receivables [Member]
Customer Financing Programs [Line Items]
Outstanding balance	$ 10	[1]			$ 10	[1]			$ 348	[1]
Maximum future payout under recourse provisions	1	[1]			1	[1]			19	[1]
Transactions that Qualify for Sales Treatment	0	[1]	0	[1]	23	[1]	2	[1]
Maximum Amount of Potential Sales of Receivables					500
Other agreements to sell trade receivables [Member]
Customer Financing Programs [Line Items]
Outstanding balance	9	[2]			9	[2]			44	[2]
Maximum future payout under recourse provisions	9	[2]			9	[2]			41	[2]
Transactions that Qualify for Sales Treatment	3	[2]	3	[2]	10	[2]	3	[2]
Agreements With Lenders [Member]
Customer Financing Programs [Line Items]
Outstanding balance	84	[3]			84	[3]			45	[3]
Maximum future payout under recourse provisions	60	[3]			60	[3]			32	[3]
Brazil Revolving Financing Program [Member]
Customer Financing Programs [Line Items]
Maximum Amount of Potential Sales of Receivables					$ 430

[1] Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

[2] Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

[3] Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

XML

Statements of Consolidated Shareholders Equity (Parenthetical) (Unaudited) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013
Statement of Stockholders' Equity [Abstract]
Cash dividends per common share	$ 0.86	$ 0.75	$ 0.86	$ 0.75	$ 1.56

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Notional Amounts of Derivative Instruments Outstanding (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014	Aug. 31, 2013
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	$ 1,192	$ 1,133
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	1,551	1,405
Foreign Exchange Contract [Member] | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	243	261
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	1,269	1,188
Commodity Contracts | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	949	872
Commodity Contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	145	217
Interest Rate Contracts [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	$ 137	$ 0

XML

SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION (Tables)

6 Months Ended

Feb. 28, 2014

Supplemental Cash Flow Information [Abstract]

Cash Payments For Interest And Taxes

Cash payments for interest and taxes were as follows:

	Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013
Interest	$	80	$	98
Taxes	233		288

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Feb. 28, 2014

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and legal proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. In addition, Monsanto has liabilities established for various product claims. With respect to certain of these proceedings, Monsanto has a liability recorded of $271 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, for the estimated contingent liabilities. Information regarding the environmental liabilities appears in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Litigation: The above liability includes amounts related to certain third-party litigation with respect to Monsanto’s business, as well as tort litigation related to Pharmacia’s former chemical business, including lawsuits involving polychlorinated biphenyls (PCBs), dioxins, and other chemical and premises liability litigation. Additional matters that are not reflected in the liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages with respect thereto in order to mitigate contesting potential liability. Following is a description of one of the more significant litigation matters reflected in the liability.

• As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, and our Report on Form 10-Q for the quarterly period ended Nov. 30, 2013, on Dec. 17, 2004, 15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al. v. Monsanto, et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia and seven other defendants. Monsanto is named as the successor in interest to the liabilities of Pharmacia. The alleged class consists of all current and former residents, workers, and students who, between 1949 and the present, were allegedly exposed to dioxins/furans contamination in counties surrounding Nitro, West Virginia. The complaint alleges that the source of the contamination is a chemical plant in Nitro, formerly owned and operated by Pharmacia and later by Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc. (Akzo Nobel). Akzo Nobel and Flexsys were named defendants in the case but Solutia was not, due to its then pending bankruptcy proceeding. The suit seeks damages for property cleanup costs, loss of real estate value, funds to test property for contamination levels, funds to test for human exposure, and future medical monitoring costs. The complaint also seeks an injunction against further contamination and punitive damages. Monsanto has agreed to indemnify and defend Akzo Nobel and the Flexsys defendant group, but on May 27, 2011, the judge dismissed both Akzo Nobel and Flexsys from the case. The class action certification hearing was held on Oct. 29, 2007. On Jan. 8, 2008, the trial court issued an order certifying the Allen (now Zina G. Bibb et al. v. Monsanto et al., because Bibb replaced Allen as class representative) case as a class action for property damage and for medical monitoring. On Nov. 2, 2011, the court, in response to defense motions, entered an order decertifying the property class. After the trial for the Bibb medical monitoring class action began on Jan. 3, 2012, the parties reached a settlement in principle as to both the medical monitoring and the property class claims. The proposed settlement provides for a 30 year medical monitoring program consisting of a primary fund of up to $21 million and an additional fund of up to $63 million over the life of the program, and a three year property remediation plan with funding up to $9 million. On Feb. 24, 2012, the court preliminarily approved the parties’ proposed settlement. A fairness hearing was held June 18, 2012, resulting in the trial court's final approval of the settlement. Certain plaintiffs objected to the approval of the settlement and appealed to the West Virginia Supreme Court of Appeals. On Nov. 22, 2013, the West Virginia Supreme Court of Appeals dismissed the appeal and upheld the fairness of the class action settlements. On Jan. 21, 2014, the objector filed a petition for writ of certiorari, which we opposed, with the U.S. Supreme Court.

In October 2007 and November 2009, a total of approximately 200 separate, single plaintiff civil actions were filed in Putnam County, West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and several of its affiliates), Flexsys America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. These cases allege personal injury occasioned by exposure to dioxin generated by the Nitro Plant during production of 2,4,5T (1949-1969) and thereafter. Monsanto has agreed to accept the tenders of defense in the matters by Pharmacia, Solutia, Akzo Nobel, Flexsys America, and Apogee Coal under a reservation of rights. During the discovery phase of these several claims, the parties reached an agreement in principle to resolve all pending personal injury claims which is reflected in the above liability.

Including litigation reflected in the liability, Monsanto is involved in various legal proceedings that arise in the ordinary course of its business or pursuant to Monsanto’s indemnification obligations to Pharmacia, as well as proceedings that management has considered to be material under SEC regulations. Some of the lawsuits seek damages in very large amounts, or seek to restrict the company’s business activities. Monsanto believes that it has meritorious legal arguments and will continue to represent its interests vigorously in all of the proceedings that it is defending or prosecuting. Management does not anticipate the ultimate liabilities resulting from such proceedings, or the proceedings reflected in the above liability, will have a material adverse effect on Monsanto’s consolidated results of operations, financial position, cash flows or liquidity.

Legal actions have been filed in Brazil that raise issues challenging the right to collect certain royalties for Roundup Ready soybeans. Although Brazilian law clearly states that the pipeline patents protecting these products have the duration of the corresponding U.S. patent (2014 for Roundup Ready soybeans), the duration (and application) of these pipeline patents is currently under judicial review in Brazil. Monsanto believes it has meritorious legal arguments and will continue to represent its interests vigorously in these proceedings. The current estimate of the company’s reasonably possible loss contingency is not material to consolidated results of operations, financial position, cash flows or liquidity.

Other Contingencies: The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith.  It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in the United States, Brazil, Europe, and Argentina can be found in Note 4 — Customer Financing Programs — of this Form 10-Q. Except as described in that note, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2013. Disclosures regarding these guarantees made by Monsanto can be found in Note 26 — Commitments and Contingencies — of the notes to the consolidated financial statements contained in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Off-Balance Sheet Arrangement: In December 2013, Monsanto executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements Monsanto has transferred the Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables the company to reduce the cost of constructing and operating the expansion by reducing certain state and local tax expenditures. Monsanto immediately leased the facility back from the County of St. Louis and has an option to purchase the facility upon tendering the Industrial Revenue Bonds received to the County. The payments due to the company in relation to the Industrial Revenue Bonds and owed by the company in relation to the lease of the facilities qualify for the right of offset under ASC 210, Balance Sheet, on the Statements of Consolidated Financial Position. As such, neither the Industrial Revenue Bonds nor the lease obligation are recorded on the Statements of Consolidated Financial Position as an asset or liability, respectively. The Chesterfield facilities and the expansion is being treated as being owned by Monsanto.

XML

SUPPLEMENTAL CASH FLOW INFORMATION

6 Months Ended

Feb. 28, 2014

Supplemental Cash Flow Information [Abstract]

SUPPLEMENTAL CASH FLOW INFORMATION

SUPPLEMENTAL CASH FLOW INFORMATION

Cash payments for interest and taxes were as follows:

	Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013
Interest	$	80	$	98
Taxes	233		288

In second quarter2014 and 2013, the board of directors declared a dividend which is payable in third quarter 2014 and 2013, respectively. As of Feb. 28, 2014, and Feb. 28, 2013, a dividend payable of $226 million and $201 million, respectively, was recorded.

XML

DEFERRED REVENUE (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013	Nov. 30, 2008
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	$ 863		$ 863		$ 517
Receivable Balance	131		131		237
Accounts Receivable, Net, Current	2,515		2,515		1,715
Deferred Revenue	94		94		138
Interest income	23	27	47	50
Pioneer Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	79		79		79
Total Receivable Under Agreement						635
Cumulative Cash Receipts Under Agreement	725		725
Deferred Revenue, Revenue Recognized	20	20	40	40
Receivable Balance	147		147		230
Accounts Receivable, Net, Current	85		85		85
Total Deferred Revenue	119		119		159	635
Interest income	1	2	2	3
Deferred Revenue, Length of Time			8 years
Syngenta Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	20		20		20
Deferred Revenue, Revenue Recognized	11	8	14	12
Receivable Balance	42		42		58
Deferred Revenue	27		27		34
Minimum Obligation Under Agreement			$ 81
Deferred Revenue, Length of Time			9 years

XML

SEGMENT AND GEOGRAPHIC DATA (Tables)

6 Months Ended

Feb. 28, 2014

Segment Reporting [Abstract]

Operating Segment Information

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Net Sales(1)
Corn seed and traits	$	3,414	$	3,280	$	4,468	$	4,419
Soybean seed and traits	820		677		1,087		908
Cotton seed and traits	49		60		186		245
Vegetable seeds	219		199		376		355
All other crops seeds and traits	146		130		207		174
Total Seeds and Genomics	$	4,648	$	4,346	$	6,324	$	6,101
Agricultural productivity	1,184		1,126		2,651		2,310
Total Agricultural Productivity	$	1,184	$	1,126	$	2,651	$	2,310
Total	$	5,832	$	5,472	$	8,975	$	8,411

Gross Profit
Corn seed and traits	$	2,253	$	2,083	$	2,903	$	2,769
Soybean seed and traits	539		395		707		513
Cotton seed and traits	28		44		120		171
Vegetable seeds	96		106		164		189
All other crops seeds and traits	77		71		104		82
Total Seeds and Genomics	$	2,993	$	2,699	$	3,998	$	3,724
Agricultural productivity	454		371		1,012		743
Total Agricultural Productivity	$	454	$	371	$	1,012	$	743
Total	$	3,447	$	3,070	$	5,010	$	4,467

EBIT(2)(3)
Seeds and Genomics	$	2,055	$	1,840	$	2,159	$	2,060
Agricultural Productivity	308		256		758		526
Total	$	2,363	$	2,096	$	2,917	$	2,586

Depreciation and Amortization Expense
Seeds and Genomics	$	140	$	123	$	271	$	246
Agricultural Productivity	30		30		61		59
Total	$	170	$	153	$	332	$	305

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $8 million and $22 million for the three and six months ended Feb. 28, 2014, respectively. Agricultural Productivity EBIT includes income from operations of discontinued businesses of $6 million and $17 million for the three and six months ended Feb. 28, 2013, respectively.

The reconciliation of EBIT to Net Income

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
EBIT(1)	$	2,363	$	2,096	$	2,917	$	2,586
Interest Expense — Net	17		8		46		36
Income Tax Provision(2)	676		605		833		728
Net Income Attributable to Monsanto Company	$	1,670	$	1,483	$	2,038	$	1,822

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

SEGMENT AND GEOGRAPHIC DATA

6 Months Ended

Feb. 28, 2014

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

Monsanto conducts its worldwide operations through global businesses, which are aggregated into reportable segments based on similarity of products, production processes, customers, distribution methods and economic characteristics. The operating segments are aggregated into two reportable segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Within the Seeds and Genomics segment, Monsanto’s significant operating segments are corn seed and traits, soybean seed and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The Agricultural Productivity reportable segment consists of the Agricultural Productivity operating segment. EBIT is defined as earnings before interest and taxes and is an operating performance measure for the two reportable segments. EBIT is useful to management in demonstrating the operational profitability of the segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. Sales between segments were not significant. Certain SG&A expenses are allocated between segments based on the segment’s relative contribution to total Monsanto operations. Allocation percentages remain relatively consistent for fiscal years 2013 and 2014.

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Net Sales(1)
Corn seed and traits	$	3,414	$	3,280	$	4,468	$	4,419
Soybean seed and traits	820		677		1,087		908
Cotton seed and traits	49		60		186		245
Vegetable seeds	219		199		376		355
All other crops seeds and traits	146		130		207		174
Total Seeds and Genomics	$	4,648	$	4,346	$	6,324	$	6,101
Agricultural productivity	1,184		1,126		2,651		2,310
Total Agricultural Productivity	$	1,184	$	1,126	$	2,651	$	2,310
Total	$	5,832	$	5,472	$	8,975	$	8,411

Gross Profit
Corn seed and traits	$	2,253	$	2,083	$	2,903	$	2,769
Soybean seed and traits	539		395		707		513
Cotton seed and traits	28		44		120		171
Vegetable seeds	96		106		164		189
All other crops seeds and traits	77		71		104		82
Total Seeds and Genomics	$	2,993	$	2,699	$	3,998	$	3,724
Agricultural productivity	454		371		1,012		743
Total Agricultural Productivity	$	454	$	371	$	1,012	$	743
Total	$	3,447	$	3,070	$	5,010	$	4,467

EBIT(2)(3)
Seeds and Genomics	$	2,055	$	1,840	$	2,159	$	2,060
Agricultural Productivity	308		256		758		526
Total	$	2,363	$	2,096	$	2,917	$	2,586

Depreciation and Amortization Expense
Seeds and Genomics	$	140	$	123	$	271	$	246
Agricultural Productivity	30		30		61		59
Total	$	170	$	153	$	332	$	305

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $8 million and $22 million for the three and six months ended Feb. 28, 2014, respectively. Agricultural Productivity EBIT includes income from operations of discontinued businesses of $6 million and $17 million for the three and six months ended Feb. 28, 2013, respectively.

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
EBIT(1)	$	2,363	$	2,096	$	2,917	$	2,586
Interest Expense — Net	17		8		46		36
Income Tax Provision(2)	676		605		833		728
Net Income Attributable to Monsanto Company	$	1,670	$	1,483	$	2,038	$	1,822

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS (Tables)

6 Months Ended

Feb. 28, 2014

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	787
Other Intangible Assets	142
Total Assets Acquired	997
Current Liabilities	10
Other Liabilities	55
Total Liabilities Assumed	65
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	138
Customer Relationships	1	1	4
Other Intangible Assets			$	142

XML

Statements of Consolidated Shareholders Equity (Unaudited) (USD $) In Millions, unless otherwise specified	Total	Common Stock	Treasury Stock	Additional Contributed Capital	Retained Earnings	Accumulated Other Comprehensive (Loss)		NonControlling Interests
Beginning Balance at Aug. 31, 2012	$ 12,036	$ 6	$ (3,045)	$ 10,371	$ 5,537	$ (1,036)	[1]	$ 203
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,525				2,482			43
Other comprehensive income (loss)	(269)					(242)	[1]	(27)
Treasury stock purchases	(1,095)		(1,095)
Restricted stock withholding	(10)			(10)
Issuance of shares under employee stock plans	257			257
Excess tax benefits from stock-based compensation	69			69
Stock-based compensation expense	97			97
Cash dividends per common share ($1.56 for 2013 and $0.86 for 2014)	(831)				(831)
Dividend payments to noncontrolling interest	(174)							(174)
Acquisition of noncontrolling interest	(10)			(1)				(9)
Proceeds from noncontrolling interest	133							133
Ending Balance at Aug. 31, 2013	12,728	6	(4,140)	10,783	7,188	(1,278)	[1]	169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,045				2,038			7
Other comprehensive income (loss)	88					82	[1]	6
Treasury stock purchases	(764)		(764)
Restricted stock withholding	(8)			(8)
Issuance of shares under employee stock plans	128			128
Excess tax benefits from stock-based compensation	37			37
Stock-based compensation expense	57			57
Cash dividends per common share ($1.56 for 2013 and $0.86 for 2014)	(451)				(451)
Dividend payments to noncontrolling interest	(19)							(19)
Ending Balance at Feb. 28, 2014	$ 13,841	$ 6	$ (4,904)	$ 10,997	$ 8,775	$ (1,196)	[1]	$ 163

[1] See Note 17 — Accumulated Other Comprehensive Loss — for further details of the components of accumulated other comprehensive income (loss).

XML

CUSTOMER FINANCING PROGRAMS (Tables)

6 Months Ended

Feb. 28, 2014

CUSTOMER FINANCING PROGRAMS (Tables) [Abstract]

Customer Financing Programs

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	10	$	348
Maximum future payout under recourse provisions	1		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	9	$	44
Maximum future payout under recourse provisions	9		41
Agreements with Lenders(3)
Outstanding balance	$	84	$	45
Maximum future payout under the guarantee	60		32

Customer Financing Programs, Sales of Receivables

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	—	$	—	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	3		3		10		3

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

XML

STOCK BASED COMPENSATION PLANS (Tables)

6 Months Ended

Feb. 28, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Components of Stock Based Compensation

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the six months ended Feb. 28,2014, and Feb. 28, 2013. Stock-based compensation cost capitalized in inventory was $3 million as of both Feb. 28, 2014, and Aug. 31, 2013.

	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Cost of Goods Sold	$	2		$	3		$	4		$	7
Selling, General and Administrative Expenses	23			18			43			33
Research and Development Expenses	5			5			10			10
Pre-Tax Stock-Based Compensation Expense	30			26			57			50
Income Tax Benefit	(10		)	(9		)	(19		)	(17		)
Net Stock-Based Compensation Expense	$	20		$	17		$	38		$	33

Restricted Stock

The following table summarizes stock-based compensation activity for and as of the six months endedFeb. 28, 2014. Monsanto Stock Plans include employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012 and employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013. The Director Plan includes members of the Board of Directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan.

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,285,346		927,909		18,520		2,554
Weighted-average grant date fair value per share	$	38.34	$	101.30	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable (in millions)	$	91.4	$	113.9	$	0.9	$	0.1
Remaining weighted-average period of expense recognition/requisite service periods (in years)	2		2		1		1

XML

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Information of other intangible assets (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Aug. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	$ 3,195		$ 3,195		$ 3,032
Accumulated Amortization	(1,654)		(1,654)		(1,909)
Net	1,541		1,541		1,123
Total Other Intangible Assets, Carrying Amount	3,299		3,299		3,135
Total Other Intangible Assets, net	1,645		1,645		1,226
Amortization expense	33	31	60	59
Acquired Intellectual Property [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	1,187		1,187		1,095
Accumulated Amortization	(492)		(492)		(791)
Net	695		695		304
Acquired Germplasm [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	1,119		1,119		1,113
Accumulated Amortization	(735)		(735)		(717)
Net	384		384		396
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	368		368		341
Accumulated Amortization	(135)		(135)		(131)
Net	233		233		210
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	340		340		306
Accumulated Amortization	(193)		(193)		(179)
Net	147		147		127
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	181		181		177
Accumulated Amortization	(99)		(99)		(91)
Net	82		82		86
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
In Process Research & Development, Indefinite Lives	$ 104		$ 104		$ 103

XML

COMMITMENTS AND CONTINGENCIES OFF-BALANCE SHEET ARRANGEMENTS (Details) (Bond [Member], USD $) In Millions, unless otherwise specified	Dec. 31, 2013
Bond [Member]
Off Balance Sheet Arrangement [Line Items]
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Asset	$ 470

XML

Statements of Consolidated Operations (Unaudited) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended				6 Months Ended
	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Income Statement [Abstract]
Net Sales	$ 5,832	[1]	$ 5,472	[1]	$ 8,975	[1]	$ 8,411	[1]
Cost of goods sold	2,385		2,402		3,965		3,944
Gross Profit	3,447		3,070		5,010		4,467
Operating Expenses:
Selling, general and administrative expenses	625		598		1,214		1,140
Research and development expenses	404		360		813		706
Total Operating Expenses	1,029		958		2,027		1,846
Income from Operations	2,418		2,112		2,983		2,621
Interest expense	40		35		93		86
Interest income	(23)		(27)		(47)		(50)
Other expense, net	61		22		81		39
Income from Continuing Operations Before Income Taxes	2,340		2,082		2,856		2,546
Income tax provision	672		603		824		725
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	1,668		1,479		2,032		1,821
Discontinued Operations:
Income from operations of discontinued businesses	8		6		22		17
Income tax provision	4		2		9		6
Income from Discontinued Operations	4		4		13		11
Net Income	1,672		1,483		2,045		1,832
Less: Net income attributable to noncontrolling interest	2		0		7		10
Net Income Attributable to Monsanto Company	1,670		1,483		2,038		1,822
Amounts Attributable to Monsanto Company:
Income from continuing operations	1,666		1,479		2,025		1,811
Income from discontinued operations	4		4		13		11
Net Income Attributable to Monsanto Company	$ 1,670		$ 1,483		$ 2,038		$ 1,822
Basic Earnings per Share Attributable to Monsanto Company:
Income from continuing operations (in dollars per share)	$ 3.18		$ 2.77		$ 3.86		$ 3.39
Income on discontinued operations (in dollars per share)	$ 0.00		$ 0.01		$ 0.02		$ 0.02
Net Income Attributable to Monsanto Company (in dollars per share)	$ 3.18		$ 2.78		$ 3.88		$ 3.41
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations (in dollars per share)	$ 3.15		$ 2.73		$ 3.81		$ 3.35
Income on discontinued operations (in dollars per share)	$ 0.00		$ 0.01		$ 0.02		$ 0.02
Net Income Attributable to Monsanto Company (in dollars per share)	$ 3.15		$ 2.74		$ 3.83		$ 3.37
Weighted Average Shares Outstanding:
Basic (in shares)	524.8		534.8		525.9		534.8
Diluted (in shares)	530.3		540.9		531.6		540.9
Dividends Declared per Share	$ 0.86		$ 0.75		$ 0.86		$ 0.75

[1] Represents net sales from continuing operations.

XML

BACKGROUND AND BASIS OF PRESENTATION BACKGROUND AND BASIS OF PRESENTATION (Details)	6 Months Ended
	Feb. 28, 2014 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Operating Segments	2

XML

Statements of Consolidated Financial Position (Parenthetical) (Unaudited) (USD $) In Millions, except Share data, unless otherwise specified	Feb. 28, 2014	Aug. 31, 2013
Current Assets:
Cash and cash equivalents (variable interest entity restricted)	$ 15	$ 140
Trade receivables, net (variable interest entity restricted)	$ 129	$ 0
Shareowners’ Equity:
Common Stock, Authorized	1,500,000,000	1,500,000,000
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Issued	604,208,684	601,631,267
Common Stock, Outstanding	524,459,766	529,029,712
Treasury Stock, at Cost	79,748,918	72,601,555

XML

FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS Fair Value Hierarchy Levels (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014		Aug. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 3,263		$ 2,865
Short-term investments	45		254
Equity securities	47		22
Foreign currency contracts	8		5
Commodity contracts	9		19
Total Assets at Fair Value	3,372		3,165
Contingent consideration			40
Foreign currency contracts	12		8
Commodity contracts	57		85
Total Liabilities at Fair Value	69		133
Short-term Debt, Fair Value	104	[1]	51	[1]
Long-term Debt, Fair Value	3,246	[1]	2,231	[1]
Total Liabilities Not Recorded at Fair Value	3,350		2,282
Total Liabilities Recorded and Not Recorded at Fair Value	3,419		2,415
Assets, Fair Value Disclosure, Nonrecurring	0		0
Liabilities, Fair Value Disclosure, Nonrecurring	0		0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,263		2,865
Short-term investments	45		254
Equity securities	47		22
Foreign currency contracts	0		0
Commodity contracts	5		13
Total Assets at Fair Value	3,360		3,154
Contingent consideration			0
Foreign currency contracts	0		0
Commodity contracts	51		73
Total Liabilities at Fair Value	51		73
Short-term Debt, Fair Value	0	[1]	0	[1]
Long-term Debt, Fair Value	0	[1]	0	[1]
Total Liabilities Not Recorded at Fair Value	0		0
Total Liabilities Recorded and Not Recorded at Fair Value	51		73
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Short-term investments	0		0
Equity securities	0		0
Foreign currency contracts	8		5
Commodity contracts	4		6
Total Assets at Fair Value	12		11
Contingent consideration			0
Foreign currency contracts	12		8
Commodity contracts	6		12
Total Liabilities at Fair Value	18		20
Short-term Debt, Fair Value	104	[1]	51	[1]
Long-term Debt, Fair Value	3,246	[1]	2,231	[1]
Total Liabilities Not Recorded at Fair Value	3,350		2,282
Total Liabilities Recorded and Not Recorded at Fair Value	3,368		2,302
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Short-term investments	0		0
Equity securities	0		0
Foreign currency contracts	0		0
Commodity contracts	0		0
Total Assets at Fair Value	0		0
Contingent consideration			40
Foreign currency contracts	0		0
Commodity contracts	0		0
Total Liabilities at Fair Value	0		40
Short-term Debt, Fair Value	0	[1]	0	[1]
Long-term Debt, Fair Value	0	[1]	0	[1]
Total Liabilities Not Recorded at Fair Value	0		0
Total Liabilities Recorded and Not Recorded at Fair Value	$ 0		$ 40

[1] Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

XML

INVENTORY (Tables)

6 Months Ended

Feb. 28, 2014

Inventory Disclosure [Abstract]

Components of Inventory

Components of inventory are:

	As of
(Dollars in millions)	Feb. 28, 2014			Aug. 31, 2013
Finished Goods	$	1,700		$	1,079
Goods In Process	1,679			1,619
Raw Materials and Supplies	479			418
Inventory at FIFO Cost	3,858			3,116
Excess of FIFO over LIFO Cost	(166		)	(169		)
Total	$	3,692		$	2,947

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
United States Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	$ 15	$ 16	$ 30	$ 36
Interest Cost on Benefit Obligation	23	18	46	40
Assumed Return on Plan Assets	(34)	(32)	(69)	(72)
Amortization of Unrecognized Net Loss (Gain)	15	17	31	38
Curtailment and Settlement Charge	0	0	0	0
Total Net Periodic Benefit Cost	19	19	38	42
Defined Benefit Plan Additional Information [Abstract]
Employer Contributions			30	11
Estimated Future Employer Contributions			30
Foreign Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	3	2	6	5
Interest Cost on Benefit Obligation	2	2	4	4
Assumed Return on Plan Assets	(2)	(2)	(4)	(4)
Amortization of Unrecognized Net Loss (Gain)	(1)	1	0	2
Curtailment and Settlement Charge	1	1	2	2
Total Net Periodic Benefit Cost	3	4	8	9
Defined Benefit Plan Additional Information [Abstract]
Estimated Future Employer Contributions			6
Pension Plan, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	18	18	36	41
Interest Cost on Benefit Obligation	25	20	50	44
Assumed Return on Plan Assets	(36)	(34)	(73)	(76)
Amortization of Unrecognized Net Loss (Gain)	14	18	31	40
Curtailment and Settlement Charge	1	1	2	2
Total Net Periodic Benefit Cost	22	23	46	51
Postretirement and ESOP Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	1	1	4	6
Interest Cost on Benefit Obligation	1	1	4	4
Amortization of Unrecognized Net Loss (Gain)	(4)	(1)	(8)	(4)
Total Net Periodic Benefit Cost	(2)	1	0	6
Foreign Postretirement Benefit Plan, Defined Benefit [Member]
Defined Benefit Plan Additional Information [Abstract]
Employer Contributions			$ 12	$ 9

XML

FAIR VALUE MEASUREMENTS

6 Months Ended

Feb. 28, 2014

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Monsanto determines the fair market value of its financial assets and liabilities based on quoted market prices, estimates from brokers, and other appropriate valuation techniques. The company uses the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the ASC, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with Level 3 representing the lowest level of input:

Level 1 — Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2 — Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, discounted cash flow models, or model-based valuation techniques adjusted, as necessary, for credit risk.

Level 3 — Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions would reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques could include use of option pricing models, discounted cash flow models and similar techniques.

The following tables set forth by level Monsanto’s assets and liabilities that were accounted for at fair value on a recurring basis as of Feb. 28, 2014, and Aug. 31, 2013. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.

	Fair Value Measurements at Feb. 28, 2014, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,263	$	—	$	—	$	3,263
Short-term investments	45		—		—		45
Equity securities	47		—		—		47
Derivative assets related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	5		4		—		9
Total Assets at Fair Value	$	3,360	$	12	$	—	$	3,372
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	12	$	—	$	12
Commodity contracts	51		6		—		57
Total Liabilities at Fair Value	$	51	$	18	$	—	$	69
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	104	$	—	$	104
Long-term debt instruments(1)	—		3,246		—		3,246
Total Liabilities Not Recorded at Fair Value	$	—	$	3,350	$	—	$	3,350
Total Liabilities Recorded and Not Recorded at Fair Value	$	51	$	3,368	$	—	$	3,419

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

The company’s derivative contracts are measured at fair value, including forward commodity purchase and sale contracts, exchange-traded commodity futures and option contracts, and over the counter (OTC) instruments related primarily to agricultural commodities, energy and raw materials, interest rates, and foreign currencies. Exchange-traded futures and options contracts are valued based on unadjusted quoted prices in active markets and are classified as Level 1. Fair value for forward commodity purchase and sale contracts is estimated based on exchange-quoted prices adjusted for differences in local markets. These differences are generally determined using inputs from broker or dealer quotations or market transactions in either the listed or OTC markets. When observable inputs are available for substantially the full term of the contract, it is classified as Level 2. Based on historical experience with the company’s suppliers and customers, the company’s own credit risk and knowledge of current market conditions, the company does not view nonperformance risk to be a significant input to the fair value for the majority of its forward commodity purchase and sale contracts. The effective portions of changes in the fair value of derivatives designated as cash flow hedges are recognized in the Statements of Consolidated Financial Position as a component of accumulated other comprehensive loss until the hedged items are recorded in earnings or it is probable the hedged transaction will no longer occur. Changes in the fair value of derivatives are recognized in the Statements of Consolidated Operation as a component of net sales, cost of goods sold and other expense, net.

The company’s short-term investments are comprised of commercial paper. The company’s equity securities are comprised of publicly traded equity investments. Commercial paper and publicly traded equity investments are valued using quoted market prices and are classified as Level 1.

The fair value of short-term and long-term debt was determined based on current market yields for our debt traded in the secondary market.

For the six months endedFeb. 28, 2014, and Feb. 28, 2013, the company had no transfers between Level 1, Level 2 and Level 3. Monsanto does not have any assets with fair value determined using Level 3 inputs as of Feb. 28, 2014, and Aug. 31, 2013. The following table summarizes the change in fair value of the Level 3 liability for the six months endedFeb. 28, 2014.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Feb. 28, 2014	$	—

There were no significant measurements of assets or liabilities to their implied fair value on a nonrecurring basis during the six months endedFeb. 28, 2014, and Feb. 28, 2013.

The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees, accounts payable, grower production accruals, accrued marketing programs and miscellaneous short-term accruals approximate their fair values as of Feb. 28, 2014, and Aug. 31, 2013.

Management is ultimately responsible for all fair values presented in the company’s consolidated financial statements. The company performs analysis and review of the information and prices received from third parties to ensure that the prices represent a reasonable estimate of fair value. This process involves quantitative and qualitative analysis. As a result of the analysis, if the company determines there is a more appropriate fair value based upon the available market data, the price received from the third party is adjusted accordingly.

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Feb. 28, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Net Carrying Amount of Goodwill

Changes in the net carrying amount of goodwill for the first six months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity		Total
Balance as of Aug. 31, 2013	$	3,461	$	59	$	3,520
Acquisition activity (see Note 3)	787		—		787
Effect of foreign currency translation adjustments	20		—		20
Balance as of Feb. 28, 2014	$	4,268	$	59	$	4,327

Other Intangible Assets Information

Information regarding the company’s other intangible assets is as follows:

	As of Feb. 28, 2014							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,187	$	(492	)	$	695	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,119		(735		)	384		1,113		(717		)	396
Trademarks	368		(135		)	233		341		(131		)	210
Customer Relationships	340		(193		)	147		306		(179		)	127
Other	181		(99		)	82		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,195	$	(1,654	)	$	1,541	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,299	$	(1,654	)	$	1,645	$	3,135	$	(1,909	)	$	1,226

Intangible Assets Future Amortization Expense

The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	144
2015	176
2016	173
2017	152
2018	118

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER

6 Months Ended

Feb. 28, 2014

Compensation and Retirement Disclosure [Abstract]

POSTRETIREMENT BENEFITS-PENSIONS, HEALTH CARE AND OTHER

POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER

Most of Monsanto’s U.S. employees hired prior to July 8, 2012, are covered by noncontributory pension plans sponsored by the company. Effective July 8, 2012, the U.S. pension plan was closed to new entrants; there were no changes to the U.S. pension plan for eligible employees hired prior to that date. The company also provides certain postretirement health care and life insurance benefits for retired employees through insurance contracts. The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Feb. 28, 2014									Three Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	16		$	2		$	18
Interest Cost on Benefit Obligation	23			2			25			18			2			20
Assumed Return on Plan Assets	(34		)	(2		)	(36		)	(32		)	(2		)	(34		)
Amortization of Unrecognized Net Loss	15			(1		)	14			17			1			18
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	3		$	22		$	19		$	4		$	23

	Six Months Ended Feb. 28, 2014									Six Months Ended Feb. 28, 2013
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	30		$	6		$	36		$	36		$	5		$	41
Interest Cost on Benefit Obligation	46			4			50			40			4			44
Assumed Return on Plan Assets	(69		)	(4		)	(73		)	(72		)	(4		)	(76		)
Amortization of Unrecognized Net Loss	31			—			31			38			2			40
Curtailment and Settlement Charge	—			2			2			—			2			2
Total Net Periodic Benefit Cost	$	38		$	8		$	46		$	42		$	9		$	51

Health Care and Other Postretirement Benefits	Three Months Ended						Six Months Ended
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Service Cost for Benefits Earned During the Period	$	1		$	1		$	4		$	6
Interest Cost on Benefit Obligation	1			1			4			4
Amortization of Unrecognized Net Gain	(4		)	(1		)	(8		)	(4		)
Total Net Periodic Benefit Cost	$	(2	)	$	1		$	—		$	6

Monsanto contributed $30 million to its U.S. qualified plan in the six month period ended Feb. 28, 2014, and $11 million in the six month period ended Feb. 28, 2013. Monsanto contributed $12 million to plans outside the United States in the six month period ended Feb. 28, 2014, and$9 million in the six month period ended Feb. 28, 2013. As of Feb. 28, 2014, management expects to make additional contributions of approximately $30 million and $6 million to the company’s pension plans in the United States and outside the United States, respectively, during the remainder of fiscal year 2014.

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			$ (1,278)
Other comprehensive income (loss) before reclassifications			56
Amounts reclassified from accumulated other comprehensive loss			26
Total Other Comprehensive Income (Loss), Net of Tax	(20)	44	82	92
Ending balance	(1,196)		(1,196)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax	(3)	15	(6)	20
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(831)
Other comprehensive income (loss) before reclassifications			79
Amounts reclassified from accumulated other comprehensive loss			0
Total Other Comprehensive Income (Loss), Net of Tax			79
Ending balance	(752)		(752)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			8
Other comprehensive income (loss) before reclassifications			8
Amounts reclassified from accumulated other comprehensive loss			1
Total Other Comprehensive Income (Loss), Net of Tax			9
Ending balance	17		17
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(115)
Other comprehensive income (loss) before reclassifications			(31)
Amounts reclassified from accumulated other comprehensive loss			11
Total Other Comprehensive Income (Loss), Net of Tax			(20)
Ending balance	(135)		(135)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance			(340)
Other comprehensive income (loss) before reclassifications			0
Amounts reclassified from accumulated other comprehensive loss			14
Total Other Comprehensive Income (Loss), Net of Tax			14
Ending balance	(326)		(326)
Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Defined Benefit Plan, Amortization of Gains (Losses)	2		6
Inventory [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Defined Benefit Plan, Amortization of Gains (Losses)	3		6
Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	13		26
Other Comprehensive Income (Loss), Tax	0		0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax	(3)		(6)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax	(4)		(9)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	6		11
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	9		17
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	6		14
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	10		23
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cost of Sales [Member] | Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	3		6
Reclassification out of Accumulated Other Comprehensive Income [Member] | Selling, General and Administrative Expenses [Member] | Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	7		17
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign Exchange Contract [Member] | Net Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(4)		(2)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Commodity Contract [Member] | Cost of Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	10		13
Reclassification out of Accumulated Other Comprehensive Income [Member] | Interest Rate Contracts [Member] | Interest Expense [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	3		6
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	1		1
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	1		1
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale Securities [Member] | Impairment Of Asset [Member] | Other Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ 1		$ 1

XML

Statements of Consolidated Cash Flows (Unaudited) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013
Operating Activities:
Net Income	$ 2,045	$ 1,832
Items that did not require (provide) cash:
Depreciation and amortization	332	305
Bad-debt expense	20	10
Stock-based compensation expense	57	49
Excess tax benefits from stock-based compensation	(36)	(47)
Deferred income taxes	32	52
Equity affiliate (income) expense, net	4	(2)
Net gain on sales of a business or other assets	(2)	(14)
Other items	42	(37)
Changes in assets and liabilities that provided (required) cash, net of acquisitions:
Trade receivables, net	(705)	(201)
Inventory, net	(742)	(243)
Deferred revenues	313	301
Accounts payable and other accrued liabilities	588	25
Pension contributions	(49)	(24)
Other items	(53)	(149)
Net Cash Provided by Operating Activities	1,846	1,857
Cash Flows (Required) Provided by Investing Activities:
Purchases of short-term investments	(105)	(320)
Maturities of short-term investments	314	312
Capital expenditures	(471)	(261)
Acquisition of businesses, net of cash acquired	(922)	(79)
Purchases of long-term debt and equity securities	(12)	0
Technology and other investments	(378)	(48)
Other proceeds	18	95
Net Cash Required by Investing Activities	(1,556)	(301)
Cash Flows Provided (Required) by Financing Activities:
Net change in financing with less than 90-day maturities	(44)	142
Short-term debt proceeds	28	1
Short-term debt reductions	0	(29)
Long-term debt proceeds	999	16
Long-term debt reductions	(3)	(2)
Payments on other financing	(39)	0
Debt issuance costs	(8)	0
Treasury stock purchases	(764)	(327)
Stock option exercises	128	136
Excess tax benefits from stock-based compensation	36	47
Tax withholding on restricted stock and restricted stock units	(8)	(3)
Dividend payments	(453)	(402)
Dividend payments to noncontrolling interests	(19)	(1)
Net Cash Required by Financing Activities	(147)	(422)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(6)	26
Net Increase in Cash and Cash Equivalents	137	1,160
Cash and Cash Equivalents at Beginning of Period	3,668	3,283
Cash and Cash Equivalents at End of Period	$ 3,805	$ 4,443

XML

Statements of Consolidated Comprehensive Income (Loss) (Unaudited) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Comprehensive Income Attributable to Monsanto Company
Net Income Attributable to Monsanto Company	$ 1,670	$ 1,483	$ 2,038	$ 1,822
Other Comprehensive Income (Loss), Net of Tax:
Foreign currency translation, net of tax of $(4) , $0, $(12), and $0, respectively	(48)	114	79	166
Postretirement benefit plan activity, net of tax of $4, $7, $9, and $14, respectively	6	12	14	23
Unrealized net gains on investment holdings, net of tax of $2, $0, $5, and $3, respectively	3	0	8	6
Realized net gains (losses) on investment holdings, net of tax of $0, $(4), $0, and $(3), respectively	1	(7)	1	(6)
Unrealized net derivative gains (losses), net of tax of $9, $(31), $(16), and $(37), respectively	12	(51)	(31)	(63)
Realized net derivative gains (losses), net of tax of $3, $(15), $6, and $(20), respectively	6	(24)	11	(34)
Total Other Comprehensive Income (Loss), Net of Tax	(20)	44	82	92
Comprehensive Income Attributable to Monsanto Company	1,650	1,527	2,120	1,914
Comprehensive Income Attributable to Noncontrolling Interests
Net Income Attributable to Noncontrolling Interests	2	0	7	10
Other Comprehensive Income
Foreign currency translation	1	12	6	8
Total Other Comprehensive Income	1	12	6	8
Comprehensive Income Attributable to Noncontrolling Interests	3	12	13	18
Total Comprehensive Income	$ 1,653	$ 1,539	$ 2,133	$ 1,932

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Feb. 28, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the net carrying amount of goodwill for the first six months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity		Total
Balance as of Aug. 31, 2013	$	3,461	$	59	$	3,520
Acquisition activity (see Note 3)	787		—		787
Effect of foreign currency translation adjustments	20		—		20
Balance as of Feb. 28, 2014	$	4,268	$	59	$	4,327

Goodwill increased during the six months endedFeb. 28, 2014, due to the acquisition of The Climate Corporation. See Note 3 - Business Combinations and Collaborative Arrangements - for further information. There were no events or circumstances indicating that goodwill might be impaired as of Feb. 28, 2014. The fiscal year 2014 annual goodwill impairment test will be performed as of March 1, 2014.

Information regarding the company’s other intangible assets is as follows:

	As of Feb. 28, 2014							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,187	$	(492	)	$	695	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,119		(735		)	384		1,113		(717		)	396
Trademarks	368		(135		)	233		341		(131		)	210
Customer Relationships	340		(193		)	147		306		(179		)	127
Other	181		(99		)	82		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,195	$	(1,654	)	$	1,541	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,299	$	(1,654	)	$	1,645	$	3,135	$	(1,909	)	$	1,226

The increase in total other intangible assets during the six months endedFeb. 28, 2014, is primarily related to the acquisition of The Climate Corporation and the Novozymes collaborative arrangement. Total amortization expense of other intangible assets was $33 million and $31 million in second quarter of fiscal years 2014 and 2013, respectively. Total amortization expense of other intangible assets was $60 million and $59 million for the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	144
2015	176
2016	173
2017	152
2018	118

XML

Document and Entity Information	6 Months Ended
	Feb. 28, 2014	Mar. 31, 2014
Document and Entity Information [Abstract]
Document type	10-Q
Document period end date	Feb. 28, 2014
Amendment flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	MONSANTO CO /NEW/
Entity Central Index Key	0001110783
Current Fiscal Year End Date	--08-31
Entity Filer Category	Large Accelerated Filer
Entity common stock shares outstanding		524,170,807
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

XML

INVESTMENTS

6 Months Ended

Feb. 28, 2014

Equity Method Investments and Joint Ventures [Abstract]

INVESTMENTS

INVESTMENTS

As of Feb. 28, 2014, and Aug. 31, 2013, Monsanto has short-term investments outstanding of $45 million and $254 million, respectively. The investments at Feb. 28, 2014, and Aug. 31, 2013, are comprised of commercial paper with original maturities of one year or less. See Note 13 — Fair Value Measurements.

Monsanto has investments in long-term equity securities, which are considered available-for-sale. As of Feb. 28, 2014, and Aug. 31, 2013, these long-term equity securities are recorded in other assets in the Statements of Consolidated Financial Position at a fair value of $47 million and $22 million, respectively. See Note 17 — Accumulated Other Comprehensive Loss.

Monsanto has cost basis investments recorded in other assets in the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, these investments were recorded at $81 million and $67 million, respectively. Due to the nature of these investments, the fair market value is not readily determinable. These investments are reviewed for impairment indicators.

No significant impairments were recorded on any investments for each of the three and six month periods ended Feb. 28, 2014, and Feb. 28, 2013.

XML

Statements of Consolidated Comprehensive Income (Loss) (Unaudited) (Parenthetical) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation, tax expense (benefit)	$ (4)	$ 0	$ (12)	$ 0
Postretirement benefit plan activity, tax expense (benefit)	4	7	9	14
Unrealized net gains (losses) on investment holdings, tax (expense) benefit	2	0	5	3
Realized net gains on investment holdings, tax (expense) benefit	0	(4)	0	(3)
Unrealized net derivative gains (losses), tax (expense) benefit	9	(31)	(16)	(37)
Realized net derivative gains (losses), tax (expense) benefit	$ 3	$ (15)	$ 6	$ (20)

XML

BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS

6 Months Ended

Feb. 28, 2014

Business Combinations [Abstract]

BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS

BUSINESS COMBINATIONS AND COLLABORATIVE ARRANGEMENTS

Business Combinations

2014 Acquisitions: In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper-local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s research and development ("R&D") capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The acquisition of the company qualifies as a business under the Business Combinations topic of the ASC. Acquisition costs were $17 million, of which $1 million were recorded in 2014. These costs were classified as selling, general and administrative expenses. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

The business operations and employees of the acquired entity described above were included in the Seeds and Genomics segment results upon acquisition. The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	787
Other Intangible Assets	142
Total Assets Acquired	997
Current Liabilities	10
Other Liabilities	55
Total Liabilities Assumed	65
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Pro forma information related to the 2014 acquisition is not presented because the impact of the acquisition on Monsanto's consolidated results of operations is not significant.

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	138
Customer Relationships	1	1	4
Other Intangible Assets			$	142

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co. KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. Acquisition costs were approximately $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations.  The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.  The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.  The goodwill is deductible for tax purposes.

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. Acquisition costs incurred were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

For the acquisitions described above, the business operations and employees of the acquired entities were included in the Seeds and Genomics segment results upon acquisition.

Pro forma information related to the 2013 acquisitions is not presented because the impact of these acquisitions, either individually or in the aggregate, on Monsanto's consolidated results of operations is not expected to be significant.

Collaborative Arrangements

In the normal course of business, Monsanto enters into collaborative arrangements for the research, development, manufacture and/or commercialization of agricultural products. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, such as research and development and commercialization of a collaboration product, where both Monsanto and the third party are active participants in the activities of the collaboration and are exposed to significant risks and rewards of the collaboration. These collaborations generally include cost sharing and profit sharing. Monsanto's collaboration agreements are performed with no guarantee of either technological or commercial success. The company's significant arrangements are discussed below.

Monsanto has entered into various multi-year research, development, manufacturing and commercialization collaborations related to various activities including plant biotechnology and microbial solutions. Under these collaborations, Monsanto and the third parties participate in the R&D and/or manufacturing activities and Monsanto has the primary responsibility for the commercialization of the collaboration products. The collaborations are accounted for in accordance with the Collaborative Arrangements topic of the ASC.

During both the three and six months ended Feb. 28, 2014, Monsanto expensed royalties, purchases and profit sharing payments to third parties under collaborative agreements in the amount of $4 million. These amounts were classified as cost of goods sold on the Statements of Consolidated Operations. There were no expensed royalties, purchases or profit sharing payments to third parties under collaborative agreements during both the three and six months ended Feb. 28, 2013. During each of the three months ended Feb. 28, 2014, and Feb. 28, 2013, Monsanto recorded a net R&D reimbursement from third parties under collaboration agreements in the amount of $12 million. During the six months ended Feb. 28, 2014, and Feb. 28, 2013, Monsanto recorded a net R&D reimbursement from third parties under collaboration agreements in the amounts of $20 million and $27 million, respectively. These amounts were classified as a reduction to research and development expenses on the Statements of Consolidated Operations.

XML

NEW ACCOUNTING STANDARDS

6 Months Ended

Feb. 28, 2014

NEW ACCOUNTING STANDARDS [Abstract]

NEW ACCOUNTING STANDARDS

NEW ACCOUNTING STANDARDS

In July 2013, the FASB issued accounting guidance requiring entities to present unrecognized tax benefits as a reduction to any related deferred tax assets for net operating losses, similar tax losses, or tax credit carryforwards if such settlement is required or expected in the event an uncertain tax position is disallowed. Currently, U.S. Generally Accepted Accounting Principles ("U.S. GAAP") does not provide explicit guidance on the topic. This new presentation guidance will become effective prospectively for fiscal years, and interim periods within those years, beginning after Dec. 15, 2013. Accordingly, Monsanto will adopt this standard in the first quarter of fiscal year 2015. While the company is evaluating the impact this standard will have on the presentation of unrecognized tax benefits in the company's Statements of Consolidated Financial Position, it will not affect the company's results of operations, financial condition or cash flows.

In February 2013, the Financial Accounting Standards Board ("FASB") issued "Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," which requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, entities are required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, entities are required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail on these amounts. This standard is effective prospectively for reporting periods beginning after Dec. 15, 2012. Accordingly, Monsanto adopted this standard in the first quarter of fiscal year 2014. See Note 17 - Accumulated Other Comprehensive Loss - for additional disclosures.

In July 2012, the FASB issued amendments to the Intangibles-Goodwill and Other topic of the Accounting Standards Codification ("ASC"). Prior to this amendment the company performs a two-step test as outlined by the ASC. Step one of the two-step indefinite-lived intangible asset impairment test is performed by calculating the fair value of the indefinite-lived intangible asset and comparing the fair value with its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, then the company is required to perform the second step of the impairment test to measure the amount of the impairment loss, if any. Under the amendment, an entity has the option to first assess qualitative factors to determine whether it is necessary to perform the current two-step test. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, the quantitative impairment test is required. Otherwise, no further testing is required. An entity can choose to perform the qualitative assessment on none, some or all of its indefinite-lived intangible assets. Moreover, an entity can bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to step one of the impairment test, and then resume performing the qualitative assessment in any subsequent period. The amendment is effective for annual and interim indefinite-lived intangible asset impairment tests performed for fiscal years beginning after Sep. 15, 2012. Accordingly, Monsanto will adopt this amendment in fiscal year 2014 for the annual impairment test of indefinite-lived intangible assets and does not expect the adoption to have a material impact on the consolidated financial statements.

In December 2011 and February 2013, the FASB issued an amendment to the Balance Sheet topic of the ASC, which requires entities to disclose both gross and net information about both derivatives and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting agreement. The objective of the disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of International Financial Reporting Standards. This standard is effective for fiscal years, and interim periods within those years, beginning on or after Jan. 1, 2013. Retrospective presentation for all comparative periods presented is required. Accordingly, Monsanto adopted this amendment in the first quarter of fiscal year 2014. See Note 14 - Financial Instruments - for additional disclosures.

XML

FINANCIAL INSTRUMENTS

6 Months Ended

Feb. 28, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS

Cash Flow Hedges

The company uses foreign currency forward and foreign currency option contracts to hedge anticipated sales or purchases denominated in foreign currencies. The company enters into these contracts to protect itself against the risk that the eventual net cash flows will be adversely affected by changes in exchange rates.

Monsanto’s commodity price risk management strategy is to use derivative instruments to minimize significant unanticipated earnings fluctuations that may arise from volatility in commodity prices. Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto uses commodity futures and options contracts to manage these risks. Monsanto’s energy and raw material risk management strategy is to use derivative instruments to minimize significant unanticipated manufacturing cost fluctuations that may arise from volatility in natural gas, diesel and ethylene prices.

Monsanto’s interest rate risk management strategy is to use derivative instruments, such as forward-starting interest rate swaps, to minimize significant unanticipated earnings fluctuations that may arise from volatility in interest rates of the company’s borrowings and to manage the interest rate sensitivity of its debt.

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

The maximum term over which the company is hedging exposures to the variability of cash flow (for all forecasted transactions) is 18 months for foreign currency hedges and 39 months for commodity hedges. During the next 12 months, a pretax net loss of approximately $50 million is expected to be reclassified from accumulated other comprehensive loss into earnings. During the three and six months endedFeb. 28, 2014, and Feb. 28, 2013, no cash flow hedges were discontinued.

Fair Value Hedges

The company uses commodity futures and options contracts as fair value hedges to manage the value of its soybean inventory. For derivative instruments that are designated and qualify as fair value hedges, both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. No fair value hedges were discontinued during the three and six months endedFeb. 28, 2014, and Feb. 28, 2013.

Derivatives Not Designated as Hedging Instruments

The company uses foreign exchange contracts to hedge the effects of fluctuations in exchange rates on foreign currency denominated third-party and intercompany receivables and payables. Both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.

The company uses commodity contracts to hedge anticipated cash payments to growers in the United States, Argentina, Mexico and Brazil, which can fluctuate with changes in commodity price. Because these contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC, they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts in grain. Such payments in grain are negotiated at or near the time Monsanto’s products are sold to the customers and are valued at the prevailing grain commodity prices. By entering into forward sales contracts related to grain, Monsanto mitigates the commodity price exposure from the time a contract is signed with a customer until the time a grain merchant collects the grain from the customer on Monsanto’s behalf. The forward sales contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Monsanto uses interest rate contracts to minimize the variability of forecasted cash flows arising from one of the company’s VIEs. The interest rate contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging Topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Financial instruments are neither held nor issued by the company for trading purposes.

The notional amounts of the company’s derivative instruments outstanding as of Feb. 28, 2014, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	243	$	261
Commodity contracts	949		872
Total Derivatives Designated as Hedges	$	1,192	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,269	$	1,188
Commodity contracts	145		217
Interest rate contracts	137		—
Total Derivatives Not Designated as Hedges	$	1,551	$	1,405

The net presentation of the company’s derivative instruments outstanding was as follows:

			As of Feb. 28, 2014
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts	$	2	$	—		$	2		$	—	$	2
Total trade receivables, net			2		—			2			—		2		$	2,513	$	2,515
Miscellaneous receivables
	Derivatives not designated as hedges:
		Foreign exchange contracts	8		—			8			—		8
Total miscellaneous receivables			8		—			8			—		8		660		668
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	3		(46		)	(43		)	43		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	2		(1		)	1			1		2
Total other current assets			5		(47		)	(42		)	44		2		232		234
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	2		(4		)	(2		)	2		—
Total other assets			2		(4		)	(2		)	2		—		610		610
Total Asset Derivatives			$	17	$	(51	)	$	(34	)	$	46	$	12
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	46	$	(46	)	$	—		$	—	$	—
	Derivatives not designated as hedges:
		Commodity contracts(1)	1		(1		)	—			—		—
Total other current assets			47		(47		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other assets			4		(4		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	9		—			9			—		9
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			16		—			16			—		16		$	757	$	773
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	2		—			2			—		2
Total other liabilities			2		—			2			—		2		391		393
Total Liability Derivatives			$	69	$	(51	)	$	18		$	—	$	18

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1

		Commodity contracts	4		—			4		—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7		—		7
Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(12	)	$	(6	)	Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	4		$	4		4			—			Net sales
Foreign currency contracts	(1		)	1			—			(1		)	Cost of goods sold
Commodity contracts(4)	18			(87		)	(10		)	43			Cost of goods sold
Interest rate contracts	—			—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	21			(82		)	(21		)	33
Derivatives Not Designated as Hedges:
Foreign currency contracts(5)							3			(1		)	Other expense, net
Commodity contracts							1			(12		)	Net sales
Commodity contracts							2			(3		)	Cost of goods sold
Total Derivatives Not Designated as Hedges							6			(16		)
Total Derivatives	$	21		$	(82	)	$	(15	)	$	17

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $2 million and $4 million from ineffectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and $2 million from ineffectiveness for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013.

(5) Gain and loss on foreign currency contracts not designated as hedges includes foreign currency transaction losses of $60 million and $34 million during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Six Months Ended						Six Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(14	)	$	—		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	2		$	3		2			(2		)	Net sales
Foreign currency contracts	(4		)	(3		)	—			2			Cost of goods sold
Commodity contracts(4)	(43		)	(100		)	(13		)	60			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(6		)	(6		)	Interest expense
Total Derivatives Designated as Hedges	(47		)	(100		)	(31		)	54
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							25			30			Other expense, net
Commodity contracts							3			(7		)	Net sales
Commodity contracts							7			1			Cost of goods sold
Total Derivatives Not Designated as Hedges							35			24
Total Derivatives	$	(47	)	$	(100	)	$	4		$	78

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $3 million and $4 million from ineffectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $2 million from ineffectiveness for each of the six months endedFeb. 28, 2014, and Feb. 28, 2013. No gains or losses were excluded from the assessment of hedge effectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the six months endedFeb. 28, 2014.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $101 million and $82 million during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

Several of the company’s outstanding foreign currency derivatives are covered by International Swap Dealers’ Association (ISDA) Master Agreements with the counterparties. There are no requirements to post collateral under these agreements; however, should Monsanto’s credit rating fall below a specified rating immediately following the merger of the company with another entity, the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be settled immediately at current market value, which equals carrying value. Foreign currency derivatives that are not covered by ISDA Master Agreements do not have credit-risk-related contingent provisions. Most of Monsanto’s outstanding commodity derivatives are listed commodity futures, and the company is required by the relevant commodity exchange to post collateral each day to cover the change in the fair value of these futures in the case of an unrealized loss position. Non-exchange-traded commodity derivatives may be covered by the aforementioned ISDA Master Agreements and would be subject to the same credit-risk-related contingent provisions. The aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a liability position was $9 million and $7 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, which is the amount that would be required for settlement if the credit-risk-related contingent provisions underlying these agreements were triggered.

Credit Risk Management

Monsanto invests its excess cash in deposits with major banks or money market funds throughout the world in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of Feb. 28, 2014, and Aug. 31, 2013, the company had no financial instruments that represented a significant concentration of credit risk. Limited amounts are invested in any single institution to minimize risk. The company has not incurred any credit risk losses related to those investments.

The company sells a broad range of agricultural products to a diverse group of customers throughout the world. In the United States, the company makes substantial sales to relatively few large wholesale customers. The company’s business is highly seasonal, and it is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize the risk of loss. Collateral is secured when it is deemed appropriate by the company.

Monsanto regularly evaluates its business practices to minimize its credit risk and periodically engages multiple banks in the United States, Argentina, Brazil and Europe in the development of customer financing options that involve direct bank financing of customer purchases. For further information on these programs, see Note 4 — Customer Financing Programs.

XML

DEFERRED REVENUE

6 Months Ended

Feb. 28, 2014

Deferred Revenue Disclosure [Abstract]

DEFERRED REVENUE

DEFERRED REVENUE

As of Feb. 28, 2014, and Aug. 31, 2013, short-term deferred revenue was $863 million and $517 million, respectively. This balance primarily consists of cash received related to Monsanto's prepayment programs in the United States and Brazil. These programs allow Monsanto's customers to receive a discount if they prepay by a certain date, and the short-term deferred revenue balance is consistent with the seasonality of Monsanto's business. Prepayment options are attractive to customers given the discounted pricing and the ability to utilize cash flow from the current year grain harvest to pay for the next season seed purchases. The deferred revenue balance related to these prepayment programs is considered short-term in nature and thus classified in current liabilities as the prepayments are for products to be shipped within the next 12 months.

In 2008, Monsanto entered into a corn herbicide tolerance and insect control trait technologies agreement with Pioneer Hi-Bred International, Inc. Among its provisions, the agreement modified certain existing corn license agreements between the parties. Under the agreement, which requires fixed annual payments, the company recorded a receivable and deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725 million over an eight-year period. Revenue of$20 million was recorded for each of the three months ended Feb. 28, 2014, and Feb. 28, 2013, and revenue of $40 million was recorded for each of the six months ended Feb. 28, 2014, and Feb. 28, 2013. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining receivable balance is $147 million and $230 million, respectively, of which $85 million is current in both periods and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining deferred revenue balance is $119 million and $159 million, respectively, of which $79 million is included in current deferred revenue in both periods. The interest income recorded on this receivable is $1 million and $2 million for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. Interest income recorded on this receivable is $2 million and $3 million for the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.    

In 2008, Monsanto and Syngenta entered into a Genuity Roundup Ready 2 Yield Soybean License Agreement, which grants Syngenta access to Monsanto’s Genuity Roundup Ready 2 Yield Soybean technology in consideration of royalty payments from Syngenta, based on sales. The minimum obligation from Syngenta over the nine-year contract period is $81 million. Revenue of $11 million and $8 million related to this agreement was recorded for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively, and revenue of $14 million and $12 million was recorded for the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining receivable balance is $42 million and $58 million, respectively. The majority of this balance is current and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Feb. 28, 2014, and Aug. 31, 2013, the remaining deferred revenue balance is $27 million and $34 million, respectively, of which $20 million is included in current deferred revenue in both periods.

XML

RECEIVABLES

6 Months Ended

Feb. 28, 2014

Receivables [Abstract]

RECEIVABLES

RECEIVABLES

Trade receivables on the Statements of Consolidated Financial Position are net of allowances of $72 million and $68 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively.

The company has financing receivables that represent long-term customer receivable balances related to past due accounts which are not expected to be collected within the current year. The long-term customer receivables were $128 million and $112 million with a corresponding allowance for credit losses on these receivables of $105 million and $104 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively. These long-term customer receivable balances and the corresponding allowance are included in long-term receivables, net on the Statements of Consolidated Financial Position. For these long-term customer receivables, interest is no longer accrued when the receivable is determined to be delinquent and classified as long-term based on estimated timing of collection.

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	5
Recoveries	(2		)
Write-offs	(10		)
Other(1)	8
Balance as of Feb. 28, 2014	$	105

(1)Includes reclassifications from trade receivables, net and foreign currency translation adjustments.

In addition, the company has long-term contractual receivables. These receivables are collected at fixed and determinable dates in accordance with the customer long-term agreement. The long-term contractual receivables were $108 million and $229 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, and did not have any allowance recorded related to these balances. These receivables are included in long-term receivables, net on the Statements of Consolidated Financial Position. There are no balances related to these long-term contractual receivables that are past due. These receivables are outstanding with large, reputable companies who have been timely with scheduled payments thus far and are considered to be fully collectible. Interest is accrued on these receivables in accordance with the agreements and is included within interest income in the Statements of Consolidated Operations.

On an ongoing basis, the company evaluates credit quality of its financing receivables utilizing aging of receivables, collection experience and write-offs, as well as evaluating existing economic conditions, to determine if an allowance is necessary.

XML

FAIR VALUE MEASUREMENTS Summary of the Change in Level 3 Liability (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Feb. 28, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 40
Settlement	(40)
Ending Balance	$ 0

XML

CUSTOMER FINANCING PROGRAMS

6 Months Ended

Feb. 28, 2014

CUSTOMER FINANCING PROGRAMS [Abstract]

CUSTOMER FINANCING PROGRAMS

CUSTOMER FINANCING PROGRAMS

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	10	$	348
Maximum future payout under recourse provisions	1		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	9	$	44
Maximum future payout under recourse provisions	9		41
Agreements with Lenders(3)
Outstanding balance	$	84	$	45
Maximum future payout under the guarantee	60		32

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended				Six Months Ended
(Dollars in millions)	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	—	$	—	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	3		3		10		3

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

In addition to the arrangements in the above table, Monsanto also participates in a financing program in Brazil that allowed Monsanto to transfer up to 1 billion Brazilian reais (approximately $430 million) for select customers in Brazil to a revolving financing program. Under the arrangement, a recourse provision requires Monsanto to cover the first credit losses within the program up to the amount of our investment. The company evaluated its relationship with the entity under the guidance within the Consolidation topic of the ASC and, as a result, the entity has been consolidated. For further information on this topic, see Note 5 — Variable Interest Entities.

There were no significant recourse or non-recourse liabilities for all programs as of Feb. 28, 2014, and Aug. 31, 2013. There were no significant delinquent loans for all programs as of Feb. 28, 2014, and Aug. 31, 2013.

XML

VARIABLE INTEREST ENTITIES

6 Months Ended

Feb. 28, 2014

VARIABLE INTEREST ENTITIES [Abstract]

VARIABLE INTEREST ENTITIES

VARIABLE INTEREST ENTITIES

Monsanto is involved with entities that are deemed to be variable interest entities (VIEs). Monsanto has determined that the company holds variable interests in an entity that is established as a revolving financing program. In addition, Monsanto has various variable interests in biotechnology companies that focus on plant gene and agricultural fungicide research, development and commercialization. These variable interests have also been determined to be VIEs.

Consolidated VIEs

Monsanto has a financing program in Brazil that is recorded as a consolidated VIE. For the most part, the VIE consists of a revolving financing program that is funded by investments from the company and other third parties, primarily investment funds, and have been established to service Monsanto’s customer receivables. A 91 percent senior interest in the entity is held by third parties, primarily investment funds, as of Feb. 28, 2014, and Aug. 31, 2013, and Monsanto holds the remaining nine percent interest. Under the arrangement, Monsanto is required to maintain an investment in the VIE of at least nine percent and could be required to provide additional contributions to the VIE. Monsanto currently has no unfunded commitments to the VIE. See Note 4 — Customer Financing Programs — for additional information regarding the revolving financing arrangement.

Creditors have no recourse against Monsanto in the event of default by the VIE. The company’s financial or other support provided to the VIE is limited to its investment. Even though Monsanto holds a subordinate interest in the VIE, the VIE was established to service transactions involving the company and the company determines the receivables that are included in the revolving financing program. Therefore, the determination is that Monsanto has the power to direct the activities most significant to the economic performance of the VIE. As a result, the company is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto’s consolidated financial statements. The assets of the VIE may only be used to settle the obligations of the respective entity. Third-party investors in the VIE do not have recourse to the general assets of Monsanto other than the maximum exposure to loss relating to the VIE. The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Cash and cash equivalents	$	15	$	140
Trade receivables, net	129		—
Total Assets	$	144	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	13	$	—

Monsanto has entered into several agreements with third parties to establish entities to focus on research and development related to various activities including agricultural fungicides and biologicals for agricultural applications. All entities are recorded as consolidated VIEs of Monsanto. Under each of the arrangements, Monsanto holds call options to acquire the majority of the equity interests in each VIE from the third party owners. Monsanto will fund the operations of the VIEs in return for either additional equity interests or to retain the call options. The funding, which may total up to $108 million, will be provided in separate research phases if research milestones are met over the next several years. The VIEs were established to perform agricultural-based research and development activities for the benefit of Monsanto, and Monsanto provides all funding of the VIEs' activities. Further, Monsanto has the power to direct the activities most significant to the VIEs. As a result, Monsanto is the primary beneficiary of the VIEs and the VIEs have been consolidated in Monsanto's consolidated financial statements. As of Feb. 28, 2014, and Aug. 31, 2013, the VIEs had no significant assets or liabilities. Monsanto's maximum exposure to loss was $43 million and $11 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively, which includes our current investment in the VIEs, the funding required to be provided to the VIEs during the research phases and/or the initial consideration paid related to the call options. The third party owners of the VIEs do not have recourse to the general assets of Monsanto beyond Monsanto's maximum exposure to loss at any given time relating to the VIE.

Non-Consolidated VIE

Monsanto has a variable interest through an investment with a software company that develops software with agricultural applications. The company has not provided financial or other support other than its original investment, has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity and is not significant. There were no significant assets or liabilities for the VIE as of Feb. 28, 2014, and Aug. 31, 2013.

XML

INVENTORY

6 Months Ended

Feb. 28, 2014

Inventory Disclosure [Abstract]

INVENTORY

INVENTORY

Components of inventory are:

	As of
(Dollars in millions)	Feb. 28, 2014			Aug. 31, 2013
Finished Goods	$	1,700		$	1,079
Goods In Process	1,679			1,619
Raw Materials and Supplies	479			418
Inventory at FIFO Cost	3,858			3,116
Excess of FIFO over LIFO Cost	(166		)	(169		)
Total	$	3,692		$	2,947

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Gain (Loss) from Derivatives (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Feb. 28, 2014		Feb. 28, 2013		Feb. 28, 2014		Feb. 28, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 21		$ (82)		$ (47)		$ (100)
Amount of Gain (Loss) Recognized in Income	(15)		17		4		78
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net	0		0		0		0
Discontinuation of Cash Flow Hedge	0		0		0		0
Foreign Currency Transaction Gain (Loss) Realized	(60)		(34)		(101)		(82)
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	21	[1]	(82)	[1]	(47)	[1]	(100)	[1]
Amount of Gain (Loss) Recognized in Income	(21)		33		(31)		54
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	6		(16)		35		24
Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Fair Value Hedge Ineffectiveness	2		4		3		4
Commodity Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Cash Flow Hedge Ineffectiveness	1		2		2		2
Commodity Contracts | Cost of Sales [Member] | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	2		(3)		7		1
Commodity Contracts | Net Sales [Member] | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	1		(12)		3		(7)
Foreign Exchange Contract [Member] | Other expense, net [Member] | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	3	[2]	(1)	[2]	25	[3]	30	[3]
Interest Rate Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Cash Flow Hedge Ineffectiveness					1
Fair Value Hedges | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	(12)	[4]	(6)	[4]	(14)	[5]	0	[5]
Cash Flow Hedging [Member] | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	18	[1]	(87)	[1]	(43)	[1]	(100)	[1]
Amount of Gain (Loss) Recognized in Income	(10)	[6],[7]	43	[6],[7]	(13)	[6],[8]	60	[6],[8]
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(1)	[1]	1	[1]	(4)	[1]	(3)	[1]
Amount of Gain (Loss) Recognized in Income	0	[6]	(1)	[6]	0	[6]	2	[6]
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Net Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	4	[1]	4	[1]	2	[1]	3	[1]
Amount of Gain (Loss) Recognized in Income	4	[6]	0	[6]	2	[6]	(2)	[6]
Cash Flow Hedging [Member] | Interest Rate Contracts [Member] | Interest Expense [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0	[1]	0	[1]	(2)	[1]	0	[1]
Amount of Gain (Loss) Recognized in Income	$ (3)	[6]	$ (3)	[6]	$ (6)	[6],[9]	$ (6)	[6],[9]

[1] Accumulated other comprehensive income (loss) (AOCI).

[2] Gain and loss on foreign currency contracts not designated as hedges includes foreign currency transaction losses of $60 million and $34 million during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

[3] Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $101 million and $82 million during the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

[4] Loss on fair value hedges includes a loss of $2 million and $4 million from ineffectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

[5] Loss on fair value hedges includes a loss of $3 million and $4 million from ineffectiveness during the six months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

[6] For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

[7] Loss and gain on commodity cash flow hedges includes a loss of $1 million and $2 million from ineffectiveness for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013.

[8] Loss and gain on commodity cash flow hedges includes a loss of $2 million from ineffectiveness for each of the six months ended Feb. 28, 2014, and Feb. 28, 2013. No gains or losses were excluded from the assessment of hedge effectiveness during the six months ended Feb. 28, 2014, and Feb. 28, 2013.

[9] Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the six months ended Feb. 28, 2014.

XML

STOCK BASED COMPENSATION PLANS Schedule of Stock-based Compensation Expense (Details) (USD $) In Millions, unless otherwise specified	6 Months Ended	12 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Feb. 28, 2014	Aug. 31, 2013	Feb. 28, 2014 Cost of Goods Sold [Member]	Feb. 28, 2013 Cost of Goods Sold [Member]	Feb. 28, 2014 Cost of Goods Sold [Member]	Feb. 28, 2013 Cost of Goods Sold [Member]	Feb. 28, 2014 Selling, General and Administrative Expenses [Member]	Feb. 28, 2013 Selling, General and Administrative Expenses [Member]	Feb. 28, 2014 Selling, General and Administrative Expenses [Member]	Feb. 28, 2013 Selling, General and Administrative Expenses [Member]	Feb. 28, 2014 Research and Development Expenses [Member]	Feb. 28, 2013 Research and Development Expenses [Member]	Feb. 28, 2014 Research and Development Expenses [Member]	Feb. 28, 2013 Research and Development Expenses [Member]	Feb. 28, 2014 Pre-Tax Stock-Based Compensation Expense [Member]	Feb. 28, 2013 Pre-Tax Stock-Based Compensation Expense [Member]	Feb. 28, 2014 Pre-Tax Stock-Based Compensation Expense [Member]	Feb. 28, 2013 Pre-Tax Stock-Based Compensation Expense [Member]	Feb. 28, 2014 Income Tax Benefit [Member]	Feb. 28, 2013 Income Tax Benefit [Member]	Feb. 28, 2014 Income Tax Benefit [Member]	Feb. 28, 2013 Income Tax Benefit [Member]	Feb. 28, 2014 Net Stock Based Compensation [Member]	Feb. 28, 2013 Net Stock Based Compensation [Member]	Feb. 28, 2014 Net Stock Based Compensation [Member]	Feb. 28, 2013 Net Stock Based Compensation [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Allocated Stock Based Compensation Expense			$ 2	$ 3	$ 4	$ 7	$ 23	$ 18	$ 43	$ 33	$ 5	$ 5	$ 10	$ 10	$ 30	$ 26	$ 57	$ 50	$ (10)	$ (9)	$ (19)	$ (17)	$ 20	$ 17	$ 38	$ 33
Compensation cost capitalized	$ 3	$ 3

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Fair Value of Derivatives Outstanding (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014		Aug. 31, 2013
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 17		$ 24
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(51)		(80)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(34)		(56)
Derivative Asset, Fair Value of Collateral	46		66
Derivative Asset	12		10
Accounts Receivable, Net, Current	2,515		1,715
Miscellaneous receivables	668		748
Other Assets, Current	234		166
Other Assets, Noncurrent	610		496
Derivative Liability, Fair Value, Gross Liability	69		93
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(51)		(80)
Derivative Liability, Fair Value, Amount Offset Against Collateral	18		13
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	18		13
Miscellaneous short-term accruals	773		812
Other Liabilities, Noncurrent	393		382
Trade Accounts Receivable [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2		1
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		(6)
Derivative Asset, Fair Value, Amount Offset Against Collateral	2		(5)
Derivative Asset, Fair Value of Collateral	0		5
Derivative Asset	2		0
Non-derivative Balances	2,513		1,715
Derivative Liability, Fair Value, Gross Liability			6
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			(6)
Derivative Liability, Fair Value, Amount Offset Against Collateral			0
Derivative Liability, Fair Value of Collateral			0
Derivative Liability			0
Miscellaneous receivables
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	8		9
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	8		9
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	8		9
Non-derivative Balances	660		739
Other Assets
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2		0
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(4)		(9)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(2)		(9)
Derivative Asset, Fair Value of Collateral	2		9
Derivative Asset	0		0
Non-derivative Balances	610		496
Derivative Liability, Fair Value, Gross Liability	4		9
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(4)		(9)
Derivative Liability, Fair Value, Amount Offset Against Collateral	0		0
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	0		0
Other current assets
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	5		14
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(47)		(65)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(42)		(51)
Derivative Asset, Fair Value of Collateral	44		52
Derivative Asset	2		1
Non-derivative Balances	232		165
Derivative Liability, Fair Value, Gross Liability	47		65
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(47)		(65)
Derivative Liability, Fair Value, Amount Offset Against Collateral	0		0
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	0		0
Miscellaneous short term accruals
Derivatives, Fair Value [Line Items]
Non-derivative Balances	(757)		(800)
Derivative Liability, Fair Value, Gross Liability	16		12
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	16		12
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	16		12
Other liabilities
Derivatives, Fair Value [Line Items]
Non-derivative Balances	(391)		(381)
Derivative Liability, Fair Value, Gross Liability	2		1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	2		1
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	2		1
Foreign Exchange Contract [Member] | Miscellaneous receivables | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset			3
Derivative Asset, Collateral, Obligation to Return Cash, Offset			0
Derivative Asset, Fair Value, Amount Offset Against Collateral			3
Derivative Asset, Fair Value of Collateral			0
Derivative Asset			3
Foreign Exchange Contract [Member] | Miscellaneous receivables | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	8		2
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	8		2
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	8		2
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	3		1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	3		1
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	3		1
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	9		7
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	9		7
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	9		7
Commodity Contract [Member] | Trade Accounts Receivable [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2		1	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		(6)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	2		(5)	[1]
Derivative Asset, Fair Value of Collateral	0		5	[1]
Derivative Asset	2		0	[1]
Derivative Liability, Fair Value, Gross Liability			6	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			(6)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral			0	[1]
Derivative Liability, Fair Value of Collateral			0	[1]
Derivative Liability			0	[1]
Commodity Contract [Member] | Miscellaneous receivables | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset			4
Derivative Asset, Collateral, Obligation to Return Cash, Offset			0
Derivative Asset, Fair Value, Amount Offset Against Collateral			4
Derivative Asset, Fair Value of Collateral			0
Derivative Asset			4
Commodity Contract [Member] | Other Assets | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2	[1]	0	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(4)	[1]	(9)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	(2)	[1]	(9)	[1]
Derivative Asset, Fair Value of Collateral	2	[1]	9	[1]
Derivative Asset	0	[1]	0	[1]
Derivative Liability, Fair Value, Gross Liability	4	[1]	9	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(4)	[1]	(9)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral	0	[1]	0	[1]
Derivative Liability, Fair Value of Collateral	0	[1]	0	[1]
Derivative Liability	0	[1]	0	[1]
Commodity Contract [Member] | Other current assets | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	3	[1]	9	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(46)	[1]	(61)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	(43)	[1]	(52)	[1]
Derivative Asset, Fair Value of Collateral	43	[1]	52	[1]
Derivative Asset	0	[1]	0	[1]
Derivative Liability, Fair Value, Gross Liability	46	[1]	61	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(46)	[1]	(61)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral	0	[1]	0	[1]
Derivative Liability, Fair Value of Collateral	0	[1]	0	[1]
Derivative Liability	0	[1]	0	[1]
Commodity Contract [Member] | Other current assets | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2	[1]	5	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(1)	[1]	(4)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	1	[1]	1	[1]
Derivative Asset, Fair Value of Collateral	1	[1]	0	[1]
Derivative Asset	2	[1]	1	[1]
Derivative Liability, Fair Value, Gross Liability	1	[1]	4	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(1)	[1]	(4)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral	0	[1]	0	[1]
Derivative Liability, Fair Value of Collateral	0	[1]	0	[1]
Derivative Liability	0	[1]	0	[1]
Commodity Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	3		4
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	3		4
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	3		4
Commodity Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0
Derivative Liability, Fair Value, Amount Offset Against Collateral	1
Derivative Liability, Fair Value of Collateral	0
Derivative Liability	1
Commodity Contract [Member] | Other liabilities | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	2		1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	2		1
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	$ 2		$ 1

[1] As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

XML

RECEIVABLES (Tables)

6 Months Ended

Feb. 28, 2014

Receivables [Abstract]

Allowance For Doubtful Long Term Receivables

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	5
Recoveries	(2		)
Write-offs	(10		)
Other(1)	8
Balance as of Feb. 28, 2014	$	105

(1)Includes reclassifications from trade receivables, net and foreign currency translation adjustments.

XML

INVENTORY (Details) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014	Aug. 31, 2013
Inventory Disclosure [Abstract]
Finished Goods	$ 1,700	$ 1,079
Goods In Process	1,679	1,619
Raw Materials and Supplies	479	418
Inventory at FIFO Cost	3,858	3,116
Excess of FIFO over LIFO Cost	(166)	(169)
Total	$ 3,692	$ 2,947

XML

DEBT AND OTHER CREDIT ARRANGEMENTS

6 Months Ended

Feb. 28, 2014

Debt Disclosure [Abstract]

DEBT AND OTHER CREDIT ARRANGEMENTS

DEBT AND OTHER CREDIT ARRANGEMENTS

In November 2011, Monsanto filed a new shelf registration with the SEC (2011 shelf registration) that allows the company to issue an unlimited capacity of debt, equity and hybrid offerings. The 2011 shelf registration will expire in November 2014.

In November 2013, Monsanto issued $400 million of Floating Rate Senior Notes which are due on Nov. 7, 2016, (Floating Rate Notes), $300 million of 1.85% Senior Notes which are due on Nov. 15, 2018, (2018 Senior Notes) and $300 million of 4.65% Senior Notes which are due on Nov. 15, 2043, (2043 Senior Notes). All notes were issued under the 2011 shelf registration.

The net proceeds from the sale of the Floating Rate, 2018, and 2043 Senior Notes were used for the acquisition of The Climate Corporation and general corporate purposes.

In July 2012, Monsanto issued $250 million of 2.20% Senior Notes which are due on July 15, 2022, (2022 Senior Notes) and $250 million of 3.60% Senior Notes which are due on July 15, 2042, (2042 Senior Notes). Both were issued under the 2011 shelf registration.

The net proceeds from the sale of the 2022 and 2042 Senior Notes were used for general corporate purposes, including refinancing of the company’s indebtedness.

Monsanto has a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016.

The fair value of the total short-term debt was $104 million and $51 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively. The fair value of the total long-term debt was $3,246 million and $2,231 million as of Feb. 28, 2014, and Aug. 31, 2013, respectively.

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS

6 Months Ended

Feb. 28, 2014

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the six months ended Feb. 28, 2014:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	79			8		(31		)	—			56
Amounts reclassified from accumulated other comprehensive loss	—			1		11			14			26
Net current-period other comprehensive income (loss)	79			9		(20		)	14			82
Balance as of Feb. 28, 2014	$	(752	)	$	17	$	(135	)	$	(326	)	$	(1,196	)

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three and six months ended Feb. 28, 2014:

	Amount Reclassified from Accumulated Other Comprehensive Loss						Affected Line Item in the Statement of Consolidated Operations
	Three months ended Feb. 28, 2014			Six months ended Feb. 28, 2014
Net Unrealized Gain on Available for Sale Securities:
Impairment	$	1		$	1		Other expense, net
	1			1			Total before income taxes
	—			—			Income tax provision
	$	1		$	1		Net of tax
Cash Flow Hedges:
Foreign Exchange Contracts	$	(4	)	$	(2	)	Net sales
Commodity Contracts	10			13			Cost of goods sold
Interest Rate Contracts	3			6			Interest expense
	9			17			Total before income taxes
	(3		)	(6		)	Income tax provision
	$	6		$	11		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		$	6		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	7			17			Selling, general and administrative expenses
	10			23			Total before income taxes
	(4		)	(9		)	Income tax provision
	$	6		$	14		Net of tax
Total Reclassifications For The Period	$	13		$	26		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million and $6 million of net periodic benefit cost to inventory, of which approximately $2 million and $6 million was recognized in cost of goods sold during the three and six months ended Feb. 28, 2014, respectively. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

XML

VARIABLE INTEREST ENTITIES VARIABLE INTEREST ENTITIES Schedules (Details) (USD $)	Feb. 28, 2014	Aug. 31, 2013
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 15,000,000	$ 140,000,000
Trade receivables, net	129,000,000	0
Biotechnology Company [Member]
Variable Interest Entity [Line Items]
Maximum Exposure to Loss	43,000,000	11,000,000
Variable Interest Entity, Financial or Other Support, Maximum Commitment Amount	108,000,000
Brazil Revolving Financing Program [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	15,000,000	140,000,000
Trade receivables, net	129,000,000	0
Total Assets	144,000,000	140,000,000
Total Liabilities	0	0
Maximum Exposure to Loss	$ 13,000,000	$ 0

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

6 Months Ended

Feb. 28, 2014

Equity [Abstract]

Components of Accumulated Other Comprehensive Income

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the six months ended Feb. 28, 2014:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	79			8		(31		)	—			56
Amounts reclassified from accumulated other comprehensive loss	—			1		11			14			26
Net current-period other comprehensive income (loss)	79			9		(20		)	14			82
Balance as of Feb. 28, 2014	$	(752	)	$	17	$	(135	)	$	(326	)	$	(1,196	)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three and six months ended Feb. 28, 2014:

	Amount Reclassified from Accumulated Other Comprehensive Loss						Affected Line Item in the Statement of Consolidated Operations
	Three months ended Feb. 28, 2014			Six months ended Feb. 28, 2014
Net Unrealized Gain on Available for Sale Securities:
Impairment	$	1		$	1		Other expense, net
	1			1			Total before income taxes
	—			—			Income tax provision
	$	1		$	1		Net of tax
Cash Flow Hedges:
Foreign Exchange Contracts	$	(4	)	$	(2	)	Net sales
Commodity Contracts	10			13			Cost of goods sold
Interest Rate Contracts	3			6			Interest expense
	9			17			Total before income taxes
	(3		)	(6		)	Income tax provision
	$	6		$	11		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		$	6		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	7			17			Selling, general and administrative expenses
	10			23			Total before income taxes
	(4		)	(9		)	Income tax provision
	$	6		$	14		Net of tax
Total Reclassifications For The Period	$	13		$	26		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million and $6 million of net periodic benefit cost to inventory, of which approximately $2 million and $6 million was recognized in cost of goods sold during the three and six months ended Feb. 28, 2014, respectively. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

XML

Statements of Consolidated Financial Position (Unaudited) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014	Aug. 31, 2013
Current Assets:
Cash and cash equivalents (variable interest entity restricted - 2014: $15 and 2013: $140)	$ 3,805	$ 3,668
Short-term investments	45	254
Trade receivables, net (variable interest entity restricted - 2014: $129 and 2013: $0)	2,515	1,715
Miscellaneous receivables	668	748
Deferred tax assets	591	579
Inventory, net	3,692	2,947
Other current assets	234	166
Total Current Assets	11,550	10,077
Total property, plant and equipment	9,815	9,491
Less accumulated depreciation	5,080	4,837
Property, Plant and Equipment, Net	4,735	4,654
Goodwill	4,327	3,520
Other Intangible Assets, Net	1,645	1,226
Noncurrent Deferred Tax Assets	459	454
Long-Term Receivables, Net	131	237
Other Assets	610	496
Total Assets	23,457	20,664
Current Liabilities:
Short-term debt, including current portion of long-term debt	104	51
Accounts payable	847	995
Income taxes payable	630	91
Accrued compensation and benefits	334	492
Accrued marketing programs	1,018	1,078
Deferred revenues	863	517
Grower production accruals	225	60
Dividends payable	226	228
Customer payable	31	12
Miscellaneous short-term accruals	773	812
Total Current Liabilities	5,051	4,336
Long-Term Debt	3,051	2,061
Postretirement Liabilities	333	357
Long-Term Deferred Revenue	94	138
Noncurrent Deferred Tax Liabilities	507	469
Long-Term Portion of Environmental and Litigation Liabilities	187	193
Other Liabilities	393	382
Shareowners’ Equity:
Common stock (authorized: 1,500,000,000 shares, par value $0.01) Issued 604,208,684 and 601,631,267 shares, respectively; Outstanding 524,459,766 and 529,029,712 shares, respectively	6	6
Treasury stock 79,748,918 and 72,601,555 shares, respectively, at cost	(4,904)	(4,140)
Additional contributed capital	10,997	10,783
Retained earnings	8,775	7,188
Accumulated other comprehensive loss	(1,196)	(1,278)
Total Monsanto Company Shareowners’ Equity	13,678	12,559
Noncontrolling Interest	163	169
Total Shareowners’ Equity	13,841	12,728
Total Liabilities and Shareowners’ Equity	$ 23,457	$ 20,664

XML

BACKGROUND AND BASIS OF PRESENTATION

6 Months Ended

Feb. 28, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BACKGROUND AND BASIS OF PRESENTATION

BACKGROUND AND BASIS OF PRESENTATION

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto’s seeds, biotechnology trait products, and herbicides provide farmers with solutions that improve productivity, reduce the costs of farming, and produce better foods for consumers and better feed for animals.

Monsanto manages its business in two segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and Monsanto develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other seed companies with genetic material and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the company manufactures Roundup and Harness brand herbicides and other herbicides. See Note 21 — Segment Information — for further details.

In the fourth quarter of 2008, the company announced plans to divest its animal agricultural products business, which focused on dairy cow productivity (the Dairy business) and was previously reported as part of the Agricultural Productivity segment. This transaction was consummated on Oct. 1, 2008. As a result, financial data for this business has been presented as discontinued operations.

Certain reclassifications of prior year amounts within the operating activities section of the Statement of Consolidated Cash Flows have been made to conform to current year presentation. The company has evaluated the impact and does not consider the reclassifications to be material to the consolidated financial statements.

The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first six months of fiscal year 2014 should not be annualized because of the seasonality of the company’s business.

XML

DEBT AND OTHER CREDIT ARRANGEMENTS (Details) (USD $)					1 Months Ended
	Feb. 28, 2014		Aug. 31, 2013		Nov. 30, 2013 Floating Rate Notes Due Twenty Sixteen [Member]	Nov. 30, 2013 Senior Notes Due Twenty Eighteen [Member]	Nov. 30, 2013 Senior Notes Due Twenty Forty Three [Member]	Jul. 31, 2012 Senior Notes Due 2022 [Member]	Jul. 31, 2012 Senior Notes Due 2042 [Member]	Feb. 28, 2014 Credit Facility Agreement 2011 [Member]
Debt Instrument [Line Items]
Face Amount					$ 400,000,000	$ 300,000,000	$ 300,000,000	$ 250,000,000	$ 250,000,000	$ 2,000,000,000
Interest Rate						1.85%	4.65%	2.20%	3.60%
Maturity Date					Nov. 07, 2016	Nov. 15, 2018	Nov. 15, 2043	Jul. 15, 2022	Jul. 15, 2042
Short-term debt, including current portion of long-term debt	104,000,000		51,000,000
Long-term Debt, Fair Value	$ 3,246,000,000	[1]	$ 2,231,000,000	[1]

[1] Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

XML

EARNINGS PER SHARE (Details) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Earnings Per Share [Abstract]
Weighted-Average Number of Common Shares	524.8	534.8	525.9	534.8
Dilutive Potential Common Shares	5.5	6.1	5.7	6.1
Antidilutive Potential Common Shares	1.7	1.9	1.8	1.9
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	0	0.1	0.1	0.1

XML

EARNINGS PER SHARE

6 Months Ended

Feb. 28, 2014

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

Basic earnings per share (EPS) was computed using the weighted-average number of common shares outstanding during the periods shown in the table below. The diluted EPS computation takes into account the effect of dilutive potential common shares, as shown in the table below. Potential common shares consist primarily of stock options, restricted stock, restricted stock units and directors’ deferred shares calculated using the treasury stock method and are excluded if their effect is antidilutive. Of those antidilutive options, certain options were excluded from the computations of dilutive potential common shares as their exercise prices were greater than the average market price of the common shares for the period.

	Three Months Ended		Six Months Ended
(Shares in millions)	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Weighted-Average Number of Common Shares	524.8	534.8	525.9	534.8
Dilutive Potential Common Shares	5.5	6.1	5.7	6.1
Antidilutive Potential Common Shares	1.7	1.9	1.8	1.9
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	—	0.1	0.1	0.1

XML

FINANCIAL INSTRUMENTS (Tables)

6 Months Ended

Feb. 28, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments (Notional Amounts)

The notional amounts of the company’s derivative instruments outstanding as of Feb. 28, 2014, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Feb. 28, 2014		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	243	$	261
Commodity contracts	949		872
Total Derivatives Designated as Hedges	$	1,192	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,269	$	1,188
Commodity contracts	145		217
Interest rate contracts	137		—
Total Derivatives Not Designated as Hedges	$	1,551	$	1,405

^[1]

Fair Values of Derivative Instruments

The net presentation of the company’s derivative instruments outstanding was as follows:

			As of Feb. 28, 2014
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts	$	2	$	—		$	2		$	—	$	2
Total trade receivables, net			2		—			2			—		2		$	2,513	$	2,515
Miscellaneous receivables
	Derivatives not designated as hedges:
		Foreign exchange contracts	8		—			8			—		8
Total miscellaneous receivables			8		—			8			—		8		660		668
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	3		(46		)	(43		)	43		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	2		(1		)	1			1		2
Total other current assets			5		(47		)	(42		)	44		2		232		234
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	2		(4		)	(2		)	2		—
Total other assets			2		(4		)	(2		)	2		—		610		610
Total Asset Derivatives			$	17	$	(51	)	$	(34	)	$	46	$	12
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	46	$	(46	)	$	—		$	—	$	—
	Derivatives not designated as hedges:
		Commodity contracts(1)	1		(1		)	—			—		—
Total other current assets			47		(47		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other assets			4		(4		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	9		—			9			—		9
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			16		—			16			—		16		$	757	$	773
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	2		—			2			—		2
Total other liabilities			2		—			2			—		2		391		393
Total Liability Derivatives			$	69	$	(51	)	$	18		$	—	$	18

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1

		Commodity contracts	4		—			4		—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7		—		7
Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

^[1]

Gains Losses of Derivative Instruments

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(12	)	$	(6	)	Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	4		$	4		4			—			Net sales
Foreign currency contracts	(1		)	1			—			(1		)	Cost of goods sold
Commodity contracts(4)	18			(87		)	(10		)	43			Cost of goods sold
Interest rate contracts	—			—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	21			(82		)	(21		)	33
Derivatives Not Designated as Hedges:
Foreign currency contracts(5)							3			(1		)	Other expense, net
Commodity contracts							1			(12		)	Net sales
Commodity contracts							2			(3		)	Cost of goods sold
Total Derivatives Not Designated as Hedges							6			(16		)
Total Derivatives	$	21		$	(82	)	$	(15	)	$	17

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $2 million and $4 million from ineffectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and $2 million from ineffectiveness for the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended Feb. 28, 2014, and Feb. 28, 2013.

(5) Gain and loss on foreign currency contracts not designated as hedges includes foreign currency transaction losses of $60 million and $34 million during the three months ended Feb. 28, 2014, and Feb. 28, 2013, respectively.

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Six Months Ended						Six Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Feb. 28, 2014			Feb. 28, 2013			Feb. 28, 2014			Feb. 28, 2013
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(14	)	$	—		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	2		$	3		2			(2		)	Net sales
Foreign currency contracts	(4		)	(3		)	—			2			Cost of goods sold
Commodity contracts(4)	(43		)	(100		)	(13		)	60			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(6		)	(6		)	Interest expense
Total Derivatives Designated as Hedges	(47		)	(100		)	(31		)	54
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							25			30			Other expense, net
Commodity contracts							3			(7		)	Net sales
Commodity contracts							7			1			Cost of goods sold
Total Derivatives Not Designated as Hedges							35			24
Total Derivatives	$	(47	)	$	(100	)	$	4		$	78

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss on fair value hedges includes a loss of $3 million and $4 million from ineffectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $2 million from ineffectiveness for each of the six months endedFeb. 28, 2014, and Feb. 28, 2013. No gains or losses were excluded from the assessment of hedge effectiveness during the six months endedFeb. 28, 2014, and Feb. 28, 2013.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the six months endedFeb. 28, 2014.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $101 million and $82 million during the six months endedFeb. 28, 2014, and Feb. 28, 2013, respectively.

[1] Accumulated other comprehensive income (loss) (AOCI).

XML

INCOME TAXES

6 Months Ended

Feb. 28, 2014

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

Monsanto recorded a tax benefit of $47 million in the first half of 2013 primarily as a result of a capital loss from a deemed liquidation of a subsidiary, the retroactive extension of the research and development credit pursuant to the enactment of the American Taxpayer Relief Act of 2012 on Jan. 2, 2013, and the favorable resolution of domestic and ex-US tax matters.